<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Early erythropoiesis‐stimulating agents in preterm or low birth weight infants - Ohlsson, A - 2020 | Cochrane Library</title> <meta content="Early erythropoiesis‐stimulating agents in preterm or low birth weight infants - Ohlsson, A - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004863.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Early erythropoiesis‐stimulating agents in preterm or low birth weight infants - Ohlsson, A - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004863.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004863.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Early erythropoiesis‐stimulating agents in preterm or low birth weight infants" name="citation_title"/> <meta content="Arne Ohlsson&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Sanjay M Aher" name="citation_author"/> <meta content="Neocare Hospital" name="citation_author_institution"/> <meta content="ahersm@googlemail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD004863.pub6" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/02/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004863.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004863.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004863.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anemia, Neonatal [blood, prevention &amp; control]; Enterocolitis, Necrotizing [blood, prevention &amp; control]; Erythropoiesis; Erythropoietin [administration &amp; dosage, blood]; Hematinics [*administration &amp; dosage]; Infant, Low Birth Weight [*blood]; Infant, Premature [*blood]; Randomized Controlled Trials as Topic; Retinopathy of Prematurity [blood, prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004863.pub6&amp;doi=10.1002/14651858.CD004863.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="XwNPMGod";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004863\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004863\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004863.pub6",title:"Early erythropoiesis\\u2010stimulating agents in preterm or low birth weight infants",firstPublishedDate:"Feb 11, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004863.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004863.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004863.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004863.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004863.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004863.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004863.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004863.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004863.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004863.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6165 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004863.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-sec1-0006"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/appendices#CD004863-sec1-0012"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/table_n/CD004863StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/table_n/CD004863StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Early erythropoiesis‐stimulating agents in preterm or low birth weight infants</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Deceased"><a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/information#CD004863-cr-0002">Arne Ohlsson</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004863.pub6/information#CD004863-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Sanjay M Aher</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/information/en#CD004863-sec1-0017">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 February 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004863.pub6">https://doi.org/10.1002/14651858.CD004863.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004863-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004863-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004863-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004863-abs-0002">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004863-abs-0001" lang="en"> <section id="CD004863-abs1-0001"> <h3 class="title" id="CD004863-abs1-0001">Background</h3> <p>Preterm infants have low plasma levels of erythropoietin (EPO), providing a rationale for the use of erythropoiesis‐stimulating agents (ESAs) to prevent or treat anaemia and to provide neuro protection and protection against necrotising enterocolitis (NEC). Darbepoetin (Darbe) and EPO are currently available ESAs. </p> </section> <section id="CD004863-abs1-0002"> <h3 class="title" id="CD004863-abs1-0002">Objectives</h3> <p>To assess the effectiveness and safety of ESAs (erythropoietin (EPO) and/or Darbe) initiated early (before eight days after birth) compared with placebo or no intervention in reducing red blood cell (RBC) transfusions, adverse neurological outcomes, and feeding intolerance including necrotising enterocolitis (NEC) in preterm and/or low birth weight infants. </p> <p><b>Primary objective for studies that primarily investigate the effectiveness and safety of ESAs administered early in reducing red blood cell transfusions:</b> </p> <p>To assess the effectiveness and safety of ESAs initiated early in reducing red blood cell transfusions in preterm infants. </p> <p><b>Secondary objectives:</b> </p> <p>Review authors performed subgroup analyses of low (≤ 500 IU/kg/week) and high (&gt; 500 IU/kg/week) doses of EPO and the amount of iron supplementation provided: none, low (≤ 5 mg/kg/d), and high (&gt; 5 mg/kg/d). </p> <p><b>Primary objective for studies that primarily investigate the neuro protective effectiveness of ESAs:</b> </p> <p>To assess the effectiveness and safety of ESAs initiated early in reducing adverse neurological outcomes in preterm infants. </p> <p><b>Primary objective for studies that primarily investigate the effectiveness of EPO or Darbe administered early in reducing feeding intolerance:</b> </p> <p>To assess the effectiveness and safety of ESAs administered early in reducing feeding intolerance (and NEC) in preterm infants. </p> <p><b>Other secondary objectives:</b> </p> <p>To compare the effectiveness of ESAs in reducing the incidence of adverse events and improving long‐term neurodevelopmental outcomes. </p> </section> <section id="CD004863-abs1-0003"> <h3 class="title" id="CD004863-abs1-0003">Search methods</h3> <p>We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), MEDLINE via PubMed (1966 to 10 March 2017), Embase (1980 to 10 March 2017), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to 10 March 2017). We searched clinical trials databases, conference proceedings, and reference lists of retrieved articles for randomised and quasi‐randomised controlled trials. </p> </section> <section id="CD004863-abs1-0004"> <h3 class="title" id="CD004863-abs1-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised controlled trials of early initiation of EAS treatment versus placebo or no intervention in preterm or low birth weight infants. </p> </section> <section id="CD004863-abs1-0005"> <h3 class="title" id="CD004863-abs1-0005">Data collection and analysis</h3> <p>We used the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and the GRADE approach to assess the quality of evidence. </p> </section> <section id="CD004863-abs1-0006"> <h3 class="title" id="CD004863-abs1-0006">Main results</h3> <p>This updated review includes 34 studies enrolling 3643 infants. All analyses compared ESAs versus a control consisting of placebo or no treatment. </p> <p>Early ESAs reduced the risk of 'use of one or more [red blood cell] RBC transfusions' (typical risk ratio (RR) 0.79, 95% confidence interval (CI) 0.74 to 0.85; typical risk difference (RD) ‐0.14, 95% CI ‐0.18 to ‐0.10; I<sup>2</sup> = 69% for RR and 62% for RD (moderate heterogeneity); number needed to treat for an additional beneficial outcome (NNTB) 7, 95% CI 6 to 10; 19 studies, 1750 infants). The quality of the evidence was low. </p> <p>Necrotising enterocolitis was significantly reduced in the ESA group compared with the placebo group (typical RR 0.69, 95% CI 0.52 to 0.91; typical RD ‐0.03, 95% CI ‐0.05 to ‐0.01; I<sup>2</sup> = 0% for RR and 22% for RD (low heterogeneity); NNTB 33, 95% CI 20 to 100; 15 studies, 2639 infants). The quality of the evidence was moderate. </p> <p>Data show a reduction in 'Any neurodevelopmental impairment at 18 to 22 months' corrected age in the ESA group (typical RR 0.62, 95% CI 0.48 to 0.80; typical RD ‐0.08, 95% CI ‐0.12 to ‐0.04; NNTB 13, 95% CI 8 to 25. I<sup>2</sup> = 76% for RR (high heterogeneity) and 66% for RD (moderate); 4 studies, 1130 infants). The quality of the evidence was low. </p> <p>Results reveal increased scores on the Bayley‐II Mental Development Index (MDI) at 18 to 24 months in the ESA group (weighted mean difference (WMD) 8.22, 95% CI 6.52 to 9.92; I<sup>2</sup> = 97% (high heterogeneity); 3 studies, 981 children). The quality of the evidence was low. </p> <p>The total volume of RBCs transfused per infant was reduced by 7 mL/kg. The number of RBC transfusions per infant was minimally reduced, but the number of donors to whom infants who were transfused were exposed was not significantly reduced. Data show no significant difference in risk of stage ≥ 3 retinopathy of prematurity (ROP) with early EPO (typical RR 1.24, 95% CI 0.81 to 1.90; typical RD 0.01, 95% CI ‐0.02 to 0.04; I<sup>2</sup> = 0% (no heterogeneity) for RR; I<sup>2</sup> = 34% (low heterogeneity) for RD; 8 studies, 1283 infants). Mortality was not affected, but results show significant reductions in the incidence of intraventricular haemorrhage (IVH) and periventricular leukomalacia (PVL). </p> </section> <section id="CD004863-abs1-0007"> <h3 class="title" id="CD004863-abs1-0007">Authors' conclusions</h3> <p>Early administration of ESAs reduces the use of red blood cell (RBC) transfusions, the volume of RBCs transfused, and donor exposure after study entry. Small reductions are likely to be of limited clinical importance. Donor exposure probably is not avoided, given that all but one study included infants who had received RBC transfusions before trial entry. This update found no significant difference in the rate of ROP (stage ≥ 3) for studies that initiated EPO treatment at less than eight days of age, which has been a topic of concern in earlier versions of this review. Early EPO treatment significantly decreased rates of IVH, PVL, and NEC. Neurodevelopmental outcomes at 18 to 22 months and later varied in published studies. Ongoing research should evaluate current clinical practices that will limit donor exposure. Promising but conflicting results related to the neuro protective effect of early EPO require further study. Very different results from the two largest published trials and high heterogeneity in the analyses indicate that we should wait for the results of two ongoing large trials before drawing firm conclusions. Administration of EPO is not currently recommended because limited benefits have been identified to date. Use of darbepoetin requires further study. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004863-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004863-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004863-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004863-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004863-abs-0005">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004863-abs-0004" lang="en"> <h3>Early erythropoiesis‐stimulating agents in preterm or low birth weight infants</h3> <p><b>Review questions:</b> Is early initiation of erythropoietin or darbepoetin (initiated before eight days after birth) effective and safe in reducing red blood cell transfusions among preterm and/or low birth weight infants? Does early initiation of erythropoietin or darbepoetin serve a neuro protective function? Do these agents protect against necrotising enterocolitis? </p> <p><b>Background:</b> In newborn infants, the number of red blood cells in the circulation decreases after birth. In infants born before term, this decrease is exaggerated by frequent withdrawal of blood, which may be necessary to monitor the infant's clinical condition. Therefore, infants born before term are likely to require transfusions of red blood cells. Low levels of erythropoietin (EPO), a substance in the blood that stimulates red blood cell production in preterm infants, provide a rationale for use of EPO to prevent or treat anaemia. EPO can be given 'early' (before the infant reaches eight days of age) to prevent or decrease the use of red blood cell transfusions. Increasing evidence suggests that EPO may protect against neurological damage and damage to the gut. </p> <p><b>Study characteristics:</b> We identified 34 studies that used this approach and enrolled a total of 3643 infants born before term. Studies of variable quality have been conducted in many different countries. </p> <p><b>Key results:</b> Early EPO treatment reduced the numbers of red blood cell transfusions and donor exposures following its use. However, the overall benefit of EPO may not be clinically important, as many of these infants had been exposed to red blood cell transfusions before trial entry. Early treatment with EPO does not alter the risk of death or retinopathy of prematurity and may decrease the risk of neurological damage and damage to the gut. It may also improve long‐term outcomes. </p> <p><b>Quality of evidence:</b> According to GRADE, the quality of the main outcomes ranged from high to low. </p> <p><b>Conclusions:</b> On the basis of our findings, we do not currently recommend routine early use of erythropoietin in preterm infants. Ongoing studies might shed light on the possibility that erythropoietin may reduce risks of adverse neurodevelopmental outcomes and necrotising enterocolitis. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004863-sec1-0007" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004863-sec1-0007"></div> <h3 class="title" id="CD004863-sec1-0008">Implications for practice</h3> <section id="CD004863-sec1-0008"> <p>Early administration of erythropoietin (EPO) reduces the use of one or more red blood cell transfusions, the volume of red blood cells transfused, and the numbers of donors and transfusions the infant is exposed to following study entry (low quality of evidence according to GRADE). Donor exposure probably is not avoidable, as most studies included infants who had received red cell transfusions before trial entry. Although statistically significant, these reductions are of limited clinical importance. For the present, it is important that neonatal intensive care units (NICUs) develop practice guidelines to limit blood losses and donor exposure among neonates. Use of satellite packs and adherence to conservative transfusion guidelines reduce exposure to multiple donors during the hospital stay. The need for red blood cell transfusions is linked to loss of blood associated with sampling for laboratory testing. In the current update of this review, evidence of high quality according to GRADE shows no significant increase in the rate of retinopathy of prematurity (ROP) (stage ≥ 3) with early use of EPO. Increasing evidence suggests that EPO reduces several important adverse outcomes, including intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), and necrotising enterocolitis (NEC) (all with moderate quality of evidence according to GRADE). Early EPO used for neuro protection may reduce neurodevelopmental impairment at 18 to 22 months' corrected age (low quality of evidence according to GRADE) and may increase Bayley‐II Mental Development Index (MDI) scores at 18 to 24 months (low quality of evidence according to GRADE). In view of limited clinical benefit, early administration of EPO outside of randomised controlled trials (RCTs) is not currently recommended. Evidence showing the effectiveness of Darbe is lacking because small samples have been studied and followed. </p> </section> <h3 class="title" id="CD004863-sec1-0009">Implications for research</h3> <section id="CD004863-sec1-0009"> <p>Future research should focus on strategies to minimise red blood cell donor exposure during the first week of life, when the likelihood of the need for red blood cell transfusion is at its peak. Such strategies, which include use of satellite packs in combination with late EPO treatment, may reduce further donor exposure. Currently, trialists have expressed no concern that early EPO exposure increases risk of ROP, but this should be included as an outcome in future trials. Early EPO may improve feeding intolerance and reduce the incidence of NEC; additional studies are needed in both developed and developing countries. Based on our 'Quality of evidence assessments according to GRADE', we have concerns about current evidence for the neuro protective effects of early EPO. Studies of the highest quality showed no significant reduction in adverse outcomes. One study with high risk of bias showed large significant effects of the intervention in favour of early EPO. Two currently ongoing large trials could shed light on these differences. New studies should include long‐term follow‐up. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004863-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004863-sec1-0001"></div> <div class="table" id="CD004863-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Erythropoietin compared with placebo or no treatment for complications of preterm birth ‐ primary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with low birth weight </p> <p><b>Settings:</b> NICU </p> <p><b>Intervention:</b> EPO </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>EPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of 1 or more red blood cell transfusions (low and high doses of EPO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.79 (95% CI 0.74 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1750<br/> (19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about performance bias and detection bias in 10 of the studies. We downgraded the quality of the evidence by 1 step. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 69% and for the typical RD 62% (both moderate quality). We downgraded the quality of the evidence by 1 step. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1750), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot was symmetrical for all larger studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>694 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>522 per 1000<br/> (0 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any neurodevelopmental impairment at 18 to 22 months' corrected age (in children examined)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.62 (95% CI 0.48 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1130</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about performance bias and detection bias in 1 of the studies, the largest (n = 613) (<a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>). This study carried a weight of 48.7% in the analysis. We downgraded the quality of the evidence by 1 step. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 76% (high) and for the typical RD 66% (moderate). We downgraded the quality of the evidence by 1 step. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1130), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: Although only 4 studies were included in the funnel plot, the funnel plot was symmetrical. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/> (71 to 438) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bayley‐II MDI at 18 to 24 months</p> <p>Bayley Scales of Infant Development, Second Edition, yields 2 single age‐standardised composite scores (range 50 to 150): a Mental Development Index (MDI), which measures cognition through sensory perception, knowledge, memory, problem‐solving and early language abilities; and a Psychomotor Development Index (PDI), which assesses fine and gross motor skills. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean Bayley‐II MDI ranged across control groups from 84.1 to 94.5.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean Bayley‐II MDI at 18 to 24 months in the intervention groups was 8.22 higher (95% CI 6.52 to 9.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WMD: 8.22 (95% CI 6.52 to 9.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>981<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: We had concerns about performance bias and detection bias in one of the studies (<a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>). We downgraded the quality of the evidence by 1 step. <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> carried a weight in the analysis of 76.2%. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for the WMD was 97% (high). We downgraded the quality of the evidence by 1 step. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 981), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: As only 3 studies were included, we did not prepare a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Necrotising enterocolitis (stage not reported)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.69 (95% CI 0.52 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2639<br/> (15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about performance bias and detection bias in 6 of the studies, especially for <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>, the only study that showed a significant reduction in NEC. It carried a weight in the analysis of 47.8%. We downgraded the quality of the evidence by 1 step. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 0% and for the typical RD 22% (both low). </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 2639), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000<br/> (0 to 143) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; EPO: erythropoietin; MDI: Mental Development Index; NICU: neonatal intensive care unit; NEC: necrotising enterocolitis; PDI: Psychomotor Development Index; RD: risk difference; RR: risk ratio; WMD: weighted mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004863-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Erythropoietin compared with placebo or no treatment for complications of preterm birth</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with low birth weight </p> <p><b>Settings:</b> NICU </p> <p><b>Intervention:</b> EPO </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>EPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality during initial hospital stay (all causes of mortality)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.89 (95% CI 0.68 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2212<br/> (20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> high </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about bias (lack of blinding) in 10 of the included studies, but the outcome of mortality is not likely to be affected by researchers knowing the treatment assignment. We did not downgrade the quality of evidence on this item. </p> <p>Heterogeneity/Consistency: We noted no heterogeneity (I<sup>2</sup> = 0%). </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (2212), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/> (0 to 172) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Retinopathy of prematurity (stage ≥ 3)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 1.24 (95% CI 0.81 to 1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1283<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> high </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We found no risk of bias in any of the studies, except in the smallest study that enrolled 40 neonates. We did not downgrade the quality of evidence. </p> <p>Heterogeneity/Consistency: We noted no heterogeneity for RR (I<sup>2</sup> = 0%) and low (I<sup>2</sup> = 34%) heterogeneity for RD. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1283), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot, which included 8 studies, was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (0 to 195) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intraventricular haemorrhage (grades III and IV)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.60 (95% CI 0.43 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1460<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias:The intervention was not blinded in the largest study, <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> (n= 743). That study carried a weight of 72.8% in the analysis and was the only individual study that showed a significant reduction in IVH (grades III and IV). We downgraded the quality of the evidence by 1 step. </p> <p>Heterogeneity/Consistency: Heterogeneity was low (I<sup>2</sup> = 45%). </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1460), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot, which included 8 studies, was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000<br/> (0 to 126) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Periventricular leukomalacia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.66 (95% CI 0.48 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1469<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: The intervention was not blinded in the largest study, <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> (n = 743). That study carried a weight of 89.2% in the analysis and was the only individual study that showed a significant reduction in PVL. We downgraded the quality of the evidence by 1 step. <br/> Heterogeneity/Consistency: We noted no heterogeneity (I<sup>2</sup> = 5%). </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1469), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot, which included 6 studies, was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000<br/> (0 to 150) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Survivors at discharge from hospital without severe IVH, PVL, ROP</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 1.00 (95% CI 0.93 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>443<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> high </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We noted low risk of bias.</p> <p>Heterogeneity/Consistency: N/A, as only 1 study.</p> <p>Directness of evidence: The study was conducted in the target population.</p> <p>Precision: Because of the relatively large sample size (n = 443), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: As only 1 study was included, we did not develop a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>855 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>856 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to achieve full enteral feeding (days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean time to achieve full enteral feeding was 16.3 days (SD 5.3) in the control group.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean time to achieve full enteral feeding in the intervention groups was 2.90 days shorter. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: ‐2.90 (95% CI ‐5.77 to ‐0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: We had concerns about blinding of the intervention and outcome assessments. We downgraded the quality of evidence by 1 step. </p> <p>Heterogeneity/Consistency: N/A, as only 1 study.</p> <p>Directness of evidence: The study was conducted in the target population.</p> <p>Precision: Because of the small sample size (n = 50), the 95% CI around the point estimate was wide. </p> <p>Presence of publication bias: As only 1 study was included, we did not prepare a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; EPO: erythropoietin; IVH: intraventricular haemorrhage; MD: mean difference; N/A: not applicable; NICU: neonatal intensive care unit; PVL: periventricular leukomalacia; RD: risk difference; ROP: retinopathy of prematurity; RR: risk ratio; SD: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004863-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Erythropoietin compared with placebo or no treatment for complications of preterm birth ‐ long‐term outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with low birth weight </p> <p><b>Settings:</b> NICU </p> <p><b>Intervention:</b> EPO </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>EPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cerebral palsy at 18 to 24 months' corrected age</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.72 (95% CI 0.46 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1172<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> high </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: Low risk of bias. All assessors of long‐term outcomes were blinded in all trials. In <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>, treatment allocation was known to caregivers and probably parents, who could have possibly disclosed that information to assessors at long‐term follow‐up. We did not downgrade the quality of the evidence. </p> <p>Heterogeneity/Consistency: Heterogeneity was low for this outcome (I<sup>2</sup> = 48%). We did not downgraded the evidence. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1172), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: We included 6 studies in the analysis; we did prepare a funnel plot, which was symmetrical. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<br/> (0 to 285) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; EPO: erythropoietin; NICU: neonatal intensive care unit; RR: risk ratio; WMD: weighted mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD004863-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Darbe or EPO (ESA) compared with sham injection for neuro protection ‐ long‐term outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates born preterm with low birth weight </p> <p><b>Settings:</b> NICU </p> <p><b>Intervention:</b> Darbe or EPO (ESA) </p> <p><b>Comparison:</b> sham injection </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sham injection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ESA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BSID‐III composite cognitive scores at 18 to 22 months</p> <p>The Bayley‐III has 3 main sub tests: the Cognitive Scale, which includes items such as attention to familiar and unfamiliar objects, looking for a fallen object, and pretend play; the Language Scale, which taps understanding and expression of language, for example, recognising objects and people, following directions, and naming objects and pictures; and the Motor Scale, which assesses gross and fine motor skills such as grasping, sitting, stacking blocks, and climbing stairs. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean BSID‐III in the control group was 88.7 units (SD 13.5).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean BSID‐III in the intervention group was 7.80 units higher.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 7.80 (95% CI 1.65 to 13.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: Risk of bias was low, but the sample followed was small. We did not reduce the quality of evidence. </p> <p>Heterogeneity/Consistency: Only 1 study was included, so the test for heterogeneity was N/A. </p> <p>Directness of evidence: The study was conducted in the target population.</p> <p>Precision: Because of the small sample size (n = 80), the point estimate had a wide 95% CI. We downgraded the quality of evidence by 1 step. </p> <p>Presence of publication bias: N/A, as only 1 study was included.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WPPSI‐III FSIQ at 3.5 to 4 years of age</p> <p>Composite scores have a mean of 100 and a standard deviation of 15.</p> <p>Average is 90 to 109.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean WPPSI‐III FSIQ in the control group was 79.2 units (SD 18,5).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean WPPSI‐III FSIQ in the intervention group was 11.90 units higher.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 11.90 (95% CI 0.76 to 23.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: Risk of bias was low, but the sample followed was even smaller than at 18 to 22 months of age (n = 53). We did reduce the quality of evidence by 1 step. </p> <p>Heterogeneity/Consistency: Only 1 study was included, so the test for heterogeneity was N/A. </p> <p>Directness of evidence: The study was conducted in the target population.</p> <p>Precision: Because of the small sample size (n = 53), the point estimate had a large 95% CI. We downgraded the quality of evidence by 1 step. </p> <p>Presence of publication bias: N/A, as only 1 study was included,</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> BSID‐III: Bayley Scales of Infant Development ‐ Third Edition; CI: confidence interval; EPO: erythropoietin; ESA: erythropoiesis‐stimulating agent; MD: mean difference; N/A: not applicable; NICU: neonatal intensive care unit; RR: risk ratio; SD: standard deviation; WPPSI‐III FSIQ: Wechsler Preschool and Primary Scale of Intelligence ‐ Third Edition. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004863-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004863-sec1-0002"></div> <section id="CD004863-sec2-0001"> <h3 class="title" id="CD004863-sec2-0001">Description of the condition</h3> <p>After birth, the haemoglobin concentration of newborn infants normally falls to minimal levels of 11 g/dL in term infants by 8 to 12 weeks of age, and to 7.0 to 10.0 g/dL in preterm infants by 6 weeks of age (<a href="./references#CD004863-bbs2-0105" title="StockmanJA3rd , OskiFA . Physiological anaemia of infancy and the anaemia of prematurity. Clinics in Haematology1978;7(1):3‐18. [PUBMED: 657601] ">Stockman 1978</a>). This process is called 'physiological anaemia of infancy' (<a href="./references#CD004863-bbs2-0107" title="StraussRG . Current issues in neonatal transfusions. Vox Sanguinis1986;51(1):1‐9. [PUBMED: 3526725] ">Strauss 1986</a>). In very low birth weight (VLBW) infants, hematocrit falls to approximately 24% in infants weighing 1.0 to 1.5 kg, and to 21% in infants weighing less than 1.0 kg, at birth (<a href="./references#CD004863-bbs2-0106" title="StockmanJA3rd . Anemia of prematurity. Current concepts in the issue of when to transfuse. Pediatric Clinics of North America1986;33(1):111‐28. [PUBMED: 3513096] ">Stockman 1986</a>). In extremely low birth weight (ELBW) infants, this decline in hematocrit to levels below 7.0 to 10.0 g/dL is called 'anaemia of prematurity' and is associated with clinical findings such as pallor, poor weight gain, decreased activity, tachypnoea, tachycardia, and feeding problems that prompt red blood cell (RBC) transfusions. Repeated blood draws, shortened RBC survival, rapid growth, and attenuated erythropoietin (EPO) response all contribute to anaemia of prematurity. To our knowledge, the diagnostic accuracy of different clinical signs and laboratory findings has not been studied (<a href="./references#CD004863-bbs2-0070" title="CohenA , MannoC . Transfusion practices in infants receiving assisted ventilation. Clinics in Perinatology1998;25(1):97‐111. [PUBMED: 9523077] ">Cohen 1998</a>). It is still unknown how low hematocrit levels can fall before clinical signs of anaemia of prematurity occur, and what minimal hematocrit level is acceptable in infants requiring supplemental oxygen (<a href="./references#CD004863-bbs2-0095" title="OhlsRK . Erythropoietin treatment in extremely low birth weight infants: blood in versus blood out. Journal of Pediatrics2002;141(1):3‐6. [DOI: 10.1067/mpd.2002.125853; PUBMED: 12091842] ">Ohls 2002</a>). A rational guide for transfusion therapy for all anaemic neonates, whether ventilated or not, is not available (<a href="./references#CD004863-bbs2-0070" title="CohenA , MannoC . Transfusion practices in infants receiving assisted ventilation. Clinics in Perinatology1998;25(1):97‐111. [PUBMED: 9523077] ">Cohen 1998</a>). Nevertheless, 'top‐up' transfusions are frequently used to treat low haemoglobin or low hematocrit levels. As many as 80% of VLBW infants and 95% of ELBW infants receive blood transfusions during hospitalisation (<a href="./references#CD004863-bbs2-0112" title="WidnessJA , SewardVJ , KromerIJ , BurmeiserLF , BellEF , StraussRG . Changing patterns of red blood cell transfusion in very low birth weight infants. Journal of Pediatrics1996;129(5):680‐7. [PUBMED: 8917234] ">Widness 1996</a>). A Cochrane review titled 'Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants' concludes, "The use of restrictive as compared to liberal haemoglobin thresholds in infants of very low birth weight results in modest reductions in exposure to transfusion and in haemoglobin levels. Restrictive practice does not appear to have a significant impact on death or major morbidities at first hospital discharge or at follow‐up" (<a href="./references#CD004863-bbs2-0111" title="WhyteR , KirpalaniH . Low versus high haemoglobin concentration threshold for blood transfusion for preventing morbidity and mortality in very low birth weight infants. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD000512.pub2] ">Whyte 2011</a>). </p> <p>Preterm birth and hypoxic Ischaemic encephalopathy (HIE) are conditions that frequently result in death or mental or physical impairment among survivors (<a href="./references#CD004863-bbs2-0084" title="JuulS . Neuroprotective role of erythropoietin in neonates. Journal of Maternal‐Fetal &amp; Neonatal Medicine2012;25(Suppl 4):105‐7. [DOI: 10.3109/14767058.2012.715025; PUBMED: 22958035] ">Juul 2012</a>). Several reviews examining the neuro protective and neurodegenerative effects of EPO/darbepoetin (Darbe) in the brain have been published, and evidence of its effectiveness is growing (<a href="./references#CD004863-bbs2-0090" title="LimperopoulosC . Neuroprotective effects of erythropoietin in preterm infants. Nature Reviews. Neurology2010;6(6):301‐2. [DOI: 10.1038/nrneurol.2010.66; PUBMED: 20531428] ">Limperopoulos 2010</a>; <a href="./references#CD004863-bbs2-0089" title="KumralA , TűzűnF , OnerMG , GençS , DumanN , ÖzkanH . Erythropoietin in neonatal brain protection: the past, the present and the future. Brain &amp; Development2011;33(8):632‐43. [DOI: 10.1016/j.braindev.2010.10.014; PUBMED: 21109375] ">Kumral 2011</a>; <a href="./references#CD004863-bbs2-0084" title="JuulS . Neuroprotective role of erythropoietin in neonates. Journal of Maternal‐Fetal &amp; Neonatal Medicine2012;25(Suppl 4):105‐7. [DOI: 10.3109/14767058.2012.715025; PUBMED: 22958035] ">Juul 2012</a>; <a href="./references#CD004863-bbs2-0091" title="MessierAM , OhlsRK . Neuroprotective effects of erythropoiesis‐stimulating agents in term and preterm neonates. Current Opinion in Pediatrics2014;26(2):139‐45. [DOI: 10.1097/MOP.0000000000000077; PUBMED: 24535496] ">Messier 2014</a>; <a href="./references#CD004863-bbs2-0098" title="RangarajanV , JuulSE . Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection. Pediatric Neurology2014;51(4):481‐8. [DOI: 10.1016/j.pediatrneurol.2014.06.008; PUBMED: 25266611] ">Rangarajan 2014</a>; <a href="./references#CD004863-bbs2-0097" title="PatelS , OhlsRK . Darbepoetin administration in term and preterm neonates. Clinics in Perinatology2015;42(3):557‐66. [DOI: 10.1016/j.clp.2015.04.016; PUBMED: 26250917] ">Patel 2015</a>). </p> <p>The intestinal barrier is maintained by tight junctions formed between adjacent intestinal epithelial cells. Disruption of tight junctions and loss of barrier function are associated with various gastrointestinal diseases, including neonatal necrotising enterocolitis (NEC) ‐ the leading cause of death from gastrointestinal disease in preterm infants (<a href="./references#CD004863-bbs2-0104" title="ShiouSR , YuY , ChenS , CiancioMJ , PetrofEO , SunJ , et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. Journal of Biological Chemistry2011;286(14):12123‐32. [DOI: 10.1074/jbc.M110.154625; PUBMED: 21262973] ">Shiou 2011</a>). </p> </section> <section id="CD004863-sec2-0002"> <h3 class="title" id="CD004863-sec2-0002">Description of the intervention</h3> <p>The primary goal of EPO therapy is to reduce the number of transfusions. Most transfusions are given during the first three to four weeks of life. The larger or stable preterm infants, who respond best to EPO, receive few transfusions. ELBW infants, who are sick and have the greatest need for RBC transfusions shortly after birth, have not consistently responded to EPO. This suggests that EPO is a more effective erythropoietic stimulator in more mature neonates. ELBW neonates are more likely to need transfusions even if their erythropoiesis is stimulated by EPO (<a href="./references#CD004863-bbs2-0088" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life, among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). In addition, ELBW neonates have a smaller blood volume, and the relatively larger phlebotomy volumes that are required during hospital stay often necessitate 'early' transfusions. In contrast, 'late' transfusions more often are given because of anaemia of prematurity (<a href="./references#CD004863-bbs2-0077" title='GarciaMG , HutsonAD , ChristensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a>). Most preterm infants who require blood transfusions receive their first transfusion in the first two weeks of life (<a href="./references#CD004863-bbs2-0115" title="ZipurskyA . Erythropoietin therapy for premature infants: cost without benefit?. Pediatric Research2000;48(2):136. [DOI: 10.1203/00006450‐200008000‐00002; PUBMED: 10926284] ">Zipursky 2000</a>). Reducing the number of RBC transfusions reduces the risk of transmission of viral infections and may reduce costs. Frequent RBC transfusions may be associated with retinopathy of prematurity (ROP) (<a href="./references#CD004863-bbs2-0079" title="HesseL , EberlW , SchlaudM , PoetsCF . Blood transfusion. Iron load and retinopathy of prematurity. European Journal of Pediatrics1997;156(6):465‐70. [PUBMED: 9208245] ">Hesse 1997</a>) and bronchopulmonary dysplasia (BPD). </p> <p>Preterm infants need iron for erythropoiesis. As neonatal blood volume expands with rapid growth, infants produce large amounts of haemoglobin. Several studies have observed a decrease in serum ferritin concentration during EPO treatment ‐ an indication of iron deficiency (<a href="./references#CD004863-bbs2-0075" title="FinchCA . Erythropoiesis, erythropoietin and iron. Blood1982;60:1241‐6. [PUBMED: 6753967] ">Finch 1982</a>). Use of higher, more effective doses of EPO might be expected to increase iron demand and risk of iron deficiency. Iron supplementation during EPO treatment has been observed to reduce the risk of development of iron deficiency (<a href="./references#CD004863-bbs2-0102" title="ShannonKM . Recombinant human erythropoietin in neonatal anemia. Clinics in Perinatology1995;22(3):627‐40. [PUBMED: 8521685] ">Shannon 1995a</a>). Iron doses are given to EPO‐treated infants at dosages between 1 mg/kg/d and 10 mg/kg/d (<a href="./references#CD004863-bbs2-0088" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life, among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). </p> </section> <section id="CD004863-sec2-0003"> <h3 class="title" id="CD004863-sec2-0003">How the intervention might work</h3> <p>EPO, with the addition of iron, effectively stimulates erythropoiesis. Plasma EPO levels in neonates are lower than those in older children and adults. Brown and colleagues reported that at between 2 and 30 days of life, the mean EPO concentration was 10 mIU/mL as compared with 15 mIU/mL in concurrently studied adults (<a href="./references#CD004863-bbs2-0067" title="BrownMS , PhibbsRH , GarciaJF , DallmanPR . Postnatal changes in erythropoietin levels in untransfused premature infants. Journal of Pediatrics1983;103(4):612‐7. [PUBMED: 6194281] ">Brown 1983</a>). A low plasma EPO level is an important reason that nadir hematocrit values of preterm infants are lower than those of term infants (<a href="./references#CD004863-bbs2-0071" title="DallmanPR . Anemia of prematurity. Annual Review of Medicine1981;32:143‐60. [DOI: 10.1146/annurev.me.32.020181.001043; PUBMED: 7013658] ">Dallman 1981</a>; <a href="./references#CD004863-bbs2-0106" title="StockmanJA3rd . Anemia of prematurity. Current concepts in the issue of when to transfuse. Pediatric Clinics of North America1986;33(1):111‐28. [PUBMED: 3513096] ">Stockman 1986</a>). Low plasma EPO levels provide a rationale for use of EPO in prevention or treatment of anaemia of prematurity. Studies in newborn monkeys and sheep have demonstrated that neonates have a large volume of distribution and more rapid elimination of EPO, necessitating the use of higher doses than those required for adults. A systematic review of EPO administration in VLBW infants noted a wide range of doses used ‐ from 90 to 1400 IU/kg/week (<a href="./references#CD004863-bbs2-0088" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life, among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). Side effects following EPO use in adults include hypertension, bone pain, rash, and, rarely, seizures. Only transient neutropenia has been reported in neonates (<a href="./references#CD004863-bbs2-0094" title="OhlsRK . The use of erythropoietin in neonates. Clinics in Perinatology2000;27(3):681‐96. [PUBMED: 10986635] ">Ohls 2000</a>). </p> <p>"Mechanisms of Epo neuro protection include receptor‐mediated, cell‐specific effects that occur both early and late in the healing process, and non‐specific effects that also modulate the response to injury. EPO has anti‐inflammatory, anti‐excitotoxic, antioxidant and anti‐apoptotic effects on neurons and oligodendrocytes, and promotes neurogenesis and angiogenesis, which are essential for injury repair and normal neurodevelopment. EPO effects are dose dependent, and multiple doses are more effective than single doses" (<a href="./references#CD004863-bbs2-0084" title="JuulS . Neuroprotective role of erythropoietin in neonates. Journal of Maternal‐Fetal &amp; Neonatal Medicine2012;25(Suppl 4):105‐7. [DOI: 10.3109/14767058.2012.715025; PUBMED: 22958035] ">Juul 2012</a>). </p> <p>Human milk is protective against NEC, and the human milk factor EPO has been shown to protect endothelial cell‐cell barriers (<a href="./references#CD004863-bbs2-0104" title="ShiouSR , YuY , ChenS , CiancioMJ , PetrofEO , SunJ , et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. Journal of Biological Chemistry2011;286(14):12123‐32. [DOI: 10.1074/jbc.M110.154625; PUBMED: 21262973] ">Shiou 2011</a>). In a rat NEC model, oral administration of EPO statistically significantly lowered the incidence of NEC from 45% to 23% (<a href="./references#CD004863-bbs2-0104" title="ShiouSR , YuY , ChenS , CiancioMJ , PetrofEO , SunJ , et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. Journal of Biological Chemistry2011;286(14):12123‐32. [DOI: 10.1074/jbc.M110.154625; PUBMED: 21262973] ">Shiou 2011</a>). </p> </section> <section id="CD004863-sec2-0004"> <h3 class="title" id="CD004863-sec2-0004">Why it is important to do this review</h3> <p>The efficacy of EPO in anaemia of prematurity has been systematically reviewed (<a href="./references#CD004863-bbs2-0108" title="VamvakasEC , StraussRG . Meta‐analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion2001;41(3):406‐15. [PUBMED: 11274599] ">Vamvakas 2001</a>; <a href="./references#CD004863-bbs2-0077" title='GarciaMG , HutsonAD , ChristensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a>; <a href="./references#CD004863-bbs2-0088" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life, among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). Vamvakas and coworkers concluded that variation in results of EPO studies is extreme, and stated that until this variation is better understood, it is too early to recommend EPO as standard treatment for anaemia of prematurity (<a href="./references#CD004863-bbs2-0108" title="VamvakasEC , StraussRG . Meta‐analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion2001;41(3):406‐15. [PUBMED: 11274599] ">Vamvakas 2001</a>). <a href="./references#CD004863-bbs2-0077" title='GarciaMG , HutsonAD , ChristensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a> concluded that administering EPO to VLBW neonates can result in a modest reduction in late erythrocyte transfusions, and that this effect is dependent on the dosage of EPO used. <a href="./references#CD004863-bbs2-0088" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life, among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a> concluded that if EPO is begun during the first week of life, a moderate reduction can be expected in the proportion of VLBW neonates transfused. This reduction is less significant for early than for late transfusion. </p> <p>EPO has been found to have important non‐hematopoietic functions in the brain and other organs during development (<a href="./references#CD004863-bbs2-0083" title="JuulS . Erythropoietin in the central nervous system, and its use to prevent hypoxic‐ischemic brain damage. Acta Paediatrica Supplement2002;91(438):36‐42. [PUBMED: 12477263] ">Juul 2002</a>). Administration of EPO could potentially have a neuro protective effect in preterm infants, especially among those with perinatal asphyxia (<a href="./references#CD004863-bbs2-0072" title="DameC , JuulSE , ChristensenRD . The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biology of the Neonate2001;79(3‐4):228‐35. [DOI: 47097; PUBMED: 11275657] ">Dame 2001</a>; <a href="./references#CD004863-bbs2-0083" title="JuulS . Erythropoietin in the central nervous system, and its use to prevent hypoxic‐ischemic brain damage. Acta Paediatrica Supplement2002;91(438):36‐42. [PUBMED: 12477263] ">Juul 2002</a>). This aspect of EPO use in neonates with asphyxia will be systematically reviewed separately. In this update of the review, we include administration of EPO/Darbe early in life as neuro protective agents and for protection against NEC. </p> <p>We therefore performed a series of Cochrane reviews on the use of EPO in preterm infants, including "Early erythropoietin (EPO) for preventing red blood cell transfusion in preterm or low birth weight infants" (starting in infants ≤ 7 days of age; &lt; 8 days of age), versus placebo or no treatment (this review), "Late EPO (starting in infants &gt; 7 days of age; ≥ 8 days of age) versus placebo/no treatment" (<a href="./references#CD004863-bbs2-0059" title="AherSM , OhlssonA . Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004868.pub2] ">Aher 2006a</a>) and "Early versus late EPO" (as per previous definitions) (<a href="./references#CD004863-bbs2-0060" title="AherSM , OhlssonA . Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD004865.pub2] ">Aher 2006b</a>). These reviews were all updated in 2009 and 2012 (<a href="./references#CD004863-bbs2-0061" title="AherSM , OhlssonA . Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD004868.pub3] ">Aher 2012</a>; <a href="./references#CD004863-bbs2-0062" title="AherSM , OhlssonA . Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD004865.pub2] ">Aher 2012a</a>; <a href="./references#CD004863-bbs2-0117" title="OhlssonA , AherSM . Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD004863.pub3] ">Ohlsson 2012</a>). We chose the cutoff of ≤ 7 days of age for early and &gt; 7 days of age for late treatment with EPO, although somewhat arbitrary, on the basis of previously published meta‐analyses (<a href="./references#CD004863-bbs2-0077" title='GarciaMG , HutsonAD , ChristensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a>; <a href="./references#CD004863-bbs2-0088" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life, among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>), to allow us to compare results of our reviews versus results of previously published reviews. </p> <p>This review concerns early administration of EPO (starting in infants ≤ 7 days of age). The main rationale for such EPO therapy is to reduce exposure of neonates to red blood cell transfusion and its associated risks. Between 60% and 100% of preterm infants are transfused before three weeks of age (<a href="./references#CD004863-bbs2-0102" title="ShannonKM . Recombinant human erythropoietin in neonatal anemia. Clinics in Perinatology1995;22(3):627‐40. [PUBMED: 8521685] ">Shannon 1995a</a>; <a href="./references#CD004863-bbs2-0082" title="JuulSE . Erythropoietin in the neonate. Current Problems in Pediatrics1999;29(5):133‐49. [PUBMED: 10331138] ">Juul 1999</a>; <a href="./references#CD004863-bbs2-0115" title="ZipurskyA . Erythropoietin therapy for premature infants: cost without benefit?. Pediatric Research2000;48(2):136. [DOI: 10.1203/00006450‐200008000‐00002; PUBMED: 10926284] ">Zipursky 2000</a>), and EPO administered during this period might decrease the need for RBC transfusions (<a href="./references#CD004863-bbs2-0068" title="BrownMS , BermanER , LuckeyD . Prediction of the need for transfusion during anemia of prematurity. Journal of Pediatrics1990;116(5):773‐8. ">Brown 1990</a>; <a href="./references#CD004863-bbs2-0088" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life, among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). Several studies have concentrated on the effectiveness of EPO, beginning in the first week of life, in reducing or eliminating these 'early' transfusions. We conducted a systematic review to evaluate all available studies in which investigators started EPO treatment during the first week of life to assess its effect on erythrocyte transfusions. For this update, we include early use of EPO for neuro protection and for prevention of NEC. </p> <p>A slightly modified long‐acting version of EPO, darbepoetin alfa (Darbe), has been introduced (<a href="./references#CD004863-bbs2-0074" title="EgrieJC , BrowneJK . Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer2001;84(Suppl 1):3‐10. [DOI: 10.1054/bjoc.2001.1746; PUBMED: 11308268] ">Egrie 2001</a>). Darbepoetin was created by modifying five amino acids of the original EPO protein to generate two additional carbohydrate‐binding sites, thereby significantly increasing circulating half‐life and effectiveness. Compared with EPO, darbepoetin has an approximately three‐fold longer serum half‐life and greater in vivo potency, and can be administered less frequently to obtain the same biological response. A single subcutaneous dose of Darbe has been shown to accelerate erythropoiesis in preterm infants (<a href="./references#CD004863-bbs2-0110" title="WarwoodTL , OhlsRK , WiedmeierSE , LambertDK , JonesC , ScoffieldSH , et al. Single‐dose darbepoetin administration to anemic preterm neonates. Journal of Perinatology2005;25(11):725‐30. [DOI: 10.1038/sj.jp.7211387; PUBMED: 16151471] ">Warwood 2005</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004863-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004863-sec1-0003"></div> <p>To assess the effectiveness and safety of erythropoiesis‐stimulating agents (ESAs) (erythropoietin (EPO) and/or Darbe) initiated early (before eight days after birth) compared with placebo or no intervention in reducing red blood cell (RBC) transfusions, adverse neurological outcomes, and feeding intolerance and necrotising enterocolitis (NEC) in preterm and/or low birth weight infants. </p> <section id="CD004863-sec2-0005"> <h3 class="title" id="CD004863-sec2-0005">Primary objective for studies that primarily investigate the effectiveness and safety of EPO or Darbe administered early in reducing red blood cell transfusions </h3> <p>To assess the effectiveness and safety of EPO or Darbe initiated early (before eight days after birth) in reducing red blood cell transfusions in preterm and/or low birth weight infants. </p> </section> <section id="CD004863-sec2-0006"> <h3 class="title" id="CD004863-sec2-0006">Secondary objectives</h3> <p>Review authors performed subgroup analyses of low (≤ 500 IU/kg/week) and high (&gt; 500 IU/kg/week) doses of EPO and the amount of iron supplementation provided: none, low (≤ 5 mg/kg/d), and high (&gt; 5 mg/kg/d). </p> </section> <section id="CD004863-sec2-0007"> <h3 class="title" id="CD004863-sec2-0007">Primary objective for studies that primarily investigate the neuro protective effectiveness of EPO or Darbe </h3> <p>To assess the effectiveness and safety of EPO or Darbe initiated early (before eight days after birth) in reducing adverse neurological outcomes in preterm and/or low birth weight infants. </p> </section> <section id="CD004863-sec2-0008"> <h3 class="title" id="CD004863-sec2-0008">Primary objective for studies that primarily investigate the effectiveness of EPO or Darbe administered early in reducing feeding intolerance </h3> <p>To assess the effectiveness and safety of EPO or Darbe administered early (before eight days after birth) in reducing feeding intolerance (and NEC) in preterm and/or low birth weight infants. </p> </section> <section id="CD004863-sec2-0009"> <h3 class="title" id="CD004863-sec2-0009">Other secondary objectives</h3> <p>To compare the effectiveness of ESAs in reducing the incidence of adverse events and improving long‐term neurodevelopmental outcomes. </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004863-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004863-sec1-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004863-sec1-0021">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004863-sec1-0004"></div> <section id="CD004863-sec2-0010"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004863-sec3-0001"> <h4 class="title">Types of studies</h4> <p>Randomised and quasi‐randomised controlled trials.</p> </section> <section id="CD004863-sec3-0002"> <h4 class="title">Types of participants</h4> <p>Preterm (&lt; 37 weeks' gestation) and/or low birth weight (&lt; 2500 grams) neonates at less than eight days of age. </p> </section> <section id="CD004863-sec3-0003"> <h4 class="title">Types of interventions</h4> <p>EPO initiated early (before eight days of age, using any dose, route, or duration of treatment) versus placebo or no intervention. </p> <p>For the update in 2013, we included studies that used Darbe, a novel erythropoiesis‐stimulating agent (ESA) (<a href="./references#CD004863-bbs2-0074" title="EgrieJC , BrowneJK . Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer2001;84(Suppl 1):3‐10. [DOI: 10.1054/bjoc.2001.1746; PUBMED: 11308268] ">Egrie 2001</a>; <a href="./references#CD004863-bbs2-0110" title="WarwoodTL , OhlsRK , WiedmeierSE , LambertDK , JonesC , ScoffieldSH , et al. Single‐dose darbepoetin administration to anemic preterm neonates. Journal of Perinatology2005;25(11):725‐30. [DOI: 10.1038/sj.jp.7211387; PUBMED: 16151471] ">Warwood 2005</a>). We kept analyses for EPO and Darbe separate, and we reported on studies that combined EPO and Darbe in combined analyses of ESAs. </p> <p>For the update in 2017, we included studies that were designed to study the effectiveness of EPO/Darbe administered for neuro protection and for improved feeding intolerance. We included short‐term outcomes in the same analyses, irrespective of the primary objective of the study. </p> </section> <section id="CD004863-sec3-0004"> <h4 class="title">Types of outcome measures</h4> <section id="CD004863-sec4-0001"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD004863-lst1-0001"> <li> <p>Proportion of infants exposed to one or more red blood cell (RBC) transfusions</p> </li> <li> <p>Necrotising enterocolitis (NEC) (Bell's stage II or higher, or stage not reported)</p> </li> <li> <p>Any neurodevelopmental impairment at 18 to 22 months' corrected age (in children examined)</p> </li> <li> <p>Bayley‐II Mental Development Index (MDI) at 18 to 24 months' corrected age</p> </li> </ul> </p> </section> <section id="CD004863-sec4-0002"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD004863-lst1-0002"> <li> <p>Total volume (mL/kg) of blood transfused per infant</p> </li> <li> <p>Number of transfusions per infant</p> </li> <li> <p>Number of donors to whom the infant was exposed</p> </li> <li> <p>Mortality during initial hospital stay (all causes of mortality)</p> </li> <li> <p>Retinopathy of prematurity (ROP) (any stage and stage ≥ 3)</p> </li> <li> <p>Proven sepsis (clinical symptoms, signs of sepsis, and positive blood culture for bacteria or fungi) </p> </li> <li> <p>Intraventricular haemorrhage (IVH), all grades (we included in this group results from studies that did not define the grade) and grades III and IV </p> </li> <li> <p>Periventricular leukomalacia (PVL), cystic changes in periventricular areas (Note: For this updated review, we included persistent increased echogenicity in this outcome) </p> </li> <li> <p>Length of hospital stay (days)</p> </li> <li> <p>Bronchopulmonary dysplasia (BPD) (supplementary oxygen at 28 days of age or at 36 weeks' postmenstrual age (PMA) with or without compatible X‐ray; we included an additional group in which age at BPD was not stated) </p> </li> <li> <p>Neutropenia</p> </li> <li> <p>Hypertension (not a prespecified outcome)</p> </li> <li> <p>Long‐term outcomes assessed at any age at or beyond 12 months by a validated cognitive, motor, language, or behavioural, school, or a social interaction adaptation test (Note: We reported results of Bayley Scales of Infant Development (BSID) versions II and III separately) </p> </li> <li> <p>Cerebral palsy</p> </li> <li> <p>Post hoc analysis: any side effects reported by trial investigators (it is not possible to predict every side effect that can occur with a certain intervention; however, it is important that 'new side effects' are reported) </p> </li> </ul> </p> </section> </section> </section> <section id="CD004863-sec2-0011"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the standard search method of the Cochrane Neonatal Review Group.</p> <section id="CD004863-sec3-0005"> <h4 class="title">Electronic searches</h4> <p>We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see <a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">the Cochrane Neonatal search strategy for specialized register</a>). </p> <p>For the 2017 update, we conducted a comprehensive search that included the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2) in the Cochrane Library; MEDLINE via PubMed (1966 to 10 March 2017); Embase (1980 to 10 March 2017); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to 10 March 2017), using the following search terms: (Erythropoietin OR rhuepo OR rhepo OR darbepoetin), plus database‐specific limiters for RCTs and neonates (see <a href="./appendices#CD004863-sec2-0021">Appendix 1</a> for full search strategies for each database). We did not apply language restrictions. The scope of this review has been broadened to include darbepoetin as an intervention and neuro protection as an outcome; therefore, we ran this search in all databases without date limits. </p> <p>We searched clinical trials registries for ongoing or recently completed trials (<a href="https://www.clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; the International Trials Registry and Platform of the World Health Organization (<a href="http://www.whoint/ictrp/search/en/" target="_blank">www.whoint/ictrp/search/en/</a>); and <a href="http://www.isrctn.com/" target="_blank">the ISRCTN Registry</a>). </p> <p>See <a href="./appendices#CD004863-sec2-0022">Appendix 2</a> for previous search strategies. </p> </section> <section id="CD004863-sec3-0006"> <h4 class="title">Searching other resources</h4> <p>We performed manual searches of bibliographies and personal files. We applied no language restrictions. We handsearched abstracts published from the Pediatric Academic Societies' Meetings and the European Society of Pediatric Research Meetings (published in <i>Pediatric Research</i>) from 1980 to April 2005. </p> <p>For this update in 2017, in April 2017 we electronically searched the Pediatric Academic Societies' Annual Meetings from 2000 to 2017 (Abstracts2View™). </p> </section> </section> <section id="CD004863-sec2-0012"> <h3 class="title" id="CD004863-sec2-0012">Data collection and analysis</h3> <p>We used the standard review methods of the Cochrane Neonatal Review Group to assess the methodological quality of studies. We used the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1 (<a href="./references#CD004863-bbs2-0081" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <section id="CD004863-sec3-0007"> <h4 class="title">Selection of studies</h4> <p>The two review authors (AO, SMA) assessed all abstracts and published studies identified as potentially relevant by the literature search for inclusion in the review. For studies identified as abstracts, we contacted the primary authors, when possible, to obtain further information if the full publication was not available. </p> </section> <section id="CD004863-sec3-0008"> <h4 class="title">Data extraction and management</h4> <p>For the original version of this review, both review authors extracted data separately and recorded data on a data abstraction form. We compared information and resolved differences by consensus. One review author (AO) entered data into RevMan (<a href="./references#CD004863-bbs2-0099" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>); the other (SA) cross‐checked the printout against his own data abstraction forms and corrected errors. One review author (AO) conducted the updates in 2009 and 2012. Both review authors (AO, SMA) performed the updates in 2013 and 2017. </p> </section> <section id="CD004863-sec3-0009"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AO, SMA) independently assessed risk of bias (low, high, or unclear) of all included trials using the Cochrane ‘Risk of bias’ tool (<a href="./references#CD004863-bbs2-0081" title="HigginsJP , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) for the following domains. </p> <p> <ul id="CD004863-lst1-0003"> <li> <p>Sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Any other bias.</p> </li> </ul> </p> <p>We resolved disagreements by discussion or by consultation with a third assessor. See <a href="./appendices#CD004863-sec2-0023">Appendix 3</a> for a more detailed description of risk of bias for each domain.  </p> </section> <section id="CD004863-sec3-0010"> <h4 class="title">Measures of treatment effect</h4> <p>We performed statistical analyses using Review Manager software (<a href="./references#CD004863-bbs2-0099" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We analysed categorical data using typical risk ratio (RR), typical risk difference (RD), and number needed to treat for an additional beneficial (NNTB) or harmful outcome (NNTH). We analysed continuous data using weighted mean difference (WMD) and reported the 95% confidence interval (CI) on all estimates. </p> </section> <section id="CD004863-sec3-0011"> <h4 class="title">Unit of analysis issues</h4> <p>In all studies, the individual infant was the unit of analysis.</p> </section> <section id="CD004863-sec3-0012"> <h4 class="title">Dealing with missing data</h4> <p>We approached several trial authors for additional data or for clarification of data.</p> </section> <section id="CD004863-sec3-0013"> <h4 class="title">Assessment of heterogeneity</h4> <p>We performed heterogeneity tests including the I<sup>2</sup> statistic to assess the appropriateness of pooling data (<a href="./references#CD004863-bbs2-0080" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557; PUBMED: 12958120] ">Higgins 2003</a>). We used the following criteria in describing the percentages of heterogeneity: &lt; 25% no heterogeneity, 25% to 49% low heterogeneity, 50% to 74% moderate heterogeneity, and ≥ 75% high heterogeneity. </p> </section> <section id="CD004863-sec3-0014"> <h4 class="title">Assessment of reporting biases</h4> <p>We prepared a funnel plot for the primary outcome in Comparison 1 ‐ Erythropoietin versus placebo or no treatment, outcome 1.1. Use of one or more RBC transfusions (low and high doses of EPO). </p> </section> <section id="CD004863-sec3-0015"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analysis using RevMan 5.3, as supplied by Cochrane (<a href="./references#CD004863-bbs2-0099" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For estimates of typical RR and RD, we used the Mantel‐Haenszel method. For measured quantities, we used the inverse variance method. If the RD was statistically significant, we calculated the NNTB or the NNTH. We performed all meta‐analyses by using the fixed‐effect model. </p> <section id="CD004863-sec4-0003"> <h5 class="title">Quality of evidence</h5> <p>We used the GRADE approach, as outlined in the <i>GRADE Handbook</i> (<a href="./references#CD004863-bbs2-0101" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Available from https://gdt.gradepro.org/app/handbook/handbook.html.Updated October 2013. ">Schünemann 2013</a>), to assess the quality of evidence for the following (clinically relevant) primary outcomes in infants exposed to early EPO versus placebo or sham injection. </p> <p> <ul id="CD004863-lst1-0004"> <li> <p>Use of one or more red blood cell transfusions (low and high doses of EPO).</p> </li> <li> <p>NEC (stage not reported).</p> </li> <li> <p>Any neurodevelopmental impairment at 18 to 22 months' corrected age (in children examined).</p> </li> <li> <p>Bayley‐II MDI at 18 to 24 months' corrected age.</p> </li> </ul> </p> <p>We assessed the quality of evidence for the following short‐term clinically relevant secondary outcomes. </p> <p> <ul id="CD004863-lst1-0005"> <li> <p>Mortality during initial hospital stay (all causes of mortality).</p> </li> <li> <p>Retinopathy of prematurity (ROP) (any stage and stage ≥ 3).</p> </li> <li> <p>Intraventricular haemorrhage (IVH), all grades (we included in this group results from studies that did not define the grade) and grades III and IV. </p> </li> <li> <p>Periventricular leukomalacia (PVL), cystic changes in periventricular areas. (Note: For this updated review, we included persistent increased echogenicity in this outcome.) </p> </li> <li> <p>Survivors to discharge from hospital without severe IVH, PVL, or ROP.</p> </li> <li> <p>Time to achieve full enteral feeding (days).</p> </li> </ul> </p> <p>We assessed the quality of evidence for the following long‐term clinically relevant secondary outcomes. (Note: We report results of BSID versions II and III separately.) </p> <p> <ul id="CD004863-lst1-0006"> <li> <p>Bayley‐II MDI at 18 to 24 months (included as a primary outcome above).</p> </li> <li> <p>Cerebral palsy at 18 to 24 months' corrected age.</p> </li> </ul> </p> <p>We assessed the quality of evidence for the following long‐term clinically relevant secondary outcomes in infants exposed to early Darbe or EPO (ESA) versus placebo or sham injection. </p> <p> <ul id="CD004863-lst1-0007"> <li> <p>Bayley Scales of Infant Development ‐ version III (BSID‐III) composite cognitive scores at 18 to 22 months. </p> </li> <li> <p>Wechsler Preschool and Primary Scale of Intelligence ‐ Third Edition (WPPSI‐III) Full‐Scale Intelligence Quotient (FSIQ) at 3.5 to 4 years of age. </p> </li> </ul> </p> <p>Two review authors independently assessed the quality of evidence for each of the outcomes above. We considered evidence from randomised controlled trials (RCTs) as high quality but downgraded evidence quality by one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of evidence, precision of estimates, and presence of publication bias. We used the <a href="./references#CD004863-bbs2-0078" title="McMaster University (developed by Evidence Prime), 2015.. GRADEpro GDT. Version accessed 06 March 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015., 2015. ">GRADEpro GDT</a> Guideline Development Tool to create a ‘Summary of findings’ table to report the quality of evidence. </p> <p>The GRADE approach results in an assessment of the quality of a body of evidence according to one of four grades. </p> <p> <ul id="CD004863-lst1-0008"> <li> <p>High: We are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> <section id="CD004863-sec3-0016"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were performed for low (≤ 500 IU/kg/week) and high (&gt; 500 IU/kg/week) doses of EPO and for low (≤ 5 mg/kg/d) and high (&gt; 5 mg/kg/d) doses of supplemental iron by any route (co‐intervention). Any amount of iron given intravenously (IV) was classified as high‐dose iron. </p> </section> <section id="CD004863-sec3-0017"> <h4 class="title">Sensitivity analysis</h4> <p>For the previous update, we conducted two post hoc analyses to try to explain between‐study heterogeneity for the primary outcome 'use of one or more RBC transfusions'. In the first post hoc analysis, we divided studies into two groups: 'high‐quality studies' and 'studies of uncertain quality'. In the second post hoc analysis, we analysed results for the four studies in which most of the neonatal intensive care units (NICUs) enrolling patients used satellite units of RBCs for transfusion. In a third post hoc analysis, we included results for ROP ≥ 3 for all available studies, regardless of the age of the infant at initiation of treatment with EPO. These additional analyses did not explain heterogeneity, and we deleted them from this update in 2017. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004863-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004863-sec1-0005"></div> <section id="CD004863-sec2-0013"> <h3 class="title">Description of studies</h3> <section id="CD004863-sec3-0018"> <h4 class="title">Results of the search</h4> <p>We have presented results of our searches in the 'Study flow diagram' (<a href="#CD004863-fig-0001">Figure 1</a>). Two studies reported on two separate populations in the same study; we treated these reports as separate studies for purposes of analysis (<a href="./references#CD004863-bbs2-0012" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997A</a>; <a href="./references#CD004863-bbs2-0013" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997B</a>; and <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>; <a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a>). We included seven new studies in the 2017 update (<a href="./references#CD004863-bbs2-0012" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997A</a>; <a href="./references#CD004863-bbs2-0013" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997B</a>; <a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>; <a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a>). We identified six new long‐term follow‐up reports from previously published original studies. They are listed under the primary study reports (<a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>). <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> included long‐term follow‐up in the primary report. </p> <div class="figure" id="CD004863-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update." data-id="CD004863-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> </div> <p>We included in this update 34 studies randomising 3643 infants, representing an increase of 1434 participants from the 2014 update. Studies were performed in 22 countries (Austria, Bangladesh, Belgium, Chile, China, Egypt, Finland, France, Germany, Greece, Iran, Italy, Mexico, Netherlands, New Zealand, Poland, Singapore, South Africa, Switzerland, Turkey, UK, and USA). <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> randomised 102 infants to darebpoetin alfa (Darbe), EPO, or sham injection. This was the first study conducted to assess the effectiveness and safety of Darbe. We report separately on three comparisons in that study: Darbe versus no treatment, EPO versus no treatment, and EPO and Darbe (ESA) versus no treatment. </p> <p>We excluded three additional studies from this 2017 update (<a href="./references#CD004863-bbs2-0035" title="Al MofadaSM . Safety and efficacy of early erythropoietin administration to pre‐term infants: a preliminary report. Medical Science Research1994;22(10):749‐50. [EMBASE: 1994345936] ">Al Mofada 1994</a>; <a href="./references#CD004863-bbs2-0037" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoietic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [EMBASE: 2015952409] ">Basiri 2015</a>; <a href="./references#CD004863-bbs2-0047" title="López‐CatzínJF , Bolado‐GarcíaPB , Gamboa‐LópezGJ , Medina‐EscobedoCE , Cambranes‐CatzimaLR . Decreased transfusions in preterm infants with anemia treated with erythropoietin [Disminución de transfusiones en prematuros con anemia tratados con eritropoyetina]. Revista Medica del Instituto Mexicano del Seguro Social2016;54(5):576‐80. [PUBMED: 27428338] ">López‐Catzín 2015</a>). <a href="./references#CD004863-bbs2-0035" title="Al MofadaSM . Safety and efficacy of early erythropoietin administration to pre‐term infants: a preliminary report. Medical Science Research1994;22(10):749‐50. [EMBASE: 1994345936] ">Al Mofada 1994</a> reported the volume of RBC transfusions in mL/week averaged over the study period ‐ not as total volume (mL/kg) of blood transfused per infant. In <a href="./references#CD004863-bbs2-0037" title="BasiriB , ShokouhiM , PezeshkiN , TorabianS . Beneficial erythropoietic effects of recombinant human erythropoietin in very low‐birth weight infants: a single‐center randomized double‐blinded placebo‐controlled trial. Journal of Clinical Neonatology2015;4(2):87‐90. [EMBASE: 2015952409] ">Basiri 2015</a>, infants were &gt; 6 days old at enrolment, and we will include this study in the update of the 'Late EPO' review. When contacted, one of the trial authors confirmed that <a href="./references#CD004863-bbs2-0047" title="López‐CatzínJF , Bolado‐GarcíaPB , Gamboa‐LópezGJ , Medina‐EscobedoCE , Cambranes‐CatzimaLR . Decreased transfusions in preterm infants with anemia treated with erythropoietin [Disminución de transfusiones en prematuros con anemia tratados con eritropoyetina]. Revista Medica del Instituto Mexicano del Seguro Social2016;54(5):576‐80. [PUBMED: 27428338] ">López‐Catzín 2015</a> was not an RCT. </p> <p>All included studies fulfilled our inclusion criteria of gestational age &lt; 37 weeks and/or birth weight &lt; 2500 grams. Inclusion of infants in the studies was based on postmenstrual age (PMA) or birth weight or a combination of the two. The highest cutoff for birth weight was 1800 grams, and the highest cutoff for PMA was 35 weeks (<a href="./references#CD004863-bbs2-0005" title="ChangL , LiuW , LiaoC , ZhaoX . Preventive effects of different dosages of recombinant human erythropoietin on anemia of premature infants. Journal of Tongji Medical University/Tong Ji Yi Ke da Xue Xue Bao1998;18(4):239‐42. [PUBMED: 10806855] ">Chang 1998</a>). The lowest cutoff for birth weight was 401 grams (<a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>). Most studies used an upper cutoff for birth weight of 1500 grams and a PMA of 32 to 33 weeks. </p> <p>EPO was administered subcutaneously (SC) or intravenously (IV), or IV then SC, when intravenous access was no longer available. Dosage ranged from 70 IU/kg/week in <a href="./references#CD004863-bbs2-0020" title="ObladenM , MaierR , SegererH , GrauelEL , HollandBM , StewartG , et al. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European randomized multicenter trial. Contributions to Nephrology1991;88:314‐26. [PUBMED: 2040194] ">Obladen 1991</a> to 2100 IU/kg/week in <a href="./references#CD004863-bbs2-0009" title="HaidenN , CardonaF , SchwindtJ , BergerA , KuhleS , HomoncikM , et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis2005;93(1):118‐23. [DOI: 10.1160/TH04‐02‐0093; PUBMED: 15630501] ">Haiden 2005</a>. The duration of EPO treatment ranged from two weeks in <a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a> and <a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a> to nine weeks in <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a> or to discharge from hospital (several studies). <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a> and <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a> were designed to ascertain whether IV administration of high‐dose EPO (3000 IU rhEPO/kg body weight) at three to six, 12 to 18, and 36 to 42 hours after birth would have a neuro protective effect. In those studies, no infant was treated at a later time with EPO. </p> <p>Researchers used many different EPO preparations: EPREX 2000, Santa‐Farma‐Gurel, Istanbul (<a href="./references#CD004863-bbs2-0001" title="ArifB , FerhanK . Recombinant human erythropoietin therapy in low‐birthweight preterm infants: a prospective controlled study. Pediatrics International2005;47(1):67‐71. [DOI: 10.1111/j.1442‐200x.2005.02007.x; PUBMED: 15693870] ">Arif 2005</a>); Eprex, Cilag, Italy (<a href="./references#CD004863-bbs2-0004" title="CarnielliVP , DaRiolR , MontiniG . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F44‐8. [PUBMED: 9797624] ">Carnielli 1998</a>); Cilag A.G., Zug, Switzerland (<a href="./references#CD004863-bbs2-0012" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997A</a>; <a href="./references#CD004863-bbs2-0013" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997B</a>; <a href="./references#CD004863-bbs2-0030" title="SoubasiV , KremenopoulosG , DiamandiE , TsantaliC , TsakirisD . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research1993;34(5):675‐9. [DOI: 10.1203/00006450‐199311000‐00022; PUBMED: 8284109] ">Soubasi 1993</a>; <a href="./references#CD004863-bbs2-0031" title="SoubasiV , KremenopoulosG , DiamantiE , TsantaliC , SarafidisK , TsakirisD . Follow‐up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. Journal of Pediatrics1995;127(2):291‐7. [PUBMED: 7636658] ">Soubasi 1995</a>; <a href="./references#CD004863-bbs2-0032" title="SoubasiV , KremenopoulosG , TsantaliC , SavopoulouP , MussafirisC , DimitrouM . Use of erythropoietin and its effects on blood lactate and 2,3‐diphosphoglycerate in premature neonates. Biology of the Neonate2000;78(4):281‐7. [DOI: 14280; PUBMED: 11093007] ">Soubasi 2000</a>); Eprex 4000, Cilag de Mexico S.A. de C.V. (<a href="./references#CD004863-bbs2-0015" title="Lima‐RogelV , Torres‐MontesA , Espinosa GriesseS , Villegas AlvarezC , Hernandez‐SierraF , Bissett MandevilleP , et al. Efficacy of early erythropoietin use in critically ill very‐low‐birth‐weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre1998;43(3):191‐5. [PUBMED: 9741224] ">Lima‐Rogel 1998</a>); Eprex, Janssen‐Cilag, Auckland, New Zealand (<a href="./references#CD004863-bbs2-0019" title="MeyerMP , SharmaE , CarsonsM . Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F41‐5. [PUBMED: 12496225] ">Meyer 2003</a>); Eprex, Cilag comp (<a href="./references#CD004863-bbs2-0011" title="KhatamiSF , MamouriG , TorkamanM . Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants. Indian Journal of Pediatrics2008;75(12):1227‐30. [DOI: 10.1007/s12098‐008‐0225‐0; PUBMED: 19057854] ">Khatami 2008</a>); Eprex (<a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>); Recormon, Boehringer (<a href="./references#CD004863-bbs2-0014" title="LauterbachR , KachlikP , PawlikD , BajorekI . Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatria Polska1995;70(9):739‐44. [PUBMED: 8657506] ">Lauterbach 1995</a>; <a href="./references#CD004863-bbs2-0002" title="AventM , CoryBJ , GalpinJ , BallotDE , CooperPA , ShermanG , et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of Tropical Pediatrics2002;48(4):227‐33. [PUBMED: 12200985] ">Avent 2002</a>); NeoRecormon, F. Hoffman‐La Roche, Basel, Switzerland (<a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a>); Epoetin beta, Boehringer‐Mannheim, GmbH, Germany (<a href="./references#CD004863-bbs2-0020" title="ObladenM , MaierR , SegererH , GrauelEL , HollandBM , StewartG , et al. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European randomized multicenter trial. Contributions to Nephrology1991;88:314‐26. [PUBMED: 2040194] ">Obladen 1991</a>; <a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a>); Kirin Brewery, Co., Ltd., Japan (<a href="./references#CD004863-bbs2-0005" title="ChangL , LiuW , LiaoC , ZhaoX . Preventive effects of different dosages of recombinant human erythropoietin on anemia of premature infants. Journal of Tongji Medical University/Tong Ji Yi Ke da Xue Xue Bao1998;18(4):239‐42. [PUBMED: 10806855] ">Chang 1998</a>); unnamed product (<a href="./references#CD004863-bbs2-0003" title="CarnielliV , MontiniG , DaRiolR , Dall'AmicoR , CantaruttiF . Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. Journal of Pediatrics1992;121(1):98‐102. [PUBMED: 1625101] ">Carnielli 1992</a>; <a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a>; <a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a>; <a href="./references#CD004863-bbs2-0034" title="YeoCL , ChooS , HoLY . Effect of recombinant human erythropoietin on transfusion needs in preterm infants. Journal of Paediatrics and Child Health2001;37(4):352‐8. [PUBMED: 11532054] ">Yeo 2001</a>; <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>; <a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a>; <a href="./references#CD004863-bbs2-0010" title="HeJS , HuangZL , YangH , WengKZ , ZhuSB . Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2008;10(5):586‐8. [PUBMED: 18947475] ">He 2008</a>; <a href="./references#CD004863-bbs2-0033" title="YasmeenBHN , ChowdhuryMA , HoqueMM , HossainMM , JahanR , AktarS . Effect of short term recombinant human erythropoietin therapy in the prevention of anemia of prematurity in very low birth weight infants. Bangladesh Medical Research Council Bulletin2012;38(3):119‐23. [PUBMED: 23540189] ">Yasmeen 2012</a>; <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>; <a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a>); Erypo, Janssen‐Cilag Pharmaceuticals, Vienna, Austria (<a href="./references#CD004863-bbs2-0018" title="MeisterB , MaurerH , SimmaB , KernH , UlmerH , HittmairA , et al. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem Cells1997;15(5):359‐63. [DOI: 10.1002/stem.150359; PUBMED: 9323798] ">Meister 1997</a>; <a href="./references#CD004863-bbs2-0009" title="HaidenN , CardonaF , SchwindtJ , BergerA , KuhleS , HomoncikM , et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis2005;93(1):118‐23. [DOI: 10.1160/TH04‐02‐0093; PUBMED: 15630501] ">Haiden 2005</a>); Eritropoyetina del Laboratorio Andromaco, Penalolen, Chile (<a href="./references#CD004863-bbs2-0028" title="SalvadoA , RamolfoP , EscobarM , NunezA , AguayoI , StandenJ , et al. Early erythropoietin use for the prevention of anemia in infant premature [Uso precoz de la eritropoyetina en la prevencion de la anemia del prematuro]. Revista Medica de Chile2000;128(12):1313‐7. [PUBMED: 11227239] ">Salvado 2000</a>); Epoietin beta, Roche, Basel, Switzerland (<a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>); Epoetin, SEDICO Pharmaceuticals, 6th of October City, Egypt (<a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a>). </p> <p>One study stated previous donor exposure as an exclusion criterion (<a href="./references#CD004863-bbs2-0001" title="ArifB , FerhanK . Recombinant human erythropoietin therapy in low‐birthweight preterm infants: a prospective controlled study. Pediatrics International2005;47(1):67‐71. [DOI: 10.1111/j.1442‐200x.2005.02007.x; PUBMED: 15693870] ">Arif 2005</a>). <a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a> included 28 infants (23%) in the EPO group and 17 (14%) in the control group, who had received RBC transfusions before study entry. <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a> reported that 24 (32%) of the infants in the early EPO group and 22 (31%) in the control group were exposed to donor blood before they entered the study. <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> reported that 17% of infants were transfused before study entry. Authors of the remaining studies reported their specific exclusion criteria but did not list prior transfusion as an exclusion criterion. We assumed that infants who had received prior RBC transfusions were included. </p> <p>We have provided details of the transfusion guidelines in the Additional tables (<a href="#CD004863-tbl-0009">Table 1</a>. Transfusion guidelines). As noted in the table, transfusion guidelines were based on various hematocrit (Hct) or haemoglobin (Hgb) levels. In addition, researchers used many other criteria, such as need for assisted ventilation, supplemental oxygen, age of the infant, weight gain, clinical condition, and physiological or biochemical signs thought to be associated with anaemia. For a few studies, we were unable to categorise different guidelines that could be used meaningfully for secondary analyses. We excluded from this update analyses based on transfusion information. </p> <div class="table" id="CD004863-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Transfusion guidelines</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0001" title="ArifB , FerhanK . Recombinant human erythropoietin therapy in low‐birthweight preterm infants: a prospective controlled study. Pediatrics International2005;47(1):67‐71. [DOI: 10.1111/j.1442‐200x.2005.02007.x; PUBMED: 15693870] ">Arif 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants with Hgb concentrations &lt; 7 g/dL and with a reticulocyte count lower than &lt; 100,000/µL or Hgb concentrations &lt; 8 g/dL having bradycardia, tachypnoea, or apnoea, or who were not able to gain weight despite adequate calorie intake, were chosen as candidates for blood transfusion. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0002" title="AventM , CoryBJ , GalpinJ , BallotDE , CooperPA , ShermanG , et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of Tropical Pediatrics2002;48(4):227‐33. [PUBMED: 12200985] ">Avent 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants received blood transfusions if they met the following criteria:<br/> 1. Hgb of 10 g/dL and 1 of the following: (i) an oxygen requirement greater than 30%; (ii) less than 1250 grams body weight<br/> 2. Hgb &lt; 8 g/dL and 1 of the following: (i) 3 or more episodes of apnoea (respiration absent for 20 seconds) or bradycardia (heart rate &lt; 100 beats/min) in a 24‐hour period not due to other causes and not responsive to methylxanthine treatment; (ii) fractional inspired oxygen concentrations increasing by &gt; 10% per week; and (iii) tachycardia (&gt; 170 beats/min) or tachypnoea (&gt; 70 breaths/min) sustained over a 24‐hour period associated with acute cardiac decompression </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0003" title="CarnielliV , MontiniG , DaRiolR , Dall'AmicoR , CantaruttiF . Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. Journal of Pediatrics1992;121(1):98‐102. [PUBMED: 1625101] ">Carnielli 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants were transfused during the first week of life with packed erythrocytes if the Hct level was &lt; 42% or 36%, depending on whether or not the patient was receiving supplemental oxygen. After the first week of life, indications for transfusions were Hct &lt; 36% for oxygen‐dependent patients and 32% if breathing room air. Anaemia was the only indication for giving packed erythrocytes to all infants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0004" title="CarnielliVP , DaRiolR , MontiniG . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F44‐8. [PUBMED: 9797624] ">Carnielli 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants received transfusions of packed cells during the first week of life if their peripheral Hct (heel stick) was &lt; 42% or 36%, depending on whether or not the patient was receiving supplemental oxygen.<br/> After the first week of life, indications for transfusion were Hct &lt; 36% for oxygen‐dependent patients and 32% if in room air. Hct concentrations for red blood cell transfusions for blood obtained from venipuncture or arterial samples were 4% lower than the above mentioned values (38% and 32% for oxygen‐dependent and non‐oxygen‐dependent patients in the first week, and 0.32 and 0.28 thereafter). All infants received dedicated units of red blood cells. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0005" title="ChangL , LiuW , LiaoC , ZhaoX . Preventive effects of different dosages of recombinant human erythropoietin on anemia of premature infants. Journal of Tongji Medical University/Tong Ji Yi Ke da Xue Xue Bao1998;18(4):239‐42. [PUBMED: 10806855] ">Chang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0009" title="HaidenN , CardonaF , SchwindtJ , BergerA , KuhleS , HomoncikM , et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis2005;93(1):118‐23. [DOI: 10.1160/TH04‐02‐0093; PUBMED: 15630501] ">Haiden 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants were transfused at Hct &lt; 20%:<br/> 1. if asymptomatic with reticulocytes &lt; 100,000/µL<br/> <br/> Infants were transfused at Hct &lt; 30%:<br/> 1. if receiving &lt; 35% supplemental hood oxygen<br/> 2. if on CPAP or mechanical ventilation with mean air way pressure &lt; 6 cmH<sub>2</sub>O<br/> 3. if significant apnoea and bradycardia are noted (&gt; 9 episodes in 12 hours or 2 episodes in 24 hours requiring bag and mask ventilation) while receiving therapeutic doses of methylxanthines<br/> 4. if heart rate &gt; 180 beats/min or respiratory rate &gt; 80 breaths/min persists for 24 hours<br/> 5. if weight gain &lt; 10 g/d is observed over 4 days while receiving &gt; 100 kcal/kg/d<br/> 6. if undergoing surgery<br/> <br/> Transfuse for Hct &lt; 35%<br/> 1. if receiving &gt; 35% supplemental hood oxygen<br/> 2. if intubated on CPAP or mechanical ventilation with mean airway pressure &gt; 6 to 8 cmH<sub>2</sub>O<br/> Do not transfuse:<br/> 1. to replace blood removed for laboratory tests alone<br/> 2. for low Hct alone </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0010" title="HeJS , HuangZL , YangH , WengKZ , ZhuSB . Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2008;10(5):586‐8. [PUBMED: 18947475] ">He 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines are not reported in the English abstract of this study. We have requested the full text in Chinese from trial authors. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0011" title="KhatamiSF , MamouriG , TorkamanM . Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants. Indian Journal of Pediatrics2008;75(12):1227‐30. [DOI: 10.1007/s12098‐008‐0225‐0; PUBMED: 19057854] ">Khatami 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Guidelines for red‐cell transfusions were based on the relatively strict existing policy in the nursery which was used to administer transfusions during the study period". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0012" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were ordered by the clinicians caring for each infant without consulting the investigators, based on general guidelines for erythrocyte transfusions. According to these guidelines, neonates who were well received transfusions if their hematocrit was &lt; 30% during the third week, &lt; 25% during the fourth week, and &lt; 23% after the first month of life, combined with signs referable to their anaemia, such as poor weight gain, episodes of persistent bradycardia or tachycardia, and apnoea. Neonates with severe respiratory disease (bronchopulmonary dysplasia), particularly those requiring oxygen and/or ventilator support, were given transfusions to maintain their hematocrit level at &gt; 40%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0013" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See <a href="./references#CD004863-bbs2-0012" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997A</a>, </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0014" title="LauterbachR , KachlikP , PawlikD , BajorekI . Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatria Polska1995;70(9):739‐44. [PUBMED: 8657506] ">Lauterbach 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion was given when the Hct level reached 28% and if clinical symptoms of tachypnoea, tachycardia, and bradycardia were present at Hct of 0.32. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0015" title="Lima‐RogelV , Torres‐MontesA , Espinosa GriesseS , Villegas AlvarezC , Hernandez‐SierraF , Bissett MandevilleP , et al. Efficacy of early erythropoietin use in critically ill very‐low‐birth‐weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre1998;43(3):191‐5. [PUBMED: 9741224] ">Lima‐Rogel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>According to criteria published by Klaus and Fanaroff (see text for more info)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants who were receiving ventilation or who were less than 2 weeks old and had signs of anaemia were given transfusions if their Hct fell below 40%, their Hgb concentration fell below 14 g/dL (8.7 mmol/L), or blood samples totaling at least 9 mL/kg had been obtained from them since their previous transfusion.<br/> Spontaneously breathing infants, more than 2 weeks old, whose FiO<sub>2</sub> was &lt; 0.40, were given transfusions if they had signs of anaemia and their Hct fell below 32% and their Hgb concentration below 11 g/dL (6.8 mmol/L); if they had signs of anaemia, corresponding cutoff values were 27% and 9 g/dL (5.6 mmol/L). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants with artificial ventilation or &gt; 40% of inspired oxygen were not transfused unless Hct dropped below 0.40.<br/> Spontaneously breathing infants were not transfused unless Hct dropped below 0.35 during the first 2 weeks of life, 0.30 during the third to fourth weeks, and 0.25 thereafter. Transfusion was allowed when life‐threatening anaemia or hypovolaemia was assumed by the treating neonatologist, or surgery was planned. Twelve of the 14 centres used satellite packs of the original red cell pack to reduce donor exposure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0018" title="MeisterB , MaurerH , SimmaB , KernH , UlmerH , HittmairA , et al. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem Cells1997;15(5):359‐63. [DOI: 10.1002/stem.150359; PUBMED: 9323798] ">Meister 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants more than 2 weeks old who had been breathing spontaneously and whose FiO<sub>2</sub> was less than 0.40 were given transfusions if they had signs of anaemia and their Hct fell below 11 g/dL (6.8 mmol/L); if they had no signs of anaemia, corresponding cutoff values were 27% and 9 g/dL (5.6 mmol/L). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0019" title="MeyerMP , SharmaE , CarsonsM . Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F41‐5. [PUBMED: 12496225] ">Meyer 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indications for transfusions were:<br/> 1. Hct of 36% to 40% and critically ill with requirement for oxygen &gt; 45% via CPAP; ventilation (mean airway pressure &gt; 10 cmH<sub>2</sub>O); severe sepsis; active bleeding<br/> 2. Hct of 31% to 35% and requirement for oxygen (up to 45%) via CPAP; ventilation (mean airway pressure 7 to 10 cmH<sub>2</sub>O)<br/> 3. Hct of 21% to 30% and gain less than 10 g/d averaged over 1 week; experienced at least 10 to 12 apneic or bradycardic episodes in 12 hours or 2 or more such episodes requiring bag and mask ventilation within a 24‐hour period, not owing to other causes and not responsive to methylxanthine treatment; had a sustained tachycardia (&gt; 170 beats/min) or tachypnoea (&gt; 70/min) per 24 hours and not attributable to other causes; developed cardiac decompensation secondary to a clinically apparent patent ductus arteriosus; positive‐pressure ventilation on low settings (mean airway pressure &lt; 7 cmH<sub>2</sub>O) or nasal CPAP; those requiring surgery<br/> 4. Hct 20% and reticulocyte count &lt; 100 × 10<sup>9</sup>/L </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0020" title="ObladenM , MaierR , SegererH , GrauelEL , HollandBM , StewartG , et al. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European randomized multicenter trial. Contributions to Nephrology1991;88:314‐26. [PUBMED: 2040194] ">Obladen 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indications for transfusion of packed red cells:<br/> 1. If venous Hct &lt; 42%, Hgb &lt; 14 g/dL or &gt; 9 mL/kg blood sampled since last transfusion transfuse if infant is ventilated or requires FiO<sub>2</sub> &gt; 0.40<br/> 2. If age 1 to 2 weeks and symptoms of anaemia (apneic spells, distended abdomen, failure to thrive), transfuse if venous Hct &lt; 36%, Hgb &lt; 12 g/dL, or &gt; 9 mL/kg blood sampled since last transfusion.<br/> 3. If age 3 to 5 weeks and symptoms of anaemia (apneic spells, distended abdomen, failure to thrive), transfuse if venous Hct &lt; 30%, Hgb &lt; 10 g/dL or &gt; 9 mL/kg blood sampled since last transfusion.<br/> 4. If no symptoms of anaemia, transfuse at any age if venous Hct is &lt; 27%, Hgb &lt; 9 g/dL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were given during the first 3 weeks of life if Hct was &lt; 33%, and if the infant had 1 or more symptoms thought to be due strictly to anaemia. Symptoms were defined as tachycardia (heart rate &gt; 160 beats/min, calculated as the average of all heart rates recorded by the bedside nurse during the preceding 24‐hour period), an increasing oxygen requirement (an increase in fraction of inspired oxygen of &gt; 0.20 during a 24‐hour period), "lethargy" as assessed by the primary caregiver, or an increase in the number of episodes of bradycardia requiring stimulation to increase the heart rate from less than 60 beats/min (an increase of such episodes by 3 or more per day). Infants in both groups whose Hct were &gt; 33% and yet whose phlebotomy losses exceeded 10 mL/kg body weight received an infusion of 5% albumin, administered in aliquots of not less than 10 mL/kg. Infants were not given transfusions if they were free of symptoms, even if Hct fell to &lt; 33%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were administered in both groups according to standardised transfusion criteria: For infants requiring mechanical ventilation, transfusions were given if Hct fell below 33%. For infants not receiving ventilatory support, transfusions were given if Hct fell below 28%, and if the infant was experiencing symptoms. Symptoms were defined as tachycardia (heart rate &gt; 160 beats/min, calculated as the average of all heart rates recorded by the bedside nurse over the preceding 24‐hour period), an increasing oxygen requirement (an increase in FiO<sub>2</sub> of &gt; 0.20 over a 24‐hour period, or an elevated lactate level (&gt; 2.5 mmol/L). In some instances, a new donor would be used each day for the newborn intensive care unit (University of Florida), and in other instances, a unit would be dedicated to a single infant for the life of the unit (University of New Mexico and University of Utah). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>If Hct ≤ 35%/Hgb ≤ 11 g/dL, transfuse infants requiring moderate or significant mechanical ventilation (MAP &gt; 8 cmH<sub>2</sub>O and FiO<sub>2</sub> &gt; 0.4).<br/> If Hct ≤ 30%/Hgb ≤ 10 g/dL, transfuse infants requiring minimal respiratory support (any mechanical ventilation or endotracheal/nasal CPAP &gt; 6 cmH<sub>2</sub>O and FiO<sub>2</sub> ≤ 0.4).<br/> If Hct ≤ 25%/Hgb ≤ 8 g/dL, transfuse infants not requiring mechanical ventilation but who are on supplemental O<sub>2</sub> or CPAP with an FiO<sub>2</sub> ≤ 0.4 and in whom 1 or more of the following is present: 24 hours of tachycardia (180 beats/min) or tachypnoea (&gt;80 breaths/min), an increased oxygen requirement from the previous 48 hours, defined as 4‐fold increase in nasal cannula flow (i.e. 0.25 L/min to 1 L/min), or an increase in nasal CPAP of 20% from the previous 48 hours (i.e. 5 cm to 6 cmH<sub>2</sub>O), weight gain &lt; 10 g/kg/d over the previous 4 days while receiving 100 kcal/kg/d, increase in episodes of apnoea and bradycardia (&gt; 9 episodes in a 24‐hour period or 2 episodes in 24 hours requiring bag‐mask ventilation) while receiving therapeutic doses of methylxanthines, undergoing surgery.<br/> If Hct ≤ 25%/Hgb ≤ 7 g/dL, transfuse asymptomatic infants with absolute reticulocyte count &lt; 100,000 cells/µL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The PRBC volume transfused was based on Hct/Hgb, respiratory support, and/or symptoms. </p> <p>If Hct ≤ 30/Hgb ≤ 10 and the infant required moderate/significant ventilation (MAP &gt; 8 cmH<sub>2</sub>O and FiO<sub>2</sub> &gt; 0.4), the PRBC volume to be transfused was 15 to 20 mL/kg.<br/> If Hct ≤ 25/Hgb ≤ 8 and the infant required minimal respiratory support (any mechanical ventilation with FiO<sub>2</sub> ≤ 0.4, or CPAP &gt; 6 cmH<sub>2</sub>O and FiO<sub>2</sub>≤ 0.4), the PRBC volume to be transfused was 20 mL/kg.<br/> If Hct was ≤ 20/Hgb ≤ 7 and the infant required supplemental oxygen or CPAP with FiO<sub>2</sub> ≤ 0.4, and at least 1 of the following:<br/> 1. ≥ 24 hours of tachycardia (heart rate &gt; 180) or tachypnoea (RR &gt; 60)<br/> 2. doubling of the oxygen requirement from the previous 48 hours<br/> 3. lactate ≥ 2.5 mEq/L or an acute metabolic acidosis (pH 7.20)<br/> 4. weight gain &lt; 10 g/kg/d over the previous 4 days while receiving ≥ 120 kcal/kg/d<br/> 5. undergoing surgery within 24 hours </p> <p>PRBC volume to be transfused was 20 mL/kg.</p> <p>If Hct ≤18/Hgb ≤ 6 and the infant was asymptomatic and absolute reticulocyte count (ARC) was &lt; 100,000 cells/µL, the PRBC volume to be transfused was 20 mL/kg. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants with the following respiratory needs received 10 to 15 mL/kg of RBC volume based on Hct:<br/> 1. &lt; 0.40 mechanical ventilation, FiO<sub>2</sub> &gt; 0.40<br/> 2. &lt; 0.35 mechanical ventilation, FiO<sub>2</sub> &lt; 0.40, or use of nasal CPAP at the age of &lt; 2 weeks<br/> 3. &lt; 0.30 supplemental oxygen, nasal CPAP, or apneas during later neonatal period<br/> 4. &lt; 0.25 no symptoms during later neonatal period </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0028" title="SalvadoA , RamolfoP , EscobarM , NunezA , AguayoI , StandenJ , et al. Early erythropoietin use for the prevention of anemia in infant premature [Uso precoz de la eritropoyetina en la prevencion de la anemia del prematuro]. Revista Medica de Chile2000;128(12):1313‐7. [PUBMED: 11227239] ">Salvado 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preterm infants with Hct &lt; 20%<br/> Preterm infants with Hct &lt; 30% when presenting with frequent apneas, or tachycardia &gt; 180 beats/min, or requiring surgery </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion criteria followed strict clinical criteria as used by <a href="./references#CD004863-bbs2-0055" title="Vázquez LópezMÁ , LlamasMÁ , GaleraR , SanchezAR , LendinezF , Gonzalez‐RipollM , et al. Comparison between one and three doses a week of recombinant erythropoietin in very low birth weight infants. Journal of Perinatology2011;31(2):118‐24. [DOI: 10.1038/jp.2010.80; PUBMED: 20689518] ">Vázquez López 2011</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0030" title="SoubasiV , KremenopoulosG , DiamandiE , TsantaliC , TsakirisD . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research1993;34(5):675‐9. [DOI: 10.1203/00006450‐199311000‐00022; PUBMED: 8284109] ">Soubasi 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neonates who were well were transfused if their Hct was &lt; 25% combined with signs referable to their anaemia, such as poor weight gain, persistent episodes of bradycardia or tachypnoea, and apnoea. Neonates with severe respiratory disease (BPD), particularly those requiring oxygen and/or ventilator support, received transfusions to maintain Hct level at &gt; 40%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0031" title="SoubasiV , KremenopoulosG , DiamantiE , TsantaliC , SarafidisK , TsakirisD . Follow‐up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. Journal of Pediatrics1995;127(2):291‐7. [PUBMED: 7636658] ">Soubasi 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants who were receiving mechanical ventilation or who were less than 2 weeks old were given transfusion if their Hct fell below 40%. Spontaneously breathing infants more than 2 weeks old whose FiO<sub>2</sub> was less than 0.35 were given transfusion if they had signs of anaemia and their Hct fell below 30%; if they had no signs of anaemia, transfusion was given if Hct fell below 0.25. Growing, asymptomatic infants were transfused if Hct fell below 20%. Signs of anaemia included tachycardia, (&gt; 170 beats/min) or tachypnoea (&gt; 70/min) sustained over a 24‐hour period or associated with acute cardiac decompression; recurrent apnoea (respirations absent for 20 seconds) or bradycardia (heart rate &lt; 100 beats/min) in a 24‐hour period not due to other causes and not responsive to methylxanthine treatment; an increase in fractional oxygen requirement by 20% or more over a 24‐hour period; or weight gain &lt; 10 g/d averaged over a 1‐week period while on adequate caloric intake. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0032" title="SoubasiV , KremenopoulosG , TsantaliC , SavopoulouP , MussafirisC , DimitrouM . Use of erythropoietin and its effects on blood lactate and 2,3‐diphosphoglycerate in premature neonates. Biology of the Neonate2000;78(4):281‐7. [DOI: 14280; PUBMED: 11093007] ">Soubasi 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neonates were transfused when Hct was &lt; 20%, if they were asymptomatic, or &lt; 30% if they were receiving O<sub>2</sub> &lt; 0.35 and/or unexplained breathing disorders combined with signs referable to their anaemia, such as poor weight gain, episodes of persistent bradycardia or tachycardia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0033" title="YasmeenBHN , ChowdhuryMA , HoqueMM , HossainMM , JahanR , AktarS . Effect of short term recombinant human erythropoietin therapy in the prevention of anemia of prematurity in very low birth weight infants. Bangladesh Medical Research Council Bulletin2012;38(3):119‐23. [PUBMED: 23540189] ">Yasmeen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After discharge from hospital, any patient with Hgb level ≤ 7 g/dL was readmitted to the hospital and managed with packed red cell transfusion. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0034" title="YeoCL , ChooS , HoLY . Effect of recombinant human erythropoietin on transfusion needs in preterm infants. Journal of Paediatrics and Child Health2001;37(4):352‐8. [PUBMED: 11532054] ">Yeo 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants who were receiving mechanical ventilation or who were less than 2 weeks old were given transfusion if their Hct fell below 40%. Spontaneously breathing infants more than 2 weeks old whose FiO<sub>2</sub> was less than 35% were given transfusion if they had signs of anaemia and their Hct fell below 30%; if they had no signs of anaemia, transfusion was given if Hct fell below 25%. Growing, asymptomatic infants were transfused if Hct fell below 20%. Signs of anaemia included tachycardia, (&gt; 170 beats/min) or tachypnoea (&gt; 70/min) sustained over a 24‐hour period or associated with acute cardiac decompression; recurrent apnoea (respirations absent for 20 seconds) or bradycardia (heart rate &lt; 100 beats/min) in a 24‐hour period not due to other causes and not responsive to methylxanthine treatment; increased fractional oxygen requirement by 20% or more over a 24‐hour period; or weight gain &lt; 10 g/d averaged over a 1‐week period while on adequate caloric intake. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ARC: absolute reticulocyte count.<br/> BPD: bronchopulmonary dysplasia.<br/> CPAP: continuous positive airway pressure.<br/> FiO<sub>2</sub>: fraction of inspired oxygen.<br/> Hct: hematocrit.<br/> Hgb: haemoglobin.<br/> MAP: mean airway pressure.<br/> PRBC: packed red blood cells.<br/> RBC: red blood cell.<br/> RR: respiratory rate. </p> </div> </div> <p>All but six studies reported that transfusion guidelines were in place (<a href="./references#CD004863-bbs2-0005" title="ChangL , LiuW , LiaoC , ZhaoX . Preventive effects of different dosages of recombinant human erythropoietin on anemia of premature infants. Journal of Tongji Medical University/Tong Ji Yi Ke da Xue Xue Bao1998;18(4):239‐42. [PUBMED: 10806855] ">Chang 1998</a>; <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0010" title="HeJS , HuangZL , YangH , WengKZ , ZhuSB . Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2008;10(5):586‐8. [PUBMED: 18947475] ">He 2008</a>; <a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a>). <a href="./references#CD004863-bbs2-0015" title="Lima‐RogelV , Torres‐MontesA , Espinosa GriesseS , Villegas AlvarezC , Hernandez‐SierraF , Bissett MandevilleP , et al. Efficacy of early erythropoietin use in critically ill very‐low‐birth‐weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre1998;43(3):191‐5. [PUBMED: 9741224] ">Lima‐Rogel 1998</a> referred to the third Spanish edition of 'Care of the high‐risk neonate' by Klaus and Fanaroff for the guidelines they adhered to (<a href="./references#CD004863-bbs2-0087" title="KlausM , FanaroffA . Asistencia del Recien Nacido de Alto Riesgo. 3rd Edition. Colombia: Panamericana, 1987. ">Klaus 1987</a>). We were not able to locate that book, but in the third English edition of the book, we could not find transfusion guidelines for preterm infants (<a href="./references#CD004863-bbs2-0086" title="KlausMH , FanaroffAA . Care of the High‐risk Neonate. 3rd Edition. Philadelphia, London, Toronto: W.B. Saunders Campany, 1986. ">Klaus 1986</a>). </p> <p>In <a href="./references#CD004863-bbs2-0004" title="CarnielliVP , DaRiolR , MontiniG . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F44‐8. [PUBMED: 9797624] ">Carnielli 1998</a>, all infants received dedicated units of RBCs. <a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a> stated, "In some instances a new donor would be used each day for the newborn intensive care unit (University of Florida) and in other instances a unit would be dedicated to a single infant for the life of the unit (University of New Mexico and University of Utah)". These two studies did not report on our primary outcome of 'use of one or more RBC transfusions'. In <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a>, 12 of the 14 centres used satellite packs of the original red cell pack to reduce donor exposure. In <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a> and <a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a>), study authors noted, "Whenever possible designated donor units that were capable of providing at least four transfusions were assigned to each infant (available in six of the eight participating centres)". In a secondary (post hoc) analysis, we combined the results of these three studies. <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> assigned each infant a matched, leuko‐reduced, citrate‐phosphate‐dextrose adenine anticoagulant‐preserved donor unit, made available in a sterile docking device capable of 50 mL aliquots of packed red blood cells (PRBCs) with four or more transfusions per unit, and a shelf life of 28 days. </p> <p>Three studies did not administer iron (<a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>). We are awaiting information from <a href="./references#CD004863-bbs2-0010" title="HeJS , HuangZL , YangH , WengKZ , ZhuSB . Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2008;10(5):586‐8. [PUBMED: 18947475] ">He 2008</a>, as the abstract did not mention use of iron. In most studies, both EPO and control groups received iron, but often the dosage given to the control groups was lower. In <a href="./references#CD004863-bbs2-0003" title="CarnielliV , MontiniG , DaRiolR , Dall'AmicoR , CantaruttiF . Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. Journal of Pediatrics1992;121(1):98‐102. [PUBMED: 1625101] ">Carnielli 1992</a> and <a href="./references#CD004863-bbs2-0004" title="CarnielliVP , DaRiolR , MontiniG . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F44‐8. [PUBMED: 9797624] ">Carnielli 1998</a>, infants in the control groups did not receive iron. </p> </section> <section id="CD004863-sec3-0019"> <h4 class="title">Included studies</h4> <p>For details, see the <a href="./references#CD004863-sec2-0027" title="">Characteristics of included studies</a> table. </p> <section id="CD004863-sec4-0004"> <h5 class="title">Studies primarily designed to assess the effectiveness and safety of EPO or Darbe initiated early (before eight days after birth) in reducing red blood cell transfusions in preterm and/or low birth weight infants </h5> <p><a href="./references#CD004863-bbs2-0001" title="ArifB , FerhanK . Recombinant human erythropoietin therapy in low‐birthweight preterm infants: a prospective controlled study. Pediatrics International2005;47(1):67‐71. [DOI: 10.1111/j.1442‐200x.2005.02007.x; PUBMED: 15693870] ">Arif 2005</a> was a single‐centre study performed in Istanbul, Turkey. </p> <p> <ul id="CD004863-lst1-0009"> <li> <p>Objective: to determine whether EPO would prevent anaemia of prematurity and reduce the need for transfusion. </p> </li> <li> <p>Population: preterm infants &lt; 33 weeks' gestational age (GA), birth weight &lt; 1500 grams, seven days old, with no previous blood transfusion. </p> </li> <li> <p>Intervention: The EPO group received EPO 200 IU/kg SC from the seventh day of life and continued twice weekly (low dose) for six weeks. Placebo was not given to the control group. Both groups received iron (3 to 5 mg/kg/d orally) (low dose). </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, mortality, NEC, ROP, BPD, neutropenia, side effects. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0002" title="AventM , CoryBJ , GalpinJ , BallotDE , CooperPA , ShermanG , et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of Tropical Pediatrics2002;48(4):227‐33. [PUBMED: 12200985] ">Avent 2002</a> was a two‐centre study performed in South Africa. </p> <p> <ul id="CD004863-lst1-0010"> <li> <p>Objective: to evaluate the effectiveness of early treatment with EPO (both high and low doses) in comparison with conventional treatment with packed RBC transfusions for management of anaemia of prematurity in a country with limited resources. </p> </li> <li> <p>Population: preterm infants &lt; seven days of age, in room air or requiring up to 30% oxygen at study entry, with birth weight between 900 and 1500 grams. Infants were stratified by weight &lt; 1250 grams and &gt; 1250 grams. </p> </li> <li> <p>Intervention: One group received EPO 400 IU/kg SC three times a week (high dose), and a second group received EPO 250 IU/kg SC three times a week (high dose). All infants received a therapeutic dose of 6 mg/kg (high dose) elemental iron orally every day; this dosage was increased to 8 to 10 mg/kg (high‐dose iron) if the hypochromic cells became 20% or more of the total cell population. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, total volume (mL/kg) of blood transfused per infant, number of blood transfusions per infant, mortality, sepsis. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0003" title="CarnielliV , MontiniG , DaRiolR , Dall'AmicoR , CantaruttiF . Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. Journal of Pediatrics1992;121(1):98‐102. [PUBMED: 1625101] ">Carnielli 1992</a> was a single‐centre study performed in Italy. </p> <p> <ul id="CD004863-lst1-0011"> <li> <p>Objective: to determine whether early administration of a high dose of recombinant human erythropoietin (rHuEPO) and iron to premature infants would be well tolerated and would reduce the need for blood transfusions. </p> </li> <li> <p>Population: preterm infants with birth weight ≤ 1750 grams and GA ≤ 32 weeks, two days old. </p> </li> <li> <p>Intervention: The EPO group received EPO 400 IU, three times weekly (high dose) IV or SC, and iron 20 mg/kg once a week IV (high‐dose iron) from second day of life until discharge. The control group did not receive either EPO or iron. </p> </li> <li> <p>Outcomes assessed: number and volume of transfusions, number of donor exposures, mortality during hospital stay, neutropenia, hospital stay in days. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0004" title="CarnielliVP , DaRiolR , MontiniG . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F44‐8. [PUBMED: 9797624] ">Carnielli 1998</a> was a single‐centre study performed in Italy. </p> <p> <ul id="CD004863-lst1-0012"> <li> <p>Objective: to determine whether iron supplementation would enhance erythropoiesis in preterm infants treated with EPO. </p> </li> <li> <p>Population: birth weight ≤ 1750 grams and gestational age ≤ 32 weeks, two days old.</p> </li> <li> <p>Intervention: The EPO + iron group received 400 IU/kg EPO three times a week (high dose) and 20 mg/kg/week of IV iron (high dose). The EPO + no iron group received EPO 400 IU/kg three times a week (high dose) without iron (no iron); infants in the control group received either no treatment or placebo. </p> </li> <li> <p>Outcomes assessed: number of donor exposures, BPD, IVH, sepsis, ROP, days on ventilator, days of oxygen, days in hospital, days to regain birth weight, weight gain from birth to eight weeks. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0005" title="ChangL , LiuW , LiaoC , ZhaoX . Preventive effects of different dosages of recombinant human erythropoietin on anemia of premature infants. Journal of Tongji Medical University/Tong Ji Yi Ke da Xue Xue Bao1998;18(4):239‐42. [PUBMED: 10806855] ">Chang 1998</a> was a single‐centre study performed in China. </p> <p> <ul id="CD004863-lst1-0013"> <li> <p>Objective: to assess the efficacy and optimum dose of EPO for anaemia of prematurity.</p> </li> <li> <p>Population: infants with GA ≤ 35 weeks, birth weight ≤ 1800 grams, age one day, and no rhesus (Rh) or ABO (blood group) incompatibility. </p> </li> <li> <p>Intervention: Infants in EPO group 1 received EPO 150 IU/kg three times a week for six weeks (low dose). Infants in EPO group 2 received EPO 250 IU/kg three times a week for six weeks (high dose). Infants in the control group (group 3) received no EPO treatment. Infants in all three treatment groups received oral iron 20 mg/kg/d (high dose) from day seven after birth </p> </li> </ul> <ul id="CD004863-lst1-0014"> <li> <p>Outcomes assessed: use of one or more RBC transfusions, hypertension, side effects.</p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0009" title="HaidenN , CardonaF , SchwindtJ , BergerA , KuhleS , HomoncikM , et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis2005;93(1):118‐23. [DOI: 10.1160/TH04‐02‐0093; PUBMED: 15630501] ">Haiden 2005</a> was a multi‐centre study performed at NICUs of the Department of Pediatrics, University of Vienna, Austria. </p> <p> <ul id="CD004863-lst1-0015"> <li> <p>Objective: to evaluate effects of EPO therapy on platelet reactivity and thrombopoiesis in ELBW infants. </p> </li> <li> <p>Population: preterm infants with BW ≤ 800 grams and GA ≤ 32 weeks, &lt; 8 days old.</p> </li> <li> <p>Intervention: The EPO group received 300 IU/kg/d of EPO IV (as long as IV access was available) or 700 IU/kg three times per week (2100 IU/kg/week, high dose), and iron dextran 1.5 mg/kg/d IV or iron polymerase complex 9 mg/kg/d orally (high dose). </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, number of donors, mortality, NEC, PVL, IVH (grade I to II), IVH (grade III to IV), hospital stay, BPD (age not stated), ROP (stage I to II), ROP (stage III to IV). </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0011" title="KhatamiSF , MamouriG , TorkamanM . Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants. Indian Journal of Pediatrics2008;75(12):1227‐30. [DOI: 10.1007/s12098‐008‐0225‐0; PUBMED: 19057854] ">Khatami 2008</a> was a single‐centre study performed at Ghaem Medical Center in Tehran, Iran. </p> <p> <ul id="CD004863-lst1-0016"> <li> <p>Objective: to evaluate whether EPO therapy would decrease the need for RBC transfusions and prevent anaemia of prematurity. </p> </li> <li> <p>Population: preterm infants with BW &gt; 1000 grams but &lt; 1750 grams and GA &gt; 28 weeks but &lt; 34 weeks, and between 48 and 96 hours old at the time of study entry. </p> </li> <li> <p>Intervention: The EPO group received 500 IU/kg/d of EPO SC twice weekly (1000 IU/kg/week, high dose) and iron (ferrous sulphate) 3 mg/kg/d enterally (low dose). </p> </li> <li> <p>Outcomes assessed: number of RBC transfusions per participant, weight gain, hospital stay. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0012" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997A</a>; &amp; <a href="./references#CD004863-bbs2-0013" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997B</a> </p> <p> <ul id="CD004863-lst1-0017"> <li> <p>Objective: to determine the best timing of EPO administration in infants with anaemia of prematurity. </p> </li> <li> <p>Population: 50 neonates with BW ≤ 1500 grams, PMA ≤ 31 weeks. Infants who had received transfusion before enrolment were included. </p> </li> <li> <p>Intervention: The EPO group received rHuEPO (Cilag A.G., Zug, Switzerland) 3 × 250 U/kg/week SC (750 U/kg/week – high dose) (n = 24). Treatment was given for 6 weeks. The control group (n = 26) received no intervention. All infants received elemental iron 3 mg/kg/d. Treatment was initiated at three to seven days. </p> </li> <li> <p>Outcomes assessed: transfusions/patient, patients receiving transfusions.</p> </li> <li> <p>Retrospectively, infants were divided into those without complications (without or with minimal signs of respiratory distress and no signs of sepsis) and those with complications requiring mechanical ventilation (respiratory distress syndrome (RDS) and sepsis with positive blood culture) for longer than three days (were characterized as having complications). Outcomes were reported separately for infants without complications (we listed those outcomes under <a href="./references#CD004863-bbs2-0012" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997A</a>) and for infants with complications (we listed those outcomes under <a href="./references#CD004863-bbs2-0013" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997B</a>). An additional group of 35 infants (Group B) were enrolled at three to eight weeks and will be included in the 'Late EPO' review. No information was provided regarding transfusion guidelines for either group. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0014" title="LauterbachR , KachlikP , PawlikD , BajorekI . Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatria Polska1995;70(9):739‐44. [PUBMED: 8657506] ">Lauterbach 1995</a> was a single‐centre study conducted in Poland. </p> <p> <ul id="CD004863-lst1-0018"> <li> <p>Objective: to evaluate the role of EPO for treatment of infants with anaemia of prematurity.</p> </li> <li> <p>Population: preterm infants with GA &lt; 35 weeks and birth weight ≤ 1500 grams, seven days old. </p> </li> <li> <p>Interventions: Infants in EPO group 1 received EPO 100 IU/kg twice a week between days seven and 37 (low dose), and infants in EPO group 2 received 400 IU/kg twice weekly (high dose) during the same time period; the control group received no treatment or placebo. Both EPO groups and the control group received 10 mg/kg/week of iron IV (high dose). </p> </li> <li> <p>Outcomes assessed: total volume (mL/kg) of blood transfused between days seven and 37. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0015" title="Lima‐RogelV , Torres‐MontesA , Espinosa GriesseS , Villegas AlvarezC , Hernandez‐SierraF , Bissett MandevilleP , et al. Efficacy of early erythropoietin use in critically ill very‐low‐birth‐weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre1998;43(3):191‐5. [PUBMED: 9741224] ">Lima‐Rogel 1998</a> was a single‐centre study performed in Mexico. </p> <p> <ul id="CD004863-lst1-0019"> <li> <p>Objective: to determine the efficacy of EPO in VLBW newborns at less than 72 hours of age. </p> </li> <li> <p>Population: infants with birth weight between 750 and 1500 grams, &lt; 72 hours old.</p> </li> <li> <p>Intervention: Infants in the EPO group received EPO 150 IU/kg/d (high dose) during the first six weeks, and infants in the control group received placebo. Both groups received iron 4 mg/kg/d (low dose). </p> </li> <li> <p>Outcomes assessed: number of transfusions per group, sepsis, NEC, IVH, BPD.</p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a> was a multi‐centre trial conducted at 12 centres in six European countries (Belgium, France, Germany, Netherlands, Switzerland, UK). </p> <p> <ul id="CD004863-lst1-0020"> <li> <p>Objective: to determine whether EPO would prevent anaemia and reduce the need for transfusion in infants with VLBW. </p> </li> <li> <p>Population: infants with birth weight 750 to 1499 grams, and three days old.</p> </li> <li> <p>Intervention: The EPO group received 250 IU of EPO/kg IM three times per week (750 IU/kg/week, high dose). Treatment continued until day 40 to 42 for a total of 17 doses. Infants in the control group did not receive placebo, but adhesive tape was placed on both thighs and remained there until the next visit. Oral iron 2 mg/kg/d was started on day 14 for all infants (low dose). </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, number of transfusions per infant, mortality, ROP, sepsis, NEC, IVH all grades, neutropenia, hypertension, side effects, weight gain, costs. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a> was a multi‐centre trial conducted at 14 centres in four European countries (Belgium, France, Germany, Switzerland). </p> <p> <ul id="CD004863-lst1-0021"> <li> <p>Objective: to investigate whether EPO reduced the need for transfusion in ELBW infants and to determine the optimal time for treatment. </p> </li> <li> <p>Population: infants with birth weight between 500 and 999 grams, three to five days old. </p> </li> <li> <p>Intervention: The EPO group received EPO 250 IU/kg, IV or SC, three times a week (high dose) starting on day three to five of life, for nine weeks. The control group received sham injections. Enteral iron 3 mg/kg was given to all infants from days three to five (low dose) and was increased at days 12 to 14 to 6 mg/kg/d (high dose) and to 9 mg/kg/d (high dose) at days 24 to 26 of life. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, number of donors the infant was exposed to, number of transfusions per infant, mortality during hospital stay, NEC, IVH, PVL, ROP, BPD, growth, days in oxygen, days in NICU, and days in hospital. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0018" title="MeisterB , MaurerH , SimmaB , KernH , UlmerH , HittmairA , et al. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem Cells1997;15(5):359‐63. [DOI: 10.1002/stem.150359; PUBMED: 9323798] ">Meister 1997</a> was a single‐centre trial conducted in Austria. </p> <p> <ul id="CD004863-lst1-0022"> <li> <p>Objective: to evaluate effects of EPO on circulating hematopoietic progenitor cells in anaemic premature infants. </p> </li> <li> <p>Population: preterm infants with birth weight of 750 to 1499 grams, at the age of 5 to 10 days. </p> </li> <li> <p>Intervention: The EPO group received EPO 300 IU/kg SC three times a week (high dose) for four weeks. The control group did not receive the drug and did not receive placebo. Oral iron administration was started with a dose of 6 mg/kg/d (high dose) and was increased after two weeks to 8 mg/kg/d (high dose). The control group received iron alone. </p> </li> <li> <p>Outcomes assessed: cumulative volume of blood transfused/kg.</p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0019" title="MeyerMP , SharmaE , CarsonsM . Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F41‐5. [PUBMED: 12496225] ">Meyer 2003</a> was a single‐centre trial conducted in New Zealand. </p> <p> <ul id="CD004863-lst1-0023"> <li> <p>Objective: to comprehensively identify preterm infants likely to require blood transfusion, and to investigate the effectiveness of EPO in this high‐risk subgroup. </p> </li> <li> <p>Population: preterm infants with gestation &lt; 33 weeks and birth weight &lt; 1700 grams, at the age of 48 hours. </p> </li> <li> <p>Intervention: Infants in the treatment group received EPO 1200 IU/kg/week SC in three divided doses (high dose) until three weeks of age, then the dose was reduced to 600 IU/kg/week until 34 weeks' corrected GA, or for a minimum of three weeks. Infants in the control group received sham treatment. Both groups received elemental iron. Twenty‐one infants in the control group received sham treatment to avoid subcutaneous injection. Iron at a dose of 6 mg/kg/d (high dose) was given to the EPO group once they had attained a postnatal age of two weeks and were receiving at least 50% energy intake orally. Those in the control group received 2 mg/kg/d iron (low dose) from the same age in a more dilute preparation, so that an equivalent volume was given. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, number of donors the infant was exposed to. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0020" title="ObladenM , MaierR , SegererH , GrauelEL , HollandBM , StewartG , et al. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European randomized multicenter trial. Contributions to Nephrology1991;88:314‐26. [PUBMED: 2040194] ">Obladen 1991</a> was a multi‐centre study conducted at five centres in three European countries (Germany (FRG), Germany (GDR), UK). </p> <p> <ul id="CD004863-lst1-0024"> <li> <p>Objective: to investigate whether treatment with EPO reduced anaemia of prematurity and thus the need for transfusion by one‐third in preterm infants. </p> </li> <li> <p>Population: preterm infants with GA 28 to 32 completed weeks, three days old.</p> </li> <li> <p>Intervention: The EPO group received EPO 30 IU/kg (low dose) every third day from the fourth to 25th day of life. The control group did not receive study drug and did not receive placebo. Iron treatment 2 mg/kg (low dose) orally was started on day 14 if there was no feeding intolerance. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, total volume of blood transfused per infant, mortality, chronic lung disease, IVH, NEC, BPD, hypertension. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a> was a single‐centre trial conducted in the USA. </p> <p> <ul id="CD004863-lst1-0025"> <li> <p>Objective: to determine whether administering EPO to ill VLBW infants, beginning on the first or second day of life, would reduce blood transfusions and would be cost‐effective. </p> </li> <li> <p>Population: infants at less than 48 hours of age with birth weight 750 and 1500 grams and GA &gt; 27 weeks. </p> </li> <li> <p>Intervention: The EPO group received EPO 200 IU/kg/d (high dose) IV for 14 consecutive days. The control group received a similar volume of 0.9% saline solution in similar fashion as placebo. Infants in both groups received iron 2 mg/kg/d (low dose) orally when they were taking 70 mL/kg/d enterally, which was increased to 6 mg/kg/day (high dose) when infants were receiving more than 100 mL/kg per day of feeds. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, total volume of blood transfused per infant, number of transfusions per infant, neutropenia, thrombocytopenia, neutrophilia, NEC, IVH. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a> was a multi‐centre trial conducted in the USA. </p> <p> <ul id="CD004863-lst1-0026"> <li> <p>Objective: to evaluate effects of EPO on the transfusion requirements of preterm infants weighing 750 grams or less. </p> </li> <li> <p>Population: infants with birth weight 750 grams or less at 72 hours of age or younger.</p> </li> <li> <p>Intervention: The EPO group received EPO 200 IU/kg/d (high dose) IV, for 14 consecutive days. The control group received placebo as an equivalent volume of diluent in similar fashion. All infants received 1 mg/kg/d iron dextran in total parenteral nutrition (TPN) solution during treatment period (high dose). </p> </li> <li> <p>Outcomes assessed: total volume of blood transfused per infant, number of transfusions per infant, mortality, sepsis, IVH, BPD, ROP. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a> was a multi‐centre trial conducted in the USA. </p> <p> <ul id="CD004863-lst1-0027"> <li> <p>Objective: to evaluate effects of early EPO therapy on the transfusion requirements of preterm infants weighing less than 1000 grams. </p> </li> <li> <p>Population: infants with birth weight 401 to 1000 grams, GA &lt; 32 weeks, between 24 and 96 hours of age at the time of study entry. </p> </li> <li> <p>Intervention: The EPO group received 400 IU/kg EPO three times weekly (high dose) IV or SC when IV access was not available. The placebo or control group received sham SC injections when IV access was not available. Treatment was continued until discharge, transfer, death, or 35 completed weeks' corrected gestational age. EPO‐treated infants received a weekly IV infusion of 5 mg/kg iron dextran (high dose) until they had an enteral intake of 60 mL/kg/d. Placebo or control infants received 1 mg/kg iron dextran (high dose) once a week, administered in a similar manner. Once infants in both groups had an enteral intake of 60 mg/kg/d, they were given iron at a dose of 3 mg/kg/d (low dose). The dose was gradually increased to 6 mg/kg/d (high dose) depending on enteral intake. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, mean number of erythrocyte transfusions per infant, number of donors to whom the infant was exposed, total volume of blood transfused per infant, late‐onset sepsis, mortality, chronic lung disease, ROP, severe IVH, NEC &gt; Bell's stage II, BPD, neutropenia, hypertension. In a follow‐up study of the 72 EPO‐treated and 70 placebo control infants surviving to discharge, follow‐up data at 18 to 22 months' corrected age were collected on 51 EPO ‐treated infants (71%) and 51 placebo controls (73%). Outcomes assessed were growth, psychomotor development, rehospitalization, and transfusions. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a> was a multi‐centre trial conducted in the USA. </p> <p> <ul id="CD004863-lst1-0028"> <li> <p>Objective: to evaluate effects of early EPO therapy on the transfusion requirements of preterm infants weighing less than 1250 grams. </p> </li> <li> <p>Population: infants with birth weight between 1001 grams and 1250 grams, GA &lt; 32 weeks, between 24 and 96 hours of age at the time of study entry. </p> </li> <li> <p>Intervention: The EPO group received 400 IU/kg EPO three times weekly (high dose) IV or SC when IV access was not available. The placebo control group received sham SC injections when IV access was not available. Treatment was continued until discharge, transfer, death, or 35 completed weeks' corrected GA. EPO‐treated infants received a weekly IV infusion of 5 mg/kg iron dextran (high dose) until they had an enteral intake of 60 mL/kg/d. Placebo control infants received 1 mg/kg iron dextran (high dose) once a week, administered in a similar manner. Once infants in both groups had enteral intake of 60 mg/kg/d, they were given iron at a dose of 3 mg/kg/d (low dose). The dose was gradually increased to 6 mg/kg/d (high dose) depending on enteral intake. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, mean number of erythrocyte transfusions per infant, number of donors to whom the infant was exposed, total volume of blood transfused per infant, late‐onset sepsis, mortality, chronic lung disease, ROP, severe IVH, NEC &gt; Bell's stage II, BPD, neutropenia, hypertension. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> was a multi‐centre study conducted in the USA. </p> <p> <ul id="CD004863-lst1-0029"> <li> <p>Objective: to assess whether infants would respond to Darbe by reducing transfusion needs compared with no treatment, with less frequent dosing than erythropoietin. </p> </li> <li> <p>Population: preterm infants with birth weight of 500 to 1250 grams at &lt; 48 hours of age.I </p> </li> <li> <p>Intervention: The Darbe group received 10 µg/kg one time per week SC. The EPO group received 400 U/kg three times per week SC. The control group received sham dosing. Injections continued through 35 weeks’ PMA. All infants (regardless of treatment arm) received supplemental iron, folate (50 mg per day oral), and vitamin E (15 IU per day oral). Iron dextran 3 mg/kg once a week was added to parenteral nutrition while infants were receiving 60 mL/kg/d enteral feedings. Oral iron 3 mg/kg/d was started when feedings were ≥ 60 mL/kg/d, and was increased to 6 mg/kg/d when feedings reached 120 mL/kg/day (high dose). </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, total volume (mL/kg) of blood transfused per infant, number of blood transfusions per infant, number of donors the infant was exposed to, mortality during initial hospital stay, ROP all stages and stages ≥ 3, late‐onset sepsis, NEC stage &gt; 2, IVH grade ≥ 3, PVL, length of hospital stay, BPD (oxygen dependency at 36 weeks' PMA), neutropenia, hypertension. In supplementary studies, long‐term neurodevelopmental outcomes were reported until the age of 3.5 to 4 years in limited samples. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a> was a single‐centre study conducted in Finland. </p> <p> <ul id="CD004863-lst1-0030"> <li> <p>Objective: to determine whether administration of EPO without iron supplementation decreases iron load and morbidity. </p> </li> <li> <p>Population: 39 preterm infants (BW 700 to 1500 grams, PMA ≤ 30.0 weeks).</p> </li> <li> <p>Intervention: EPO 250 IU/kg daily during the first 6 days of life (high dose). The control group received a similar volume of isotonic saline solution in similar fashion. Iron was not administered in either of the two groups. </p> </li> <li> <p>Outcomes assessed: Primary outcome was the oxygen index (OI) calculated from the need for supplemental oxygen and mechanical ventilation during the first six days of life (OI = mean airway pressure × FiO<sub>2</sub> × 100/PaO<sub>2</sub>). Secondary outcomes included requirement for red blood cell transfusions during the first two weeks of life. The incidence of mild BPD was defined as the need for supplementary oxygen at 28 days. The incidence of moderate to severe BPD was defined as the need for supplementary oxygen at 28 days and at 36 postconceptional weeks. For the diagnosis of retinopathy of prematurity (ROP), the ophthalmoscopic examination was repeated until retinas were mature and the highest stage of retinopathy was reported. Severity of ROP was graded according to the international classification. IVH grades III and IV and periventricular leukomalacia (PVL). Number of days on assisted ventilation, use of supplemental oxygen, use of postnatal corticosteroid treatment for prevention of BPD and treatment of hypotension, length of hospital stay. Nosocomial sepsis was defined as a positive blood culture after day 3 of life. Diagnostic data on hyperglycaemia, hypotension, or hypertension requiring therapy, patent ductus arteriosus (PDA) treated with prostaglandin inhibitor therapy or surgery, NEC, and intestinal perforations. Follow‐up at 2 years' corrected age. Overall development was evaluated using the Griffiths Developmental Score. Cerebral palsy was defined as described by Rosenbaum 2002. The child's growth characteristics were reported. </p> </li> <li> <p>Notes: We received clarifying information from Dr. Peltoniemi regarding this study and its results. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a> was a single‐centre study conducted in China. </p> <p> <ul id="CD004863-lst1-0031"> <li> <p>Objective: to evaluate effects of early parenteral iron supplementation combined with EPO for prevention of anaemia in preterm infants. </p> </li> <li> <p>Population: 96 preterm infants, PMA 28 to 34 weeks.</p> </li> <li> <p>Intervention: A control group receiving standard parenteral nutrition (group 1: n = 31), an iron‐supplemented group (iron sucrose IS) (group 2: IS, n = 33), and an iron‐supplemented combined erythropoietin group (group 3: IS + EPO, n = 32). The IS + EPO group received EPO 400 IU/kg twice a week for two weeks; total dose 800 IU/kg/week (1600 IU/kg in two weeks) (high dose). The IS group and the IS + EPO group received iron 200 µg/kg/d until 2 weeks after birth. </p> </li> <li> <p>Outcomes assessed: mortality, NEC, ROP.</p> </li> <li> <p>Notes: For outcome analyses, we included the IS group and the IS + EPO group.</p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0028" title="SalvadoA , RamolfoP , EscobarM , NunezA , AguayoI , StandenJ , et al. Early erythropoietin use for the prevention of anemia in infant premature [Uso precoz de la eritropoyetina en la prevencion de la anemia del prematuro]. Revista Medica de Chile2000;128(12):1313‐7. [PUBMED: 11227239] ">Salvado 2000</a> was a single‐centre trial conducted in Chile. </p> <p> <ul id="CD004863-lst1-0032"> <li> <p>Objective: to assess benefits of early EPO administration to reduce the requirement for blood transfusion in VLBW infants. </p> </li> <li> <p>Population: newborn infants with birth weight less than 1500 grams. Treatment started before 12 days of age (mean age EPO group 7.75 days, control group 7.96 days). </p> </li> <li> <p>Intervention: The EPO group received EPO 200 IU/kg SC three times a week (high dose) over four weeks. The control group received a similar volume of isotonic saline solution in similar fashion. All infants received oral iron at a dose of 3 mg/kg/d (low dose). </p> </li> <li> <p>Outcomes assessed: number of transfusions per infant, sepsis, IVH, days on ventilator.</p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0030" title="SoubasiV , KremenopoulosG , DiamandiE , TsantaliC , TsakirisD . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research1993;34(5):675‐9. [DOI: 10.1203/00006450‐199311000‐00022; PUBMED: 8284109] ">Soubasi 1993</a> was a single‐centre study conducted in Greece. </p> <p> <ul id="CD004863-lst1-0033"> <li> <p>Objective: to assess whether EPO treatment is safe and reduces the need for transfusion.</p> </li> <li> <p>Population: infants with GA ≤ 31 weeks, birth weight ≤ 1500 grams, age one to seven days, no history of haemolytic disease, who were clinically stable. </p> </li> <li> <p>Intervention: The EPO group received 150 IU/kg/dose of EPO twice a week (low dose) during four weeks. The control group received no placebo. From the 15th day of life, iron was started at 3 mg/kg/d (low dose) for all infants. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, number of transfusions per infant, mortality, sepsis, neutropenia, weight gain, hospital stay. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0031" title="SoubasiV , KremenopoulosG , DiamantiE , TsantaliC , SarafidisK , TsakirisD . Follow‐up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. Journal of Pediatrics1995;127(2):291‐7. [PUBMED: 7636658] ">Soubasi 1995</a> was a single‐centre study conducted in Greece. </p> <p> <ul id="CD004863-lst1-0034"> <li> <p>Objective: to follow up with VLBW infants after EPO treatment.</p> </li> <li> <p>Population: infants with GA ≤ 31 weeks, birth weight ≤ 1500 grams, age one to seven days, no history of haemolytic disease, who were clinically stable. </p> </li> <li> <p>Intervention: The EPO 300 group received EPO 150 IU/kg twice weekly (low dose), and the EPO 750 group received EPO 250 IU/kg three times a week (high dose). The control group did not receive any study drug and did not receive placebo. All infants received oral elemental iron 3 mg/kg/d from day 15 of life (low dose). </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, number of blood transfusions per infant, mortality, follow‐up to one year of age, weight gain, hospital stay. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0032" title="SoubasiV , KremenopoulosG , TsantaliC , SavopoulouP , MussafirisC , DimitrouM . Use of erythropoietin and its effects on blood lactate and 2,3‐diphosphoglycerate in premature neonates. Biology of the Neonate2000;78(4):281‐7. [DOI: 14280; PUBMED: 11093007] ">Soubasi 2000</a> was a single‐centre trial conducted in Greece. </p> <p> <ul id="CD004863-lst1-0035"> <li> <p>Objective: to investigate effects of EPO on oxygen affinity and adequate oxygen delivery to the tissues of stable preterm infants. </p> </li> <li> <p>Population: infants with GA ≤ 31 weeks and birth weight ≤ 1300 grams with clinical stability at the time of entry. Although trial authors did not state age at entry, we assumed from a graph (Figure 6) in the publication that age was seven days. </p> </li> <li> <p>Intervention: The EPO group received 200 IU/kg every alternate day (high dose) SC. The control group did not receive EPO and did not receive placebo. Infants received oral iron at a dose of 12 mg/kg/d (high dose) in the EPO group and 4 mg/kg/d (low dose) in the control group. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, number of transfusions per infant. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0033" title="YasmeenBHN , ChowdhuryMA , HoqueMM , HossainMM , JahanR , AktarS . Effect of short term recombinant human erythropoietin therapy in the prevention of anemia of prematurity in very low birth weight infants. Bangladesh Medical Research Council Bulletin2012;38(3):119‐23. [PUBMED: 23540189] ">Yasmeen 2012</a> was a single‐centre study conducted in Dhaka, Bangladesh. </p> <p> <ul id="CD004863-lst1-0036"> <li> <p>Objective: to investigate effects of short‐term administration of EPO with iron and folic acid in prevention of anaemia of prematurity and reduction in the number of transfusions in preterm VLBW infants. </p> </li> <li> <p>Population: infants with GA &lt; 35 weeks, birth weight &lt; 1500 grams, and age &lt; 7 days.</p> </li> <li> <p>Intervention: The EPO group received 200 IU/kg three times/week (high dose) SC. The control group did not receive EPO and did not receive placebo. All infants received oral iron at a dose of 6 mg/kg/d (high dose) and 0.5 mg of folic acid every alternate day up to 12 weeks of life. Administration of both iron and folic acid started from day 14 of life, or as soon as enteral feeding was initiated after day 14. </p> </li> <li> <p>Outcome assessed: mortality.</p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0034" title="YeoCL , ChooS , HoLY . Effect of recombinant human erythropoietin on transfusion needs in preterm infants. Journal of Paediatrics and Child Health2001;37(4):352‐8. [PUBMED: 11532054] ">Yeo 2001</a> was a single‐centre study conducted in Singapore. </p> <p> <ul id="CD004863-lst1-0037"> <li> <p>Objective: to study the efficacy, safety, and cost‐effectiveness of EPO in reducing transfusion needs among VLBW infants. </p> </li> <li> <p>Population: VLBW infants with GA ≤ 33 weeks, age five days.</p> </li> <li> <p>Intervention: The EPO group received EPO 250 IU/kg/dose SC three times a week (high dose) from day 5 to day 40. Infants in the control group did not receive placebo. Infants in both groups received elemental iron 3 mg/kg/d (low dose) orally from day 10, increased to 6 mg/kg/d (high dose) when full feeds were well tolerated. </p> </li> <li> <p>Outcomes assessed: use of one or more RBC transfusions, mean number of erythrocyte transfusions per infant, total volume of blood transfused per infant, mortality, ROP, sepsis, NEC, BPD, hypertension, BPD, costs. </p> </li> </ul> </p> </section> <section id="CD004863-sec4-0005"> <h5 class="title">Studies designed to primarily assess the effectiveness of EPO administered early as a neuro protective agent </h5> <p><a href="./references#CD004863-bbs2-0010" title="HeJS , HuangZL , YangH , WengKZ , ZhuSB . Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2008;10(5):586‐8. [PUBMED: 18947475] ">He 2008</a> was a single‐centre study performed in the Department of Neonatology, Zhangzhou Municipal Hospital, Zhangzhou, Fujian, China. </p> <p> <ul id="CD004863-lst1-0038"> <li> <p>Objective: to evaluate effects of early EPO therapy on neuro behavioural development in preterm infants. </p> </li> <li> <p>Population: preterm infants, seven days old.</p> </li> <li> <p>Intervention: The EPO group received 250 IU/kg/d three times weekly IV for four weeks (750 IU/kg/week, high dose). The use of iron was not stated. </p> </li> <li> <p>Outcomes assessed: Neonatal Behavioral Neurological Assessment at 40 weeks PMA, Gesell Developmental Schedule at 6 and 12 months after birth. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a> was a single‐centre study performed in Switzerland. </p> <p> <ul id="CD004863-lst1-0039"> <li> <p>Objective: to investigate whether high‐dose EPO administered to very preterm infants shortly after birth and subsequently during the first two days was safe in terms of short‐term outcomes and may reduce perinatal brain injury (IVH and PVL). </p> </li> <li> <p>Population: preterm infants with GA 24 0/7 to 31 6/7 weeks.</p> </li> <li> <p>Intervention: Infants in EPO group received 3000 IU rhEpo/kg IV 3 to 6, 12 to 18, and 36 to 42 hours after birth. The placebo group received an equal volume of normal saline. Iron was not administered. </p> </li> <li> <p>Outcomes assessed: mortality, IVH (all grades and grades III to IV), persistent periventricular echodensity (included in the analysis for periventricular leukomalacia (PVL)), ROP (at all stages and at stages 3 to 4), sepsis, NEC (stage not reported), BPD (36 weeks' PMA), side effects. </p> </li> <li> <p>Notes: All infants who were born at 26 weeks' PMA or later were reported on in <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>. From the 2008 study, we reported only on infants who were &lt; 26 weeks' PMA. We received additional information on these eight infants from Dr. Fauchère. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a> was a multi‐centre study performed in Switzerland. </p> <p> <ul id="CD004863-lst1-0040"> <li> <p>Objective: to investigate the safety and short‐term outcome of high‐dose EPO given shortly after birth and subsequently over the first two days for neuro protection to very preterm infants. </p> </li> <li> <p>Population: preterm infants with PMA of 26 0/7 to 31 6/7 weeks.</p> </li> <li> <p>Intervention: infants in EPO group received 3000 IU rhEpo/kg IV 3 to 6, 12 to 18, and 36 to 42 hours after birth. The placebo group received an equal volume of normal saline. Iron was not administered. </p> </li> <li> <p>Outcomes assessed: mortality, IVH (all grades and grades III to IV), persistent periventricular echodensity (included in the analysis for periventricular leukomalacia (PVL)), ROP (at all stages and at stage 3 to 4), sepsis, NEC (stage not reported), BPD (36 weeks' PMA), side effects. Brain MRI abnormalities at term‐equivalent age and long‐term outcomes at two years of age reported separately. </p> </li> </ul> </p> <p><a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> was a single‐centre study conducted in Zhengzhou, China. </p> <p> <ul id="CD004863-lst1-0041"> <li> <p>Objective: to evaluate the efficacy and safety of repeated low‐dose EPO for improvement of neurological outcomes in very preterm infants. </p> </li> <li> <p>Population: preterm infants with GA ≤ 32 weeks, enrolled within 72 hours after birth.</p> </li> <li> <p>Intervention: The EPO group received rhEPO at 500 U/kg IV every other day for 2 weeks. Cumulative dose of 3500 U/kg. First dose within 72 hours after birth. Placebo group received an equivalent volume of normal saline. </p> </li> <li> <p>Outcomes assessed: Primary outcome was death or moderate to severe neurological disability assessed at 18 months' corrected age. Moderate or severe disabilities were defined as survival with at least 1 of the following complications: cerebral palsy, MDI &lt; 70, deafness (defined as a hearing disability that required amplification, or blindness defined as visual corrected acuity of, 20/200). Secondary outcomes at 18 months' corrected age were individual components of the composite outcome. Short‐term outcomes included intraventricular haemorrhage grade III to IV, PVL, ROP (grade not stated), NEC, BPD (at 36 weeks' PMA), sepsis. </p> </li> </ul> </p> </section> <section id="CD004863-sec4-0006"> <h5 class="title">Studies designed to primarily assess the effectiveness of EPO administered early in improving feeding tolerance </h5> <p><a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a> was a single‐centre study conducted in Cairo, Egypt. </p> <p> <ul id="CD004863-lst1-0042"> <li> <p>Objective: to evaluate the efficacy and safety of enteral recombinant granulocyte colony‐stimulating factor (rh‐CSF) and recombinant human erythropoietin (rhEPO) in preventing feeding intolerance. </p> </li> </ul> <ul id="CD004863-lst1-0043"> <li> <p>Population: preterm infants with PMA ≤ 33 weeks.</p> </li> <li> <p>Intervention: Neonates were assigned to four groups: 20 received rhG‐CSF, 20 received rhEPO, 20 received both, and 30 received distilled water (placebo control). </p> </li> <li> <p>Outcomes assessed: time to achieve full enteral feeding (150 mL/kg/d), mortality, NEC, duration of hospital stay. </p> </li> </ul> <ul id="CD004863-lst1-0044"> <li> <p>Notes: We included in analyses the 20 infants who received EPO and the 30 infants who received placebo. </p> </li> </ul> </p> </section> </section> <section id="CD004863-sec3-0020"> <h4 class="title">Excluded studies</h4> <p>We excluded 22 studies (see <a href="./references#CD004863-sec2-0028" title="">Characteristics of excluded studies</a> table). </p> </section> </section> <section id="CD004863-sec2-0014"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias graph (<a href="#CD004863-fig-0002">Figure 2</a>) shows our evaluations of individual studies, which are summarised in the 'Risk of bias' summary (<a href="#CD004863-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD004863-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004863-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004863-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004863-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD004863-sec3-0021"> <h4 class="title">Allocation</h4> <p>Information regarding whether the allocation was concealed was often missing. Twelve studies reported proper random sequence generation (<a href="./references#CD004863-bbs2-0030" title="SoubasiV , KremenopoulosG , DiamandiE , TsantaliC , TsakirisD . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research1993;34(5):675‐9. [DOI: 10.1203/00006450‐199311000‐00022; PUBMED: 8284109] ">Soubasi 1993</a>; <a href="./references#CD004863-bbs2-0031" title="SoubasiV , KremenopoulosG , DiamantiE , TsantaliC , SarafidisK , TsakirisD . Follow‐up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. Journal of Pediatrics1995;127(2):291‐7. [PUBMED: 7636658] ">Soubasi 1995</a>; <a href="./references#CD004863-bbs2-0018" title="MeisterB , MaurerH , SimmaB , KernH , UlmerH , HittmairA , et al. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem Cells1997;15(5):359‐63. [DOI: 10.1002/stem.150359; PUBMED: 9323798] ">Meister 1997</a>; <a href="./references#CD004863-bbs2-0032" title="SoubasiV , KremenopoulosG , TsantaliC , SavopoulouP , MussafirisC , DimitrouM . Use of erythropoietin and its effects on blood lactate and 2,3‐diphosphoglycerate in premature neonates. Biology of the Neonate2000;78(4):281‐7. [DOI: 14280; PUBMED: 11093007] ">Soubasi 2000</a>; <a href="./references#CD004863-bbs2-0019" title="MeyerMP , SharmaE , CarsonsM . Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F41‐5. [PUBMED: 12496225] ">Meyer 2003</a>; <a href="./references#CD004863-bbs2-0001" title="ArifB , FerhanK . Recombinant human erythropoietin therapy in low‐birthweight preterm infants: a prospective controlled study. Pediatrics International2005;47(1):67‐71. [DOI: 10.1111/j.1442‐200x.2005.02007.x; PUBMED: 15693870] ">Arif 2005</a>; <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>). We interpreted allocation to study groups as concealed in 17 studies (<a href="./references#CD004863-bbs2-0020" title="ObladenM , MaierR , SegererH , GrauelEL , HollandBM , StewartG , et al. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European randomized multicenter trial. Contributions to Nephrology1991;88:314‐26. [PUBMED: 2040194] ">Obladen 1991</a>; <a href="./references#CD004863-bbs2-0030" title="SoubasiV , KremenopoulosG , DiamandiE , TsantaliC , TsakirisD . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research1993;34(5):675‐9. [DOI: 10.1203/00006450‐199311000‐00022; PUBMED: 8284109] ">Soubasi 1993</a>; <a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a>; <a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a>; <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>; <a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a>; <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a>; <a href="./references#CD004863-bbs2-0019" title="MeyerMP , SharmaE , CarsonsM . Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F41‐5. [PUBMED: 12496225] ">Meyer 2003</a>; <a href="./references#CD004863-bbs2-0009" title="HaidenN , CardonaF , SchwindtJ , BergerA , KuhleS , HomoncikM , et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis2005;93(1):118‐23. [DOI: 10.1160/TH04‐02‐0093; PUBMED: 15630501] ">Haiden 2005</a>; <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0011" title="KhatamiSF , MamouriG , TorkamanM . Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants. Indian Journal of Pediatrics2008;75(12):1227‐30. [DOI: 10.1007/s12098‐008‐0225‐0; PUBMED: 19057854] ">Khatami 2008</a>; <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>; <a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a>). Fourteen studies used placebo or sham injections (<a href="./references#CD004863-bbs2-0030" title="SoubasiV , KremenopoulosG , DiamandiE , TsantaliC , TsakirisD . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research1993;34(5):675‐9. [DOI: 10.1203/00006450‐199311000‐00022; PUBMED: 8284109] ">Soubasi 1993</a>; <a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a>; <a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a>; <a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a>; <a href="./references#CD004863-bbs2-0015" title="Lima‐RogelV , Torres‐MontesA , Espinosa GriesseS , Villegas AlvarezC , Hernandez‐SierraF , Bissett MandevilleP , et al. Efficacy of early erythropoietin use in critically ill very‐low‐birth‐weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre1998;43(3):191‐5. [PUBMED: 9741224] ">Lima‐Rogel 1998</a>; <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>; <a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a>; <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a>; <a href="./references#CD004863-bbs2-0019" title="MeyerMP , SharmaE , CarsonsM . Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F41‐5. [PUBMED: 12496225] ">Meyer 2003</a>; <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>; <a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a>). </p> </section> <section id="CD004863-sec3-0022"> <h4 class="title">Blinding</h4> <p>Fourteen studies blinded personnel (<a href="./references#CD004863-bbs2-0030" title="SoubasiV , KremenopoulosG , DiamandiE , TsantaliC , TsakirisD . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research1993;34(5):675‐9. [DOI: 10.1203/00006450‐199311000‐00022; PUBMED: 8284109] ">Soubasi 1993</a>; <a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a>; <a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a>; <a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a>; <a href="./references#CD004863-bbs2-0015" title="Lima‐RogelV , Torres‐MontesA , Espinosa GriesseS , Villegas AlvarezC , Hernandez‐SierraF , Bissett MandevilleP , et al. Efficacy of early erythropoietin use in critically ill very‐low‐birth‐weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre1998;43(3):191‐5. [PUBMED: 9741224] ">Lima‐Rogel 1998</a>; <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>; <a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a>; <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a>; <a href="./references#CD004863-bbs2-0019" title="MeyerMP , SharmaE , CarsonsM . Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F41‐5. [PUBMED: 12496225] ">Meyer 2003</a>; <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>; <a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a>). We interpreted that blinding of outcome assessment was appropriate in 14 studies (<a href="./references#CD004863-bbs2-0030" title="SoubasiV , KremenopoulosG , DiamandiE , TsantaliC , TsakirisD . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research1993;34(5):675‐9. [DOI: 10.1203/00006450‐199311000‐00022; PUBMED: 8284109] ">Soubasi 1993</a>; <a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a>; <a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a>; <a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a>; <a href="./references#CD004863-bbs2-0015" title="Lima‐RogelV , Torres‐MontesA , Espinosa GriesseS , Villegas AlvarezC , Hernandez‐SierraF , Bissett MandevilleP , et al. Efficacy of early erythropoietin use in critically ill very‐low‐birth‐weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre1998;43(3):191‐5. [PUBMED: 9741224] ">Lima‐Rogel 1998</a>; <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>; <a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a>; <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a>; <a href="./references#CD004863-bbs2-0019" title="MeyerMP , SharmaE , CarsonsM . Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F41‐5. [PUBMED: 12496225] ">Meyer 2003</a>; <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>; <a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a>). </p> </section> <section id="CD004863-sec3-0023"> <h4 class="title">Incomplete outcome data</h4> <p>Risk of attrition bias was clear in two studies (<a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a>; <a href="./references#CD004863-bbs2-0033" title="YasmeenBHN , ChowdhuryMA , HoqueMM , HossainMM , JahanR , AktarS . Effect of short term recombinant human erythropoietin therapy in the prevention of anemia of prematurity in very low birth weight infants. Bangladesh Medical Research Council Bulletin2012;38(3):119‐23. [PUBMED: 23540189] ">Yasmeen 2012</a>). Six studies reported long‐term (18 to 22/24 months' corrected age) outcomes (<a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>; <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>). In <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>, follow‐up rates were low; among 72 EPO‐treated and 70 placebo control infants surviving to discharge, follow‐up data at 18 to 22 months' corrected age were collected on 51 of 72 EPO‐treated infants (71%) and 51 of 70 placebo/controls (73%). <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> enrolled 102 infants and at the end of hospitalisation evaluated 94 infants. These investigators evaluated 80 children at follow‐up at corrected age of 18 to 22 months (Darbe n = 27 (84%), EPO n = 29 (91%), placebo/sham injection n = 24 (80%)). A report of preschool assessment (at age 3.5 to 4 years) was published in 2016 (Ohls 2016, follow up to <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>). This study assessed 53 children (Darbe n = 15 (47%), EPO n = 24 (75%), placebo n =14 (47%)). In 2017, Lowe 2017 (follow up to <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>) reported on behavioural measures in 49 children (Darbe or EPO n = 35 (55%), placebo n = 14 (47%)). The two groups given Darbe and EPO were combined and were referred to as the erythropoiesis‐stimulating agents (ESA) group. Percentages are based on the number of infants evaluated at the end of hospitalisation. Follow‐up rates beyond 18 to 22 months were low. For <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>, we obtained information from the first author on outcomes of eight infants born at &lt; 26 weeks' PMA; five deaths and long‐term follow‐up were reported on three surviving infants. In <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>, long‐term outcomes were reported for 365 infants (81%): 191 infants (83%) assigned to the EPO group and 174 infants (79%) assigned to the placebo group. In <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>, of 20 surviving children at two years of age, 19 were enrolled and 10 (50%) were evaluated by Griffiths Developmental Scale. Of 16 surviving placebo group children at 2 years of age, all were enrolled and 9 (56%) were evaluated by Griffiths Developmental Scale. Follow‐up rates for Griffiths Developmental Scale were low. In the large study <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>, all 743 randomised infants were accounted for in short‐term outcomes. For outcomes at 18 months, 309 children in the EPO group and 304 in the placebo group were assessed. In the EPO group, 36 children had been lost to follow‐up, as were 39 children in the control group. Twenty‐one infants in the EPO group had died, as had 34 children in the control group. Follow‐up rate at 18 months was 90% in the EPO group and 87% in the control group. </p> </section> <section id="CD004863-sec3-0024"> <h4 class="title">Selective reporting</h4> <p>For most included studies, the study protocol was not available to us. Therefore we could not ascertain whether deviations from the protocol occurred. We were able to locate study protocols for <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>; and <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>. <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> was registered as NCT00334737 in June 2006 and showed no major deviations from the protocol, except that primary outcomes included MDI at 18 to 22 months and Psychomotor Development Index (PDI) as a secondary outcome. MDI and PDI are not reported in the primary publication. <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a> was registered as NCT00413946 in December 2006 after the last patient had been enrolled in November 2006. Registration applies to the larger study published in 2015 (<a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>). The protocol for the early part of the study was not available to us; therefore we cannot ascertain whether deviations from the protocol occurred. We noted no deviations from the protocol in <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>. <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> was registered as NCT02036073 in December 2013, after recruitment had been completed. This study started to recruit patients in January 2009. Therefore, we were unable to detect any deviations from a study protocol established before the start of the study. In the protocol, the primary outcome measured was incidence of MDI &lt; 70 at corrected age of 18 months, and secondary outcome measures were incidence of ROP at corrected age 42 weeks. In the full report, primary outcomes are listed as death, disability, or death + disability at 18 months' corrected age. ROP is listed as a neonatal complication. The protocol for <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a> was written in Finnish. We contacted Dr. Peltoniemi, who contacted Dr. Antilla, a co‐author, who assured us that no deviations from the protocol occurred. </p> <p>All studies accounted for all enrolled infants.</p> </section> <section id="CD004863-sec3-0025"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any other sources of potential bias. Sample sizes were generally small, ranging from 19 infants enrolled in <a href="./references#CD004863-bbs2-0014" title="LauterbachR , KachlikP , PawlikD , BajorekI . Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatria Polska1995;70(9):739‐44. [PUBMED: 8657506] ">Lauterbach 1995</a> to 743 in <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>. Three original studies (<a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>) reported study details as required by the CONSORT statement (<a href="./references#CD004863-bbs2-0065" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA1996;276(8):637‐9. [PUBMED: 8773637] ">Begg 1996</a>). </p> </section> </section> <section id="CD004863-sec2-0015"> <h3 class="title" id="CD004863-sec2-0015">Effects of interventions</h3> <p>See: <a href="./full#CD004863-tbl-0001"><b>Summary of findings for the main comparison</b> </a>; <a href="./full#CD004863-tbl-0002"><b>Summary of findings 2</b> </a>; <a href="./full#CD004863-tbl-0003"><b>Summary of findings 3</b> </a>; <a href="./full#CD004863-tbl-0004"><b>Summary of findings 4</b> </a> </p> <section id="CD004863-sec3-0026"> <h4 class="title">Studies designed to primarily investigate the effectiveness and safety of EPO or Darbe administered early in reducing red blood cell transfusions or providing neuro protection or protection against necrotising enterocolitis </h4> <section id="CD004863-sec4-0007"> <h5 class="title">Erythropoietin versus placebo or no treatment (Comparison 1)</h5> <p>All analyses reported for Comparison 1 compared EPO versus placebo or no intervention (sham injection). </p> <p>We indicated the primary outcomes and noted that those not indicated as such were secondary outcomes. For outcomes included in 'Summary of findings' tables, we included our assessments of evidence quality according to GRADE. </p> <section id="CD004863-sec5-0001"> <h6 class="title">Use of one or more red blood cell transfusions (low (&lt; 500 IU/kg/week) and high (&gt; 500 IU/kg/week) doses of EPO) ‐ Primary outcome (Outcome 1.1) </h6> <p>A total of 19 studies enrolling 1750 infants reported on the use of one or more RBC transfusions. Early EPO significantly reduced the proportion of infants who received one or more RBC transfusions (typical risk ratio (RR) 0.79, 95% confidence interval (CI) 0.74 to 0.85; typical risk difference (RD) ‐0.14, 95% CI ‐0.18 to ‐0.10; number needed to treat for an additional beneficial outcome (NNTB) 7, 95% CI 6 to 10). Heterogeneity for this outcome was moderate (RR: I<sup>2</sup> = 69%; RD: I<sup>2</sup> = 62%) (<a href="./references#CD004863-fig-00101" title="">Analysis 1.1</a>; <a href="#CD004863-fig-0004">Figure 4</a>). The funnel plot was asymmetrical with relative absence of smaller studies not having a protective effect (<a href="#CD004863-fig-0005">Figure 5</a>). The quality of the evidence was low. </p> <div class="figure" id="CD004863-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Erythropoietin versus placebo or no treatment, outcome: 1.1 Use of 1 or more red blood cell transfusions (low and high doses of EPO)." data-id="CD004863-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Erythropoietin versus placebo or no treatment, outcome: 1.1 Use of 1 or more red blood cell transfusions (low and high doses of EPO). </p> </div> </div> </div> <div class="figure" id="CD004863-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Erythropoietin versus placebo or no treatment, outcome: 1.1 Use of 1 or more red blood cell transfusions (low and high doses of EPO)." data-id="CD004863-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Erythropoietin versus placebo or no treatment, outcome: 1.1 Use of 1 or more red blood cell transfusions (low and high doses of EPO). </p> </div> </div> </div> <p>We conducted further analyses by including studies that used a high dose of EPO (&gt; 500 U/kg/week) or a low dose of EPO (≤ 500 U/kg/week). </p> </section> <section id="CD004863-sec5-0002"> <h6 class="title">Use of one or more red blood cell transfusions (high dose of EPO (&gt; 500 U/kg/week)) (Outcome 1.2) </h6> <p>A total of 17 studies enrolling 1317 patients testing a high dose of EPO reported on this outcome. A high dose of EPO significantly reduced the proportion of infants who received one or more RBC transfusions (typical RR 0.79, 95% CI 0.74 to 0.86; typical RD ‐0.15, 95% CI ‐0.19 to ‐0.10; NNTB 7, 95% CI 5 to 10). Heterogeneity for this outcome was moderate (RR: I<sup>2</sup> = 71%; RD: I<sup>2</sup> = 64%) (<a href="./references#CD004863-fig-00102" title="">Analysis 1.2</a>). </p> <p>We conducted a subgroup analysis for a high dose of EPO in combination with a high dose of iron (Outcome Table 1.2.1). A total of 11 studies enrolling 863 infants reported on this outcome. A high dose of EPO given with a high dose of iron significantly reduced the proportion of infants who received one or more RBC transfusions (typical RR 0.84, 95% CI 0.77 to 0.92; typical RD ‐0.11, 95% CI ‐0.16 to ‐0.05; NNTB 9, 95% CI 6 to 20). We noted low or no heterogeneity for this outcome (RR: I<sup>2</sup> = 32%; RD: I<sup>2</sup> = 22%). </p> <p>A total of six studies enrolling 454 infants testing a high dose of EPO and a low dose of iron (Outcome Table 1.2.2) reported on this outcome. A high dose of EPO and a low dose of iron significantly reduced the proportion of infants who received one or more RBC transfusions (typical RR 0.71, 95% CI 0.62 to 0.82; typical RD ‐0.21, 95% CI ‐0.29 to ‐0.14; NNTB 5, 95% CI 3 to 7). Heterogeneity for this outcome was high for RR (I<sup>2</sup> = 91%) and RD (I<sup>2</sup> = 84%). </p> </section> <section id="CD004863-sec5-0003"> <h6 class="title">Use of one or more red blood cell transfusions (low dose of EPO (&lt; 500 U/kg/week)) (Outcome 1.3) </h6> <p>A total of four studies including 484 participants testing a low dose of EPO reported on this outcome. A low dose of EPO resulted in a significant reduction in the proportion of infants who received one or more RBC transfusions (typical RR 0.77, 95% CI 0.65 to 0.91; typical RD ‐0.13, 95% CI ‐0.22 to ‐0.05; NNTB 8, 95% CI 5 to 20). Heterogeneity was low and moderate for this outcome (RR: I<sup>2</sup> = 47%; RD: I<sup>2</sup> = 55%) (<a href="./references#CD004863-fig-00103" title="">Analysis 1.3</a>). </p> <p>We conducted a subgroup analysis for a low dose of EPO in combination with a high dose of iron (Outcome Table 1.3.1). Two studies enrolling 322 infants reported on this outcome. One of these studies reported no outcomes for either group. The significant RR was 0.75 (95% CI 0.61 to 0.93); the test for heterogeneity was not applicable. The significant typical RD was ‐0.14 (95% CI ‐0.24 to ‐0.04). Heterogeneity was not applicable for RR and was high for RD (I<sup>2</sup> = 81%). The NNTB was 7 (95% CI 4 to 25). </p> <p>Two studies enrolling 162 infants tested the effectiveness of a low dose of EPO in combination with a low dose of iron (Outcome Table 1.3.2) and reported on this outcome. A low dose of EPO combined with a low dose of iron did not significantly reduce the proportion of infants who received one or more RBC transfusions (typical RR 0.80, 95% CI 0.60 to 1.07; typical RD ‐0.12, 95% CI ‐0.26 to 0.03). Heterogeneity was moderate (I<sup>2</sup> = 70%) for RR and low for RD (I<sup>2</sup> = 48%). </p> <p>Only one study included a group that received no iron (<a href="./references#CD004863-bbs2-0004" title="CarnielliVP , DaRiolR , MontiniG . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F44‐8. [PUBMED: 9797624] ">Carnielli 1998</a>); however, this study did not report on the primary outcome of interest: 'use of one or more RBC transfusions'. In <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a> and <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>, no group received iron. These studies did not report on the primary outcome of interest: 'use of one or more RBC transfusions'. </p> </section> <section id="CD004863-sec5-0004"> <h6 class="title">Total volume (mL/kg) of red blood cells transfused per infant (Outcome 1.4)</h6> <p>Seven studies enrolling 581 infants reported on the total volume of RBCs transfused per infant. The significant weighted mean difference (WMD) was a reduction of 6.8 mL/kg of blood transfused per infant (95% CI ‐11.5 to ‐ 2.1). Heterogeneity was moderate for this outcome (I<sup>2</sup> = 63%) (<a href="./references#CD004863-fig-00104" title="">Analysis 1.4</a>). </p> <p><a href="./references#CD004863-bbs2-0004" title="CarnielliVP , DaRiolR , MontiniG . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F44‐8. [PUBMED: 9797624] ">Carnielli 1998</a> reported on the mean volume of blood (mL/kg) transfused for the three groups: EPO + iron 16.7 (95% CI 4.9 to 28.6); EPO only 20.1 (95% CI 6.2 to 34.2), and control 44.4 (95% CI 29.0 to 59.7) (EPO vs control P = 0.028; EPO + iron vs control P = 0.009) (P values according to trial authors). </p> <p><a href="./references#CD004863-bbs2-0014" title="LauterbachR , KachlikP , PawlikD , BajorekI . Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatria Polska1995;70(9):739‐44. [PUBMED: 8657506] ">Lauterbach 1995</a> reported that infants treated with 800 IU of EPO/kg/week required a statistically significantly lower volume (mL/kg) of packed erythrocytes in comparison with untreated infants both between days 7 and 37 of life (18.6 mL vs 46.8 mL) and between day seven of life and the day of discharge (35.8 mL vs 94.2 mL) (P &lt; 0.04 for both comparisons). </p> <p><a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a> reported on the mean (SD) volume of blood transfused as mL/kg/d: early EPO group 0.7 (1.2) and control group 1.1 (1.2) (P value not provided). <a href="./references#CD004863-bbs2-0018" title="MeisterB , MaurerH , SimmaB , KernH , UlmerH , HittmairA , et al. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem Cells1997;15(5):359‐63. [DOI: 10.1002/stem.150359; PUBMED: 9323798] ">Meister 1997</a> reported on the median (first and third quartile) volume of blood transfused as mL/kg/d: EPO group 0 (0 to 0.47) and control group 0.86 (0.5 to 1.1). </p> </section> <section id="CD004863-sec5-0005"> <h6 class="title">Number of red blood cell transfusions per infant (Outcome 1.5)</h6> <p>A total of 16 studies enrolling 1744 infants reported on the number of RBC transfusions per infant. The significant weighted mean difference (WMD) for the number of RBC transfusions per infant was ‐0.57 (95% CI ‐0.68 to ‐0.45). Heterogeneity was high for this outcome (I<sup>2</sup> = 80%) (<a href="./references#CD004863-fig-00105" title="">Analysis 1.5</a>). </p> <p><a href="./references#CD004863-bbs2-0004" title="CarnielliVP , DaRiolR , MontiniG . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F44‐8. [PUBMED: 9797624] ">Carnielli 1998</a> reported on the mean number of RBC transfusions for three groups: EPO + iron 1.0 (95% CI 0.28 to 1.18); EPO only 1.3 (95% CI 0.54 to 2.06); and control 2.9 (95% CI 1.84 to 3.88) (control vs EPO P = 0.065; control vs EPO + iron P = 0.035) (P values according to trial authors). </p> <p><a href="./references#CD004863-bbs2-0002" title="AventM , CoryBJ , GalpinJ , BallotDE , CooperPA , ShermanG , et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of Tropical Pediatrics2002;48(4):227‐33. [PUBMED: 12200985] ">Avent 2002</a> reported the median and range of number of transfusions across three groups: low‐dose EPO 0 (0 to 1); high‐dose EPO 0 (0 to 2); and control 0 (0 to 4) (P = 0.03 across the three groups). <a href="./references#CD004863-bbs2-0009" title="HaidenN , CardonaF , SchwindtJ , BergerA , KuhleS , HomoncikM , et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis2005;93(1):118‐23. [DOI: 10.1160/TH04‐02‐0093; PUBMED: 15630501] ">Haiden 2005</a> reported the number of transfusions: EPO 2 (0 to 15) and control 4.5 (0 to 12) (not statistically significant according to trial authors). </p> </section> <section id="CD004863-sec5-0006"> <h6 class="title">Number of donors to whom the infant was exposed (Outcome 1.6)</h6> <section id="CD004863-sec6-0001"> <p><b>Number of donors the infant was exposed to among all randomised infants (Outcome 1.6.1)</b></p> <p>Three studies enrolling 254 infants reported on this outcome as means and standard deviations (SDs). The significant WMD for the number of donors to whom the infant was exposed was ‐0.54 (95% CI ‐0.89 to ‐0.20). We noted no heterogeneity for this outcome (I<sup>2</sup> = 0%) (<a href="./references#CD004863-fig-00106" title="">Analysis 1.6</a>). </p> </section> <section id="CD004863-sec6-0002"> <p><b>Number of donors the infant was exposed to among infants who were transfused (Outcome 1.6.2)</b></p> <p>Two studies enrolling 290 infants reported on this outcome. The non‐significant WMD for the number of donors the infant was exposed to among infants who were transfused was 0.05 (95% CI ‐0.33 to 0.42). Heterogeneity was moderate for this outcome (I<sup>2</sup> = 63%) (<a href="./references#CD004863-fig-00106" title="">Analysis 1.6</a>). </p> <p><a href="./references#CD004863-bbs2-0003" title="CarnielliV , MontiniG , DaRiolR , Dall'AmicoR , CantaruttiF . Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. Journal of Pediatrics1992;121(1):98‐102. [PUBMED: 1625101] ">Carnielli 1992</a> reported that the number of donor exposures ranged from zero to five in the EPO group and from zero to six in the control group (P value not provided). <a href="./references#CD004863-bbs2-0009" title="HaidenN , CardonaF , SchwindtJ , BergerA , KuhleS , HomoncikM , et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis2005;93(1):118‐23. [DOI: 10.1160/TH04‐02‐0093; PUBMED: 15630501] ">Haiden 2005</a> reported on this outcome in a similar fashion: EPO group 1 donor (0 to 10), control group 3 donors (0 to 5) (not statistically significant according to trial authors). </p> </section> </section> <section id="CD004863-sec5-0007"> <h6 class="title">Mortality during initial hospital stay (all causes of mortality) (Outcome 1.7)</h6> <p>A total of 20 studies enrolling 2212 infants reported on this outcome. Mortality was not significantly altered by the use of EPO (typical RR 0.89, 95% CI 0.68 to 1.16; typical RD ‐0.01, 95% CI ‐0.03 to 0.01). We noted no heterogeneity for this outcome (RR and RD: I<sup>2</sup> = 0%) (<a href="./references#CD004863-fig-00107" title="">Analysis 1.7</a>). The quality of the evidence was high. </p> </section> <section id="CD004863-sec5-0008"> <h6 class="title">Retinopathy of prematurity (ROP) (all stages or stage not stated by trial authors) (Outcome 1.8) </h6> <p>A total of 11 studies enrolling 2185 infants reported on ROP. We obtained unpublished data from <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a> on the highest grade of ROP recorded during the study among examined survivors. Data show no significant difference in the incidence of ROP (all stages or stage not stated by trial authors) (typical RR 0.92, 95% CI 0.79 to 1.08; typical RD ‐0.02, 95% CI ‐0.05 to 0.02). We noted no heterogeneity for this outcome (RR and RD: I<sup><i>2</i> </sup> = 0%) (<a href="./references#CD004863-fig-00108" title="">Analysis 1.8</a>). </p> </section> <section id="CD004863-sec5-0009"> <h6 class="title">Retinopathy of prematurity (ROP) (stage ≥ 3) (Outcome 1.9)</h6> <p>A total of eight studies enrolling 1283 infants reported on severe ROP (stage ≥ 3). Data show no significant differences in ROP (stage ≥ 3) between groups (typical RR 1.24, 94% CI 0.81 to 1.90; typical RD 0.01, 95% CI ‐0.01 to 0.04). We noted no heterogeneity for this outcome for RR (I<sup>2</sup> = 0%) and low heterogeneity for RD (I<sup>2</sup> = 34%) (<a href="./references#CD004863-fig-00109" title="">Analysis 1.9</a>). The quality of the evidence was high. </p> <p><a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a> reported no differences in ROP (stage ≥ 3) rates between groups (data not provided). </p> </section> <section id="CD004863-sec5-0010"> <h6 class="title">Proven sepsis (clinical symptoms and signs of sepsis and positive blood culture for bacteria or fungi) (Outcome 1.10) </h6> <p>Twelve studies including 2180 infants reported on this outcome. EPO did not significantly change rates of proven sepsis (typical RR 0.87, 95% CI 0.74 to 1.02; typical RD ‐0.03, 95% CI ‐0.06 to 0.00). We noted no heterogeneity (RR and RD: I<sup>2</sup> = 0%) (<a href="./references#CD004863-fig-00110" title="">Analysis 1.10</a>). </p> </section> <section id="CD004863-sec5-0011"> <h6 class="title">Necrotising enterocolitis (NEC) (stage &gt; 2 or stage not reported) (Outcome 1.11)</h6> <p>We included in this analysis any outcome stated as NEC. We include 15 studies reporting on 2639 infants. EPO significantly reduced the rate of NEC (typical RR 0.69, 95% CI 0.52 to 0.91; typical RD ‐0.03, 95% CI ‐0.05 to ‐0.01). We noted no heterogeneity for this outcome (RR: I<sup>2</sup> = 0%, RD: I<sup>2</sup> = 22%; NNTB 33, 95% CI 20 to 100) (<a href="./references#CD004863-fig-00111" title="">Analysis 1.11</a>). The quality of evidence was moderate. </p> <p><a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a> reported no differences in NEC rates between groups (data not provided). The quality of the evidence was low. </p> </section> <section id="CD004863-sec5-0012"> <h6 class="title">Intraventricular haemorrhage (IVH); all grades (Outcome 1.12)</h6> <p>Many trial authors did not state the grade of IVH. We included in this outcome studies in which authors did not state the grade and excluded IVH grades III and IV when known. A total of ten studies including 1226 infants reported on this outcome. EPO did not significantly change the rate of IVH (all grades) (typical RR 0.98, 95% CI 0.76 to 1.26; typical RD ‐0.00, 95% CI ‐0.04 to 0.04) (<a href="./references#CD004863-fig-00112" title="">Analysis 1.12</a>). We noted no heterogeneity for this outcome for RR and RD (I<sup>2</sup> = 0%). <a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a> and <a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a> reported no differences in IVH rates between groups (data not provided). </p> </section> <section id="CD004863-sec5-0013"> <h6 class="title">Intraventricular haemorrhage (IVH); grades III and IV (Outcome 1.13)</h6> <p>Eight studies enrolling 1460 infants reported on this outcome. EPO significantly reduced the rate of IVH (grades III and IV) (typical RR 0.60, 95% CI 0.43 to 0.85; typical RD ‐0.04, 95% CI ‐0.07 to ‐0.02; NNTB 25, 95% CI 14 to 50). Heterogeneity was low for this outcome for RR (I<sup>2</sup> = 45%) but high for RD (I<sup>2</sup> = 79%) (<a href="./references#CD004863-fig-00113" title="">Analysis 1.13</a>). The quality of the evidence was moderate. </p> </section> <section id="CD004863-sec5-0014"> <h6 class="title">Periventricular leukomalacia (PVL); cystic changes in periventricular areas (Outcome 1.14) </h6> <p>Six studies enrolling 1469 infants reported on PVL. EPO significantly reduced the rate of PVL (typical RR 0.66, 95% CI 0.48 to 0.92; typical RD ‐0.04, 95% CI ‐0.07 to ‐0.01; NNTB 25, 95% CI 14 to 100). We noted no heterogeneity for this outcome for RR (I<sup>2</sup> = 5%) but high heterogeneity for RD (I<sup>2</sup> = 79%) (<a href="./references#CD004863-fig-00114" title="">Analysis 1.14</a>). The quality of the evidence was moderate. </p> </section> <section id="CD004863-sec5-0015"> <h6 class="title">Length of hospital stay (days) (Outcome 1.15)</h6> <p>Eight studies enrolling 970 infants reported on length of hospital stay. EPO significantly reduced length of hospital stay (typical MD ‐3.20 days, 95% CI ‐5.34 to ‐1.06). Heterogeneity was moderate for this outcome (I<sup>2</sup> = 58%) (<a href="./references#CD004863-fig-00115" title="">Analysis 1.15</a>). </p> <p><a href="./references#CD004863-bbs2-0002" title="AventM , CoryBJ , GalpinJ , BallotDE , CooperPA , ShermanG , et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of Tropical Pediatrics2002;48(4):227‐33. [PUBMED: 12200985] ">Avent 2002</a> reported the median and range (days) for hospital stay across three groups: low‐dose EPO 32 (5 to 54), high‐dose EPO 32 (16 to 74), and control 30 (14 to 46) (P = 0.10 across the three groups). <a href="./references#CD004863-bbs2-0009" title="HaidenN , CardonaF , SchwindtJ , BergerA , KuhleS , HomoncikM , et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis2005;93(1):118‐23. [DOI: 10.1160/TH04‐02‐0093; PUBMED: 15630501] ">Haiden 2005</a> reported on hospital stay (days, median and range): EPO group 97 (59 to 162) and control group 89 (77 to157) (not statistically significant according to trial authors). <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a> reported on the median (quartiles) for hospital stay: early EPO 87 (73 to 107), control 87 (69 to 108). </p> </section> <section id="CD004863-sec5-0016"> <h6 class="title">Bronchopulmonary dysplasia (BPD) (Outcome 1.16)</h6> <section id="CD004863-sec6-0003"> <p><b>Bronchopulmonary dysplasia (BPD) (supplemental oxygen at 28 days of age) (Outcomes Table 1.16.1)</b></p> <p>Two studies enrolling 136 infants reported on use of supplemental oxygen at 28 days. EPO did not significantly change the rate of BPD (supplemental oxygen at 28 days of age) (RR 0.86, 95% CI 0.50 to 1.47; RD ‐0.04, 95% CI ‐0.19 to 0.10). We noted no heterogeneity for this outcome (RR and RD: I<sup>2</sup> = 0%) (<a href="./references#CD004863-fig-00116" title="">Analysis 1.16</a>). </p> <p><a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a> and <a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a> reported no differences in BPD rates between groups (data not provided). </p> </section> <section id="CD004863-sec6-0004"> <p><b>Bronchopulmonary dysplasia (BPD) (supplemental oxygen at 36 weeks' postmenstrual age (PMA)) (Outcomes Table 1.16.2)</b></p> <p>Seven studies enrolling 1719 infants reported on use of supplemental oxygen at 36 weeks' PMA. EPO did not significantly change the rate of BPD (supplementary oxygen at 36 weeks' PMA) (typical RR 0.95, 95% CI 0.81 to 1.11; typical RD ‐0.01, 95% CI ‐0.05 to 0.02). We noted no heterogeneity for this outcome (RR and RD: I<sup>2</sup> = 0%) (<a href="./references#CD004863-fig-00116" title="">Analysis 1.16</a>). </p> </section> <section id="CD004863-sec6-0005"> <p><b>Bronchopulmonary dysplasia (BPD) (age at diagnosis not stated) (Outcomes Table 1.16.3)</b></p> <p>A total of five studies enrolling 528 infants reported on this outcome. EPO did not significantly change the rate of BPD (age at diagnosis not stated) (typical RR 0.98, 95% CI 0.61 to 1.56; typical RD ‐0.00, 95% CI ‐0.05 to 0.05). We noted no heterogeneity for this outcome (RR and RD: I<sup>2</sup> = 0%) (<a href="./references#CD004863-fig-00116" title="">Analysis 1.16</a>). </p> </section> </section> <section id="CD004863-sec5-0017"> <h6 class="title">Neutropenia (Outcome 1.17)</h6> <p>Ten studies including 966 infants reported on neutropenia. The non‐significant typical RR was 0.81 (95% CI 0.53 to 1.24); the typical RD was ‐0.01 (95% CI ‐0.05 to 0.02). We noted no heterogeneity for this outcome (RR and RD: I<sup>2</sup> = 0%) (<a href="./references#CD004863-fig-00117" title="">Analysis 1.17</a>). </p> </section> <section id="CD004863-sec5-0018"> <h6 class="title">Hypertension (Outcome 1.18)</h6> <p>A total of six studies enrolling 706 infants reported on hypertension. Five studies reported no outcomes in treatment or control groups. Therefore, these five studies did not provide information for the typical RR estimate. The typical RR was 0.97 (95% CI 0.14 to 6.69). All six studies were included in the typical RD of ‐0.00 (95% CI ‐0.02 to 0.02). We noted no heterogeneity for this outcome (RR: I<sup>2</sup> = 0%; RD: I<sup>2</sup> = 0%) (<a href="./references#CD004863-fig-00118" title="">Analysis 1.18</a>). </p> </section> <section id="CD004863-sec5-0019"> <h6 class="title">Hemangioma (Outcome 1.19)</h6> <p>One study reported on hemangioma among 443 infants. The RR was 1.33 (95% CI 0.79 to 2.26), and the RD was 0.03 (95% CI ‐0.03 to 0.09). Tests for heterogeneity were not applicable (<a href="./references#CD004863-fig-00119" title="">Analysis 1.19</a>). </p> </section> <section id="CD004863-sec5-0020"> <h6 class="title">Neonatal Behavioural Neurological Assessment (NBNA) at 40 weeks' PMA (Outcome 1.20)</h6> <p>One study reported on NBNA at 40 weeks' PMA in 44 infants. The significant MD was 1.80 (95% CI 1.26 to 2.34) favouring the EPO group. Tests for heterogeneity were not applicable (<a href="./references#CD004863-fig-00120" title="">Analysis 1.20</a>). </p> </section> <section id="CD004863-sec5-0021"> <h6 class="title">Infants with white matter injury at term‐corrected PMA (Outcome 1.21)</h6> <p>One study reported on 165 infants. Data show a non‐significant reduction in white matter injury in the EPO group compared with the control group (RR 0.61, 95% CI 0.37 to 1.00; NS) but significant reduction in the RD (‐0.14, 95% CI ‐0.28 to ‐0.01; NNTB 7, 95% CI 4 to 100; tests for heterogeneity N/A) (<a href="./references#CD004863-fig-00121" title="">Analysis 1.21</a>). </p> </section> <section id="CD004863-sec5-0022"> <h6 class="title">Infants with white matter signal abnormality injury at term‐corrected PMA (Outcome 1.22) </h6> <p>One study reported on 165 infants. Study authors described a non‐significant reduction in white matter signal abnormality in the EPO group compared with the control group (RR 0.23, 95% CI 0.05 to 1.01; NS) but a significant reduction in the RD (‐0.09, 95% CI ‐0.16 to ‐0.01; NNTB 11, 95% CI 6 to 100; tests for heterogeneity N/A) (<a href="./references#CD004863-fig-00122" title="">Analysis 1.22</a>). </p> </section> <section id="CD004863-sec5-0023"> <h6 class="title">Infants with periventricular white matter loss at term‐corrected PMA (Outcome 1.23)</h6> <p>One study reported on 165 infants and noted a significant reduction in periventricular white matter loss in the EPO group compared with the control group (RR 0.55, 95% CI 0.32 to 0.97; RD ‐0.15, 95% CI ‐0.28 to ‐0.02; NNTB 7, 95% CI 4 to 50; tests for heterogeneity N/A) (<a href="./references#CD004863-fig-00123" title="">Analysis 1.23</a>). </p> </section> <section id="CD004863-sec5-0024"> <h6 class="title">Infants with grey matter injury at term‐corrected PMA (Outcome 1.24)</h6> <p>One study reported on 165 infants and noted a significant reduction in grey matter injury in the EPO group compared with the control group (RR 0.34, 95% CI 0.13 to 0.87; RD ‐0.13, 95% CI ‐0.23 to ‐0.03; NNTB 8, 95% CI 4 to 33; tests for heterogeneity N/A) (<a href="./references#CD004863-fig-00124" title="">Analysis 1.24</a>). </p> </section> <section id="CD004863-sec5-0025"> <h6 class="title">Survivors at discharge from hospital without severe IVH, PVL, or ROP (Outcome 1.25)</h6> <p>One study reported on 443 infants and noted no significant differences between groups for the outcome 'Survivors at discharge from hospital without severe IVH, PVL, or ROP' (RR 1.00, 95% CI 0.93 to 1.08; RD 0.00, 95% CI ‐0.06 to 0.07). Tests for heterogeneity were not applicable (<a href="./references#CD004863-fig-00125" title="">Analysis 1.25</a>). The quality of the evidence was high. </p> </section> </section> <section id="CD004863-sec4-0008"> <h5 class="title">Long‐term outcomes assessed at any age beyond one year of age by a validated cognitive, motor, language, or behavioural, school, and social interaction adaptation test </h5> <section id="CD004863-sec5-0026"> <h6 class="title">Bayley‐II Mental Development Index (MDI) &lt; 70 at 18 to 24 months' corrected age (Outcome 1.26) </h6> <p>Four studies reported on 1071 children. Data show a significant reduction in infants with MDI &lt; 70 at 18 to 24 months' corrected age (typical RR 0.55, 95% CI 0.39 to 0.77; typical RD ‐0.07, 95% CI ‐0.11 to ‐ 0.03; NNTB 14, 95% CI 9 to 33). Heterogeneity was moderate for RR (I<sup>2</sup> = 60%) and low for RD (I<sup>2</sup> = 31%) (<a href="./references#CD004863-fig-00126" title="">Analysis 1.26</a>). </p> </section> <section id="CD004863-sec5-0027"> <h6 class="title">Psychomotor Developmental Index (PDI) &lt; 70 at 18 to 22 months' corrected age (Outcome 1.27) </h6> <p>Three studies reported on this outcome in 458 children following EPO treatment, noting no significant effects of EPO compared with control. The typical RR was 1.43 (95% CI 0.88 to 2.33); the typical RD was 0.04 (95% CI ‐0.02 to 0.11). Heterogeneity was low for RR (I<sup>2</sup> = 46%) and for RD (I<sup>2</sup> = 42%) (<a href="./references#CD004863-fig-00127" title="">Analysis 1.27</a>). </p> <p><b>Bayley‐II MDI at 18 to 24 months (Outcome 1.28)</b> </p> <p>Three studies reported on this outcome in 981 children following EPO treatment. Data show a significant increase in Bayley‐II MDI at 18 to 24 months in the EPO group compared with the control group. The WMD was 8.22 (95% CI 6.52 to 9.92). Heterogeneity was high for this outcome (I<sup>2</sup> = 97%) (<a href="./references#CD004863-fig-00128" title="">Analysis 1.28</a>). The quality of the evidence was low. </p> </section> <section id="CD004863-sec5-0028"> <h6 class="title">Bayley‐II PDI at 18 to 24 months (Outcome 1.29)</h6> <p><a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a> reported on this outcome in three infants. We obtained unpublished data from the trial author and were not able to use the data in RevMan (<a href="./references#CD004863-bbs2-0099" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>; <a href="./references#CD004863-fig-00129" title="">Analysis 1.29</a>). </p> </section> <section id="CD004863-sec5-0029"> <h6 class="title">Cerebral palsy at 18 to 22 months' corrected age (Outcome 1.30)</h6> <p>Six studies reported on this outcome in 1172 children following EPO treatment. The non‐significant typical RR was 0.72 (95% CI 0.46 to 1.13); RD was ‐0.02 (95% CI ‐0.05 to 0.01). Heterogeneity was low (RR: I<sup>2</sup> = 48%; RD: I<sup>2</sup> = 41%) (<a href="./references#CD004863-fig-00130" title="">Analysis 1.30</a>). The quality of the evidence was high. </p> </section> <section id="CD004863-sec5-0030"> <h6 class="title">Any neurodevelopmental impairment at 18 to 22 months' corrected age (Outcome 1.31)</h6> <p>Four studies reported on this outcome in 1130 children following EPO treatment. The typical RR was 0.62 (95% CI 0.48 to 0.80); typical RD was ‐0.08 (95% CI ‐0.12 to ‐0.04); NNTB was 13 (95 % CI 8 to 25). Heterogeneity was high for RR (I<sup>2</sup> = 76%) and moderate for RD (I<sup>2</sup> = 66%) (<a href="./references#CD004863-fig-00131" title="">Analysis 1.31</a>). The quality of the evidence was low. </p> </section> <section id="CD004863-sec5-0031"> <h6 class="title">Visual impairment at 18 to 22 months' corrected age (Outcome 1.32)</h6> <p>Five studies reported on this outcome in 1132 children following EPO treatment. Data show no significant differences between groups (typical RR 0.80, 95% CI 0.26 to 2.49; RD ‐0.00, 95% CI ‐0.01 to 0.01). We noted no heterogeneity for this outcome (I<sup>2</sup> = 0% for both RR and RD) (<a href="./references#CD004863-fig-00132" title="">Analysis 1.32</a>). </p> </section> <section id="CD004863-sec5-0032"> <h6 class="title">Hearing impairment at 18 to 22 months' corrected age (Outcome 1.33)</h6> <p>Five studies reported on this outcome in 1132 children following EPO treatment. Data show no significant differences between groups (typical RR 0.41, 95% CI 0.13 to 1.23; RD ‐0.01, 95% CI ‐0.02 to 0.00). We noted no heterogeneity for RR (I<sup>2</sup> = 11%) and low heterogeneity for RD (I<sup>2</sup> = 38%) (<a href="./references#CD004863-fig-00133" title="">Analysis 1.33</a>). </p> </section> <section id="CD004863-sec5-0033"> <h6 class="title">Bayley Scales of Infant Development (BSID‐III) cognitive scores at 18 to 22 months (Outcome 1.34) </h6> <p>One study reported on this outcome in 53 infants. Scores were significantly higher in the group that received EPO (mean difference (MD) 9.2, 95% CI 1.70 to 16.70). Tests for heterogeneity were not applicable (<a href="./references#CD004863-fig-00134" title="">Analysis 1.34</a>). </p> <p><a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>, with small sample sizes at both times of follow‐up, reported secondary outcomes (53 and 38 children, respectively) for which none of the results reached statistical significance. Results are presented in the analyses: BSID‐III composite language score (<a href="./references#CD004863-fig-00135" title="">Analysis 1.35</a>), BSID‐III composite social/emotional score (<a href="./references#CD004863-fig-00136" title="">Analysis 1.36</a>), BSID‐III object performance (OP) score (<a href="./references#CD004863-fig-00137" title="">Analysis 1.37</a>), Wechsler Preschool and Primary Scale of Intelligence ‐ Third Edition Full‐Scale Intelligence Quotient (WPPSI‐III FSIQ) at 3.5 to 4 years of age (<a href="./references#CD004863-fig-00138" title="">Analysis 1.38</a>), WPPSI‐III Verbal Intelligence Quotient (VIQ) at 3.5 to 4 years of age (<a href="./references#CD004863-fig-00139" title="">Analysis 1.39</a>), WPPSI‐III Performance Intelligence Quotient (PIQ) at 3.5 to 4 years of age (<a href="./references#CD004863-fig-00140" title="">Analysis 1.40</a>), WPPSI‐III General Language Composite score (GLC) at 3.5 to 4 years of age (<a href="./references#CD004863-fig-00141" title="">Analysis 1.41</a>), Executive function at 3.5 to 4 years of age (<a href="./references#CD004863-fig-00142" title="">Analysis 1.42</a>), Working memory at 3.5 to 4 years of age (<a href="./references#CD004863-fig-00143" title="">Analysis 1.43</a>), and Inhibition at 3.5 to 4 years of age (<a href="./references#CD004863-fig-00144" title="">Analysis 1.44</a>). In addition, <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a> reported on the Griffiths Developmental Scale at two years of age for 19 infants, noting no statistical differences between groups (<a href="./references#CD004863-fig-00145" title="">Analysis 1.45</a>). </p> </section> <section id="CD004863-sec5-0034"> <h6 class="title">Survival without major neurological or neurodevelopmental disorders at two years of age (Outcome 1.46) </h6> <p>Two studies reported on this outcome in 404 children. Data show no statistically significant differences between EPO and control groups (typical RR 0.99, 95% CI 0.91 to 1.08; RD ‐0.01, 95% CI ‐0.08 to 0.06). We noted no heterogeneity for this outcome (RR: I<sup>2</sup> = 20%, RD: I<sup>2</sup> = 22%) (<a href="./references#CD004863-fig-00146" title="">Analysis 1.46</a>). </p> </section> <section id="CD004863-sec5-0035"> <h6 class="title">Death or moderate/severe neurological disability at 18 to 24 months (Outcome 1.47)</h6> <p>One study reported on this outcome in 668 children. Data show a significantly reduced rate of this outcome in the EPO group (RR 0.48, 95% CI 0.35 to 0.67; RD ‐0.14, 95% CI ‐0.20 to ‐0.08; NNTB 7, 95% CI 5 to 13). Tests for heterogeneity were not applicable (<a href="./references#CD004863-fig-00147" title="">Analysis 1.47</a>). </p> </section> <section id="CD004863-sec5-0036"> <h6 class="title">Moderate/severe neurological disability at 18 to 24 months (Outcome 1.48)</h6> <p>One study reported on this outcome in 613 children, noting a significantly reduced rate of this outcome in the EPO group (RR 0.38, 95% CI 0.24 to 0.60; RD ‐0.12, 95% CI ‐0.17 to ‐0.06; NNTB 8, 95% CI 6 to 17). Tests for heterogeneity were not applicable (<a href="./references#CD004863-fig-00148" title="">Analysis 1.48</a>). </p> </section> <section id="CD004863-sec5-0037"> <h6 class="title">Any side effects reported in these trials (no outcomes table)</h6> <p>Nine trials specifically reported that side effects did not occur (<a href="./references#CD004863-bbs2-0003" title="CarnielliV , MontiniG , DaRiolR , Dall'AmicoR , CantaruttiF . Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. Journal of Pediatrics1992;121(1):98‐102. [PUBMED: 1625101] ">Carnielli 1992</a>; <a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a>; <a href="./references#CD004863-bbs2-0014" title="LauterbachR , KachlikP , PawlikD , BajorekI . Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatria Polska1995;70(9):739‐44. [PUBMED: 8657506] ">Lauterbach 1995</a>; <a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a>; <a href="./references#CD004863-bbs2-0018" title="MeisterB , MaurerH , SimmaB , KernH , UlmerH , HittmairA , et al. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem Cells1997;15(5):359‐63. [DOI: 10.1002/stem.150359; PUBMED: 9323798] ">Meister 1997</a>; <a href="./references#CD004863-bbs2-0005" title="ChangL , LiuW , LiaoC , ZhaoX . Preventive effects of different dosages of recombinant human erythropoietin on anemia of premature infants. Journal of Tongji Medical University/Tong Ji Yi Ke da Xue Xue Bao1998;18(4):239‐42. [PUBMED: 10806855] ">Chang 1998</a>; <a href="./references#CD004863-bbs2-0015" title="Lima‐RogelV , Torres‐MontesA , Espinosa GriesseS , Villegas AlvarezC , Hernandez‐SierraF , Bissett MandevilleP , et al. Efficacy of early erythropoietin use in critically ill very‐low‐birth‐weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre1998;43(3):191‐5. [PUBMED: 9741224] ">Lima‐Rogel 1998</a>; <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0011" title="KhatamiSF , MamouriG , TorkamanM . Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants. Indian Journal of Pediatrics2008;75(12):1227‐30. [DOI: 10.1007/s12098‐008‐0225‐0; PUBMED: 19057854] ">Khatami 2008</a>). <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> reported that side effects were minimal and were not different between groups. </p> </section> </section> <section id="CD004863-sec4-0009"> <h5 class="title">Darbepoetin alfa versus placebo or no treatment (Comparison 2)</h5> <p>We identified only one study for this comparison (<a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>); therefore tests for heterogeneity were not applicable for any of the analyses. </p> <p>We indicate the primary outcome. All other analyses were performed for secondary outcomes.</p> <section id="CD004863-sec5-0038"> <h6 class="title">Use of one or more red blood cell transfusions (Outcome 2.1) ‐ Primary outcome</h6> <p>One study including 66 infants reported on this outcome. The RR of 0.62 (95% CI 0.38 to 1.02) was not significantly reduced, but the RD of ‐0.24 was significantly reduced (95% CI ‐0.48 to ‐0.01; NNTB 4, 95% CI 2 to 100) (<a href="./references#CD004863-fig-00201" title="">Analysis 2.1</a>). </p> <p><a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> reported the following secondary outcomes, which were not statistically significantly different between Darbe and no treatment groups: Total volume (mL/kg) of blood transfused per infant (all infants) (Outcome 2.2) (<a href="./references#CD004863-fig-00202" title="">Analysis 2.2</a>); Total volume (mL/kg) of blood transfused in transfused infants only (Outcome 2.3) (<a href="./references#CD004863-fig-00203" title="">Analysis 2.3</a>); Number of blood transfusions per infant (Outcome 2.4) (<a href="./references#CD004863-fig-00204" title="">Analysis 2.4</a>); Number of donors the infant was exposed to (Outcome 2.5) (<a href="./references#CD004863-fig-00205" title="">Analysis 2.5</a>); Mortality during initial hospital stay (all causes of mortality) (Outcome 2.6) (<a href="./references#CD004863-fig-00206" title="">Analysis 2.6)</a>; Retinopathy of prematurity (all stages) (Outcome 2.7) (<a href="./references#CD004863-fig-00207" title="">Analysis 2.7</a>); Retinopathy of prematurity (stage ≥ 3) (Outcome 2.8) (<a href="./references#CD004863-fig-00208" title="">Analysis 2.8</a>); Necrotising enterocolitis (stage &gt; 2) (Outcome 2.9) (<a href="./references#CD004863-fig-00209" title="">Analysis 2.9</a>); Proven sepsis (Outcome 2.10) (<a href="./references#CD004863-fig-00210" title="">Analysis 2.10</a>); Intraventricular haemorrhage (grades III and IV) (Outcome 2.11) (<a href="./references#CD004863-fig-00211" title="">Analysis 2.11</a>); Periventricular leukomalacia (Outcome 2.12) (<a href="./references#CD004863-fig-00212" title="">Analysis 2.12</a>); Bronchopulmonary dysplasia (supplemental oxygen at 36 weeks' PMA) (Outcome 2.13) (<a href="./references#CD004863-fig-00213" title="">Analysis 2.13</a>); Length of hospital stay (days) (Outcome 2.14) (<a href="./references#CD004863-fig-00214" title="">Analysis 2.14</a>); Neutropenia (Outcome 2.15) (<a href="./references#CD004863-fig-00215" title="">Analysis 2.15</a>); and Hypertension (Outcome 2.16) (<a href="./references#CD004863-fig-00216" title="">Analysis 2.16</a>). </p> </section> <section id="CD004863-sec5-0039"> <h6 class="title">Cerebral palsy (CP) at 18 to 22 months (Outcome 2.17)</h6> <p>One study including 51 infants reported on this outcome. The non‐significant RR was 0.08 (95% CI 0.00 to 1.40; P = 0.08), and the significantly reduced RD in favour of Darbe was ‐0.21 (95% CI ‐0.38 to ‐0.04; P = 0.02); the NNTB was 5 (95% CI 3 to 25) (<a href="./references#CD004863-fig-00217" title="">Analysis 2.17</a>). </p> </section> <section id="CD004863-sec5-0040"> <h6 class="title">Neurodevelopmental impairment (NDI) (having CP, visual defect<i>,</i> or cognitive score &lt; 85) at 18 to 22 months (Outcome 2.18) </h6> <p>One study including 51 infants reported on this outcome. The significantly reduced RR was 0.27 (95% CI 0.08 to 0.86), and the significantly reduced RD was ‐0.31 (95% CI ‐0.54 to ‐0.08); the NNTB was 3 (95% CI 2 to 13) in favour of Darbe (<a href="./references#CD004863-fig-00218" title="">Analysis 2.18</a>). </p> </section> <section id="CD004863-sec5-0041"> <h6 class="title">BSID‐III composite cognitive scores at 18 to 22 months (Outcome 2.19)</h6> <p>One study including 51 infants reported on this outcome. The significantly increased MD in favour of Darbe was 7.50 (95% CI 1.44 to 13.56) (<a href="./references#CD004863-fig-00219" title="">Analysis 2.19</a>). </p> </section> <section id="CD004863-sec5-0042"> <h6 class="title">BSID‐III composite language score at 18 to 22 months (Outcome 2.20)</h6> <p>One study including 51 infants reported on this outcome. The significantly increased MD in favour of Darbe was 8.80 (95% CI 1.57 to 16.03) (<a href="./references#CD004863-fig-00220" title="">Analysis 2.20</a>). </p> </section> <section id="CD004863-sec5-0043"> <h6 class="title">BSID‐III social/emotional score at 18 to 22 months (Outcome 2.21)</h6> <p>One study including 51 infants reported on this outcome. The non‐significant MD was 6.80 (95% CI ‐3.82 to 17.42) (<a href="./references#CD004863-fig-00221" title="">Analysis 2.21</a>). </p> </section> <section id="CD004863-sec5-0044"> <h6 class="title">Object performance (OP) score at 18 to 22 months (Outcome 2.22)</h6> <p>One study including 51 infants reported on this outcome. The significant MD in favour of Darbe was 0.60 (95% CI 0.17 to 1.03) (<a href="./references#CD004863-fig-00222" title="">Analysis 2.22</a>). </p> </section> <section id="CD004863-sec5-0045"> <h6 class="title">WPPSI‐III FSIQ at 3.5 to 4 years of age (Outcome 2.23)</h6> <p>One study reported on this outcome in 29 infants. The significant MD in favour of Darbe was 15.27 (95% CI 2.60 to 27.94) (<a href="./references#CD004863-fig-00223" title="">Analysis 2.23</a>). </p> </section> <section id="CD004863-sec5-0046"> <h6 class="title">WPPSI‐III VIQ at 3.5 to 4 years of age (Outcome 2.24)</h6> <p>One study reported on this outcome in 29 infants. The non‐significant MD was 9.17 (95% CI ‐2.86 to 21.20) (<a href="./references#CD004863-fig-00224" title="">Analysis 2.24</a>). </p> </section> <section id="CD004863-sec5-0047"> <h6 class="title">WPPSI‐III PIQ at 3.5 to 4 years of age (Outcome 2.25)</h6> <p>One study reported on this outcome in 29 infants. The significant MD in favour of Darbe was 14.97 (95% CI 1.89 to 28.05) (<a href="./references#CD004863-fig-00225" title="">Analysis 2.25</a>). </p> </section> <section id="CD004863-sec5-0048"> <h6 class="title">WPPSI‐III GLC at 3.5 to 4 years of age (Outcome 2.26)</h6> <p>One study reported on this outcome in 29 infants. The non‐significant MD was 7.94 (95% CI ‐4.18 to 20.06) (<a href="./references#CD004863-fig-00226" title="">Analysis 2.26</a>). </p> </section> <section id="CD004863-sec5-0049"> <h6 class="title">Executive function at 3.5 to 4 years (Outcome 2.27)</h6> <p>One study reported on this outcome in 29 infants. The significant MD in favour of Darbe was 10.81 (95% CI 2.83 to 18.79) (<a href="./references#CD004863-fig-00227" title="">Analysis 2.27</a>). </p> </section> <section id="CD004863-sec5-0050"> <h6 class="title">Working memory at 3.5 to 4 years (Outcome 2.27)</h6> <p>One study reported on this outcome in 29 infants. The significant MD in favour of Darbe was 12.77 (95% CI 2.68 to 22.86) (<a href="./references#CD004863-fig-00228" title="">Analysis 2.28</a>). </p> </section> <section id="CD004863-sec5-0051"> <h6 class="title">Inhibition at 3.5 to 4 years of age (Outcome 2.28)</h6> <p>One study reported on this outcome in 29 infants. The non‐significant MD was 8.77 (95% CI ‐2.47 to 20.01) (<a href="./references#CD004863-fig-00228" title="">Analysis 2.28</a>). </p> </section> </section> <section id="CD004863-sec4-0010"> <h5 class="title">Darbepoietin alfa or erythropoietin (ESA) versus placebo or no treatment (Comparison 3) </h5> <p>We identified only one study for this comparison (<a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>); therefore tests for heterogeneity were not applicable for any of these analyses. </p> <p>We indicate the primary outcome. All other analyses were performed for secondary outcomes.</p> <section id="CD004863-sec5-0052"> <h6 class="title">BSID‐III composite cognitive scores at 18 to 22 months (Outcome 3.1) ‐ Primary outcome</h6> <p>One study including 80 infants reported on this outcome. The significantly increased MD in favour of ESA was 7.80 (95% CI 1.65 to 13.95) (<a href="./references#CD004863-fig-00301" title="">Analysis 3.1</a>). The quality of the evidence was moderate. </p> </section> <section id="CD004863-sec5-0053"> <h6 class="title">BSID‐III composite language score at 18 to 22 months (Outcome 3.2)</h6> <p>One study including 80 infants reported on this outcome. The significantly increased MD in favour of ESA was 7.10 (95% CI 0.49 to 13.71) (<a href="./references#CD004863-fig-00302" title="">Analysis 3.2</a>). </p> </section> <section id="CD004863-sec5-0054"> <h6 class="title">BSID‐III social/emotional score at 18 to 22 months (Outcome 3.3)</h6> <p>One study including 80 infants reported on this outcome. The non‐significant MD was 4.20 (95% CI ‐5.06 to 13.46) (<a href="./references#CD004863-fig-00303" title="">Analysis 3.3</a>). </p> </section> <section id="CD004863-sec5-0055"> <h6 class="title">OP score at 18 to 22 months (Outcome 3.4)</h6> <p>One study including 80 infants reported on this outcome. The non‐significant MD was 0.40 (95% CI ‐0.04 to 0.84) (<a href="./references#CD004863-fig-00304" title="">Analysis 3.4</a>). </p> </section> <section id="CD004863-sec5-0056"> <h6 class="title">Behavior Assessment System for Children (BASC‐2) composite scores at 3.5 to 4 years ‐ Adaptive skills (Outcome 3.5) </h6> <p>One study including 49 infants reported on this outcome. The non‐significant MD was 2.54 (95% CI ‐3.58 to 8.66) (<a href="./references#CD004863-fig-00305" title="">Analysis 3.5</a>). </p> </section> <section id="CD004863-sec5-0057"> <h6 class="title">BASC‐2 composite scores at 3.5 to 4 years ‐ Behaviour symptoms (Outcome 3.6)</h6> <p>One study including 49 infants reported on this outcome. The non‐significant MD was ‐8.66 (95% CI ‐18.01 to 0.69) (<a href="./references#CD004863-fig-00306" title="">Analysis 3.6</a>). </p> </section> <section id="CD004863-sec5-0058"> <h6 class="title">BASC‐2 composite scores at 3.5 to 4 years ‐ Externali<i>s</i>ing problems (Outcome 3.7) </h6> <p>One study including 49 infants reported on this outcome. The significantly reduced MD in favour of ESA was ‐8.00 (95% CI ‐15.94 to ‐0.06) (<a href="./references#CD004863-fig-00307" title="">Analysis 3.7</a>). </p> </section> <section id="CD004863-sec5-0059"> <h6 class="title">BASC‐2 composite scores at 3.5 to 4 years ‐ Internali<i>s</i>ing problems (Outcome 3.8) </h6> <p>One study including 49 infants reported on this outcome. The non‐significant MD was ‐2.56 (95% CI ‐9.25 to 4.13) (<a href="./references#CD004863-fig-00308" title="">Analysis 3.8</a>). </p> </section> <section id="CD004863-sec5-0060"> <h6 class="title">WPPSI‐III FSIQ at 3.5 to 4 years of age (Outcome 3.9) ‐ Primary outcome</h6> <p>One study reported on this outcome in 53 infants. The significantly increased MD in favour of ESA was 11.90 (95% CI 0.76 to 23.04) (<a href="./references#CD004863-fig-00309" title="">Analysis 3.9</a>). The quality of the evidence was low. </p> </section> <section id="CD004863-sec5-0061"> <h6 class="title">WPPSI‐III VIQ at 3.5 to 4 years of age (Outcome 3.10)</h6> <p>One study reported on this outcome in 53 infants. The non‐significant MD in favour of ESA was 8.80 (95% CI ‐1.75 to 19.35) (<a href="./references#CD004863-fig-00310" title="">Analysis 3.10</a>). </p> </section> <section id="CD004863-sec5-0062"> <h6 class="title">WPPSI‐III PIQ at 3.5 to 4 years of age (Outcome 3.11)</h6> <p>One study reported on this outcome in 53 infants. The significant MD in favour of ESA was 13.50 (95% CI 1.98 to 25.02) (<a href="./references#CD004863-fig-00311" title="">Analysis 3.11</a>). </p> </section> <section id="CD004863-sec5-0063"> <h6 class="title">WPPSI‐III GLC at 3.5 to 4 years of age (Outcome 3.12)</h6> <p>One study reported on this outcome in 53 infants. The significant MD in favour of ESA was 5.13 (95% CI ‐5.30 to 15.56) (<a href="./references#CD004863-fig-00312" title="">Analysis 3.12</a>). </p> </section> <section id="CD004863-sec5-0064"> <h6 class="title">Executive function at 3.5 to 4 years (Outcome 3.13)</h6> <p>One study reported on this outcome in 53 infants. The significant MD n favour of ESA was 8.36 (95% CI 0.51 to 16.21) (<a href="./references#CD004863-fig-00313" title="">Analysis 3.13</a>). </p> </section> <section id="CD004863-sec5-0065"> <h6 class="title">Working memory at 3.5 to 4 years (Outcome 3.14)</h6> <p>One study reported on this outcome in 53 infants. The non‐significant MD was 9.06 (95% CI ‐1.06 to 19.18) (<a href="./references#CD004863-fig-00314" title="">Analysis 3.14</a>). </p> </section> <section id="CD004863-sec5-0066"> <h6 class="title">Inhibition at 3.5 to 4 years of age (Outcome 3.15)</h6> <p>One study reported on this outcome in 53 infants. The non‐significant MD was 7.60 (95% CI ‐2.79 to 17.99) (<a href="./references#CD004863-fig-00315" title="">Analysis 3.15</a>). </p> </section> </section> </section> <section id="CD004863-sec3-0027"> <h4 class="title">Effectiveness of EPO administered early versus placebo in improving feeding tolerance and decreasing NEC </h4> <section id="CD004863-sec4-0011"> <h5 class="title">Erythropoietin versus placebo or no treatment (Comparison 4)</h5> <section id="CD004863-sec5-0067"> <h6 class="title">Time to achieve full enteral feeding (days) (Outcome 4<i>.</i>1) ‐ Primary outcome </h6> <p>One study (<a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a>) reported on this outcome in 50 infants. EPO significantly reduced the time (days) to achieve full enteral feeding (MD ‐2.90 days, 95% CI ‐5.77 to ‐0.03). Testing for heterogeneity was not applicable. The quality of the evidence was low. </p> <p>The outcome of NEC in this study is reported in <a href="./references#CD004863-fig-00111" title="">Analysis 1.11</a>, the outcome of mortality in <a href="./references#CD004863-fig-00107" title="">Analysis 1.7</a>, and the outcome of length of hospital stay in <a href="./references#CD004863-fig-00115" title="">Analysis 1.15</a>. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004863-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004863-sec1-0006"></div> <section id="CD004863-sec2-0016"> <h3 class="title" id="CD004863-sec2-0016">Summary of main results</h3> <section id="CD004863-sec3-0028"> <h4 class="title">Short‐term outcomes</h4> <p>We included in this update 34 studies reporting on 3643 infants, representing an increase of 1434 trial participants from the 2014 update. Studies were performed in 22 countries. We excluded 22 studies. The quality of evidence ranged from high to low, according to GRADE (for specifics, see <a href="#CD004863-sec2-0018">Quality of the evidence</a> below). </p> <p>Evidence from 19 of these 34 studies (n = 1750) indicates that early initiation of low or high doses of erythropoietin (EPO) administered at less than eight days of age reduced the need for one or more red blood cell transfusions. The total volume (mL/kg) of blood transfused per infant was reduced, as was the number of donors to whom the infant was exposed, among all randomised infants ‐ but not among infants who were transfused. Most studies included infants who had received transfusions before study entry. Many studies followed guidelines (with tremendous variation between studies) for red blood cell transfusions (see Additional tables, <a href="#CD004863-tbl-0009">Table 1</a>). </p> <p>Mortality during initial hospital stay was not affected by EPO treatment (n = 2212).</p> <p>Most important, good evidence now shows that early EPO does not increase the risk of retinopathy of prematurity (ROP) (stage ≥ 3) (n = 1165), which was a matter of concern in previous versions of this review. </p> <p>This update of the review reports a significant reduction in the incidence of necrotising enterocolitis (NEC) in a very large sample (n = 2639). In a single small study (n = 50), mean time to achieve full enteral feeds was significantly reduced. </p> <p>The incidence of intraventricular haemorrhage (IVH) (grades III and IV) (n = 1460) was significantly reduced, as was the incidence of periventricular leukomalacia (PVL) (n = 1469). It has been postulated that early red blood cell transfusions may increase the risk of extension of IVH grade I to higher grades (<a href="./references#CD004863-bbs2-0063" title="BaerVL , LambertDK , HenryE , SnowGL , ChristensenRD . Red blood cell transfusion of preterm neonates with grade 1 intraventricular hemorrhage is associated with extension to a grade 3 or 4 hemorrhage. Transfusion2011;51(9):1933‐9. [DOI: 10.1111/j.1537‐2995.2011.03081.x; PUBMED: 21382049] ">Baer 2011</a>), and that late red blood cell transfusions may be associated with NEC (<a href="./references#CD004863-bbs2-0066" title="BlauJ , CaloJM , DozorD , SuttonM , AlpanG , LaGammaEF . Transfusion‐related acute gut injury: necrotizing enterocolitis in very low birth weight neonates after packed red blood cell transfusion. Journal of Pediatrics2011;158(3):403‐9. [DOI: 10.1016/j.jpeds.2010.09.015; PUBMED: 21067771] ">Blau 2011</a>). It has been suggested that even small reductions in the number of transfusions given to neonates could have an impact on the occurrence of IVH and NEC (<a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0096" title="OhlsRK . Why study erythropoietin in preterm infants?. Acta Paediatrica2013;102(6):567‐8. [DOI: 10.1111/apa.12234; PUBMED: 23551714] ">Ohls 2013a</a>). As most IVHs and extensions of IVHs occur within the first 72 hours of life (<a href="./references#CD004863-bbs2-0073" title="DolfinT , SkidmoreMB , FongKW , HoskinsEM , ShennanAT . Incidence, severity, and timing of subependymal and intraventricular hemorrhages in preterm infants born in a perinatal unit as detected by serial real‐time ultrasound. Pediatrics1983;71(4):541‐6. [PUBMED: 6835737] ">Dolfin 1983</a>), it is difficult to imagine that early EPO treatment with a very small reduction in transfusions over the whole study period (&lt; 1) could have an impact on the incidence of IVH and on extension from a grade I to a grade III or IV haemorrhage. Previously (before the use of EPO for neuro protection), most studies had started the intervention beyond 72 hours of age. Our previous EPO review found no significant reductions in IVH or NEC (<a href="./references#CD004863-bbs2-0118" title="OhlssonA , AherSM . Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD004863.pub4] ">Ohlsson 2014</a>). Results showing a possible association between transfusions in neonates and occurrence of transfusion‐associated NEC vary depending on study design (<a href="./references#CD004863-bbs2-0085" title="KirpalaniH , ZupancicJA . Do transfusions cause necrotizing enterocolitis? The complementary role of randomized trials and observational studies. Seminars in Perinatology2012;36(4):269‐76. [DOI: 10.1053/j.semperi.2012.04.007; PUBMED: 22818547] ">Kirpalani 2012</a>). A lower incidence of NEC was found to be associated with more transfusions in randomised controlled trials ‐ an effect opposite to that seen in observational studies (transfusions are associated with NEC) (<a href="./references#CD004863-bbs2-0085" title="KirpalaniH , ZupancicJA . Do transfusions cause necrotizing enterocolitis? The complementary role of randomized trials and observational studies. Seminars in Perinatology2012;36(4):269‐76. [DOI: 10.1053/j.semperi.2012.04.007; PUBMED: 22818547] ">Kirpalani 2012</a>). </p> <p>Length of hospital stay was significantly reduced in the EPO group (n = 970).</p> <p>Investigators reported no significant differences between EPO and control groups in the incidence of bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA) (n = 1719), nor in the incidence of proven sepsis (n = 2180). </p> <p>Ultrasonographic signs of brain injury (IVH, PVL), BPD, severe ROP, and infection strongly predict risk of later death or neurosensory impairment as 18‐month outcomes of extremely low birth weight infants (<a href="./references#CD004863-bbs2-0100" title="SchmidtB , AsztalosEV , RobertsRS , RobertsonCM , SauveRS , WhitfieldMF , et al. Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low‐birth‐weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA2003;289(9):1124‐9. [PUBMED: 12622582] ">Schmidt 2003</a>; <a href="./references#CD004863-bbs2-0064" title="BasslerD , StollBJ , SchmidtB , AsztalosEV , RobertsRS , RobertsonCM , et al. Trial of Indomethacin Prophylaxis in Preterm Investigators. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics2009;123(1):313‐8. [DOI: 10.1542/peds.2008‐0377; PUBMED: 19117897] ">Bassler 2009</a>). As evidence now suggests that EPO reduces the incidence of IVH and PVL ‐ although not of BPD, ROP, or sepsis ‐ it is possible that early treatment with EPO could have a neuro protective effect among preterm infants. However, data show no significant differences in 'Survivors at discharge from hospital without severe IVH, PVL, or ROP' in a high‐quality study including 443 infants. </p> </section> <section id="CD004863-sec3-0029"> <h4 class="title">Neuroprotection</h4> <p>This aspect of EPO use in neonates has been systematically reviewed outside of Cochrane (see the section <a href="#CD004863-sec2-0020">Agreements and disagreements with other studies or reviews</a>). Four studies included in this review were designed to assess EPO as a neuro protective agent (<a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>; <a href="./references#CD004863-bbs2-0010" title="HeJS , HuangZL , YangH , WengKZ , ZhuSB . Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2008;10(5):586‐8. [PUBMED: 18947475] ">He 2008</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>). In addition, <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> reported on possible neuro protective effects of EPO and Darbe in follow‐up reports of the original cohort, although the objective of her primary study was to assess whether infants would respond to Darbe with reduced transfusion needs compared with no treatment, with less frequent dosing than with EPO. <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a> used early EPO with the goal of providing neuro protection to very preterm infants. The primary hypothesis of this pilot study was that "the rate of survivors without brain injury (IVH and PVL) including ROP [is] not affected by administration of three high doses of EPO early after birth". The percentage of infants who survived without brain injury or ROP was 53% in the EPO group and 60% in the placebo group. However, five infants in the EPO group versus none in the placebo group died. The risk ratio (RR) for mortality was higher in this study when compared with results of other trials. </p> <p>The purpose of <a href="./references#CD004863-bbs2-0010" title="HeJS , HuangZL , YangH , WengKZ , ZhuSB . Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2008;10(5):586‐8. [PUBMED: 18947475] ">He 2008</a> was to evaluate the effect of early EPO therapy on neuro behavioural development in preterm seven‐day‐old infants. This study was written in Chinese, and we were able to understand only the abstract, which was available in English (we have contacted trial authors to request additional information but have not received an answer). Neonatal Behavioral Neurological Assessment at 40 weeks' PMA and Gesell Developmental Schedule at 6 and 12 months after birth were used to assess infant participants. Results favoured the EPO group. </p> <p>In our meta‐analyses, we identified conflicting results for short‐ and long‐term neurological outcomes. Data show significant reductions in white matter injury, signal abnormality, periventricular white matter loss, and grey matter injury among infants at term. At 18 to 24 months of age, incidences of Bayley‐II Mental Development Index (MDI) &lt; 70, but not of Bayley‐II Psychomotor Development Index (PDI) &lt; 70, were reduced. The Bayley‐II MDI at 18 to 24 months (n = 981) was significantly increased in the EPO group compared with the placebo group, but heterogeneity was high (I<sup>2</sup> = 97%). The Bayley Scales of Infant Development ‐ Third Edition (BSID‐III) composite cognitive scores at 18 to 22 months were increased in favour of EPO in a small study (n = 53). In the same single study, the BSID‐III composite cognitive score at 18 to 22 months was increased in favour of erythropoiesis‐stimulating agents (ESAs) (n = 80), as was the Wechsler Preschool and Primary Scale of Intelligence ‐ Third Edition Full‐Scale Intelligence Quotient (WPPSI‐III FSIQ) score at 3.5 to 4 years of age (n = 53). </p> <p>We found no significant difference in the incidence of 'Cerebral palsy at 18 to 24 months' corrected age' between EPO and placebo groups (n = 1172) but a significant reduction in 'Any neurodevelopmental impairment at 18 to 22 months' in the EPO group compared with the placebo group (n = 1130). 'Survival without major neurological or neurodevelopmental disorders at 2 years of age' was not reduced in the EPO group compared with the placebo group (n = 404). Death or moderate/severe neurological disability at 18 to 24 months was significantly reduced in the EPO group in a single study (n = 668), as was 'Moderate/severe disability at 18 to 24 months' (n = 613). The Darbe versus no treatment study (n = 51) reported a significant reduction for risk difference (RD) but not for risk ratio (RR) in 'Cerebral palsy at 18 to 22 months' in favour of Darbe. The same comparison revealed reduced risk of neurological developmental impairment (having cerebral palsy (CP), visual defect, hearing defect, or cognitive score &lt; 85) at 18 to 22 months (n = 51). In the same study, BSID‐III composite cognitive scores, language scores, and objective permanence (OP) scores were significantly increased (n = 51), and in a smaller sample (n = 29), results were significantly better in the Darbe group compared with the no treatment group for WPPSI‐III Full‐Scale Intelligence Quotient (FSIQ), Performance Intelligence Quotient (PIQ), Executive function, and Working memory at 3.5 to 4 years of age. </p> </section> </section> <section id="CD004863-sec2-0017"> <h3 class="title" id="CD004863-sec2-0017">Overall completeness and applicability of evidence</h3> <p>This review provides evidence that early administration of EPO significantly reduces the 'use of one or more blood transfusions' following study entry with a low number needed to treat for an additional beneficial outcome (NNTB) of 7 and a narrow 95% confidence interval (CI) of 6 to 10. From our results, we cannot make a recommendation with regard to the best combination of a high or low dose of EPO and a high or low dose of iron. We had arbitrarily set a cutoff of ≤ 5 mg/kg/d of oral intake for low and high doses of iron. When we conducted the review, we discovered that several studies started with intravenous administration of iron in variable doses, and we considered any intravenous dose of iron as a high dose. Early EPO significantly reduces the total volume of red blood cells transfused, the number of red blood cell transfusions per infant, and the number of donor exposures. For these outcomes, effect sizes were small and are likely to be of limited clinical importance. Overall, early EPO provides very limited clinical benefit with regards to a reduction in the use of red blood cell transfusion; therefore, its use for this purpose is not recommended. </p> <p>Good evidence suggests that early use of EPO does not have a statistically significant effect on mortality. This update of the review provides high‐quality evidence obtained by GRADE to show that early EPO does not increase the risk of ROP (stage ≥ 3). </p> <p>In this update of the review, some important short‐term outcomes are now statistically significantly reduced: IVH (grades III and IV) (<a href="./references#CD004863-fig-00113" title="">Analysis 1.13</a>), PVL (<a href="./references#CD004863-fig-00114" title="">Analysis 1.14</a>), and NEC (<a href="./references#CD004863-fig-00111" title="">Analysis 1.11</a>) (all moderate‐quality evidence by GRADE). In these analyses, the only study that showed a significant reduction in the incidence of these outcomes was <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> ‐ a large study (n = 743) ‐ and in the analyses, this study carried weights of 72.8% for IVH, 89.2% for PVL, and 47.8% for NEC. The second largest included study ‐ <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a> (n = 443) ‐ did not show significant differences among these three outcomes. It is expected that results of the two ongoing large studies (<a href="./references#CD004863-bbs2-0057" title="NCT01378273 . Preterm Erythropoietin Neuroprotection Trial (PENUT Trial). clinicaltrials.gov/show/NCT01378273 (first received 20 June 2011). ">NCT01378273</a>; <a href="./references#CD004863-bbs2-0058" title="NCT02550054 . Erythropoietin in Premature Infants to Prevent Encephalopathy [Erythropoietin in Premature Infants to Prevent Encephalopathy: A Multi‐centre Randomized Blinded Controlled Study of the Efficacy of Erythropoietin in China]. clinicaltrials.gov/show/NCT02550054 (first received 04 September 2015). ">NCT02550054</a>) will shed light on these conflicting results. Until that time, early EPO is not recommended to reduce IVH, PVL, or NEC. </p> <p>As noted above, results of long‐term follow‐up studies are conflicting; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> (n = 613) reported a marked increase in the Bayley‐II MDI at 18 to 24 months by 11 points (<a href="./references#CD004863-fig-00128" title="">Analysis 1.28</a>), whereas <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a> (n = 365) showed a non‐significant decrease of one point. Heterogeneity for this outcome was extreme (I<sup>2</sup> = 97%). For the outcome 'Any neurodevelopmental impairment at 18 to 22 months' corrected age', evidence shows large differences between the two largest studies: <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> (n = 613) showed a highly statistically significant reduction in the outcome, whereas <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a> (n = 365) did not. </p> <p>Again, it is hoped that the ongoing studies referenced above will resolve these conflicting results; until that time, early EPO is not recommended for neuro protection or for improved long‐term neurodevelopmental outcomes. </p> </section> <section id="CD004863-sec2-0018"> <h3 class="title" id="CD004863-sec2-0018">Quality of the evidence</h3> <p>Evidence shows statistically significant (moderate) heterogeneity for the primary outcome ('use of one or more blood transfusions') as well as for two important secondary outcomes ('total volume of blood transfused per infant' and 'number of transfusions per infant'). In previous versions of this review, we have tried to explain heterogeneity by performing secondary analyses based on perceived study quality and different transfusion practices. As we were not able to present an explanation, we excluded those analyses from this update. We have presented our concerns about heterogeneity both above and in the 'Summary of findings' tables (<a href="./full#CD004863-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD004863-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD004863-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD004863-tbl-0004">summary of findings Table 4</a>). </p> <p>We have presented in the 'Summary of findings' tables our judgements according to GRADE, regarding quality of the evidence for important primary and secondary outcomes (<a href="./full#CD004863-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD004863-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD004863-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD004863-tbl-0004">summary of findings Table 4</a>). </p> <p>We rated the quality of evidence (GRADE) as high for 'Mortality during initial hospital stay', 'ROP (stage ≥ 3)', 'Survivors at discharge from hospital without severe IVH, PVL, ROP', and 'Cerebral palsy at 18 to 24 months'. We rated the quality of evidence (GRADE) as moderate for 'NEC', 'IVH', 'PVL', and 'BSID‐III composite cognitive scores at 18 to 22 months'. We rated the quality of evidence (GRADE) as low for 'Use of one or more red blood cell transfusions (low and high doses of EPO)', 'Any neurodevelopmental impairment at 18 to 22 months' corrected age', 'Bayley‐II MDI at 18 to 24 months', 'Time to achieve full enteral feeding', and 'WPPSI‐III FSIQ at 3.5 to 4 years of age'. </p> <p>Among the few infants studied to date, Darbe appears to have effectiveness similar to that of EPO. Too few infants have been studied for assessment of its safety. Darbepoetin does offer the advantage of fewer injections required, thus reducing painful stimuli for this vulnerable population. </p> <p>A funnel plot for the primary outcome 'use of one or more red blood cell transfusions' was asymmetrical, with relative absence of smaller studies not having a protective effect (<a href="#CD004863-fig-0005">Figure 5</a>). This may indicate that smaller studies with 'negative' results have not been published. </p> </section> <section id="CD004863-sec2-0019"> <h3 class="title" id="CD004863-sec2-0019">Potential biases in the review process</h3> <p>We are not aware of any potential biases in our review process.</p> </section> <section id="CD004863-sec2-0020"> <h3 class="title" id="CD004863-sec2-0020">Agreements and disagreements with other studies or reviews</h3> <p>Early systematic reviews (which included fewer studies than were included in our reviews) have not included ROP or other common neonatal outcomes as outcome measures (<a href="./references#CD004863-bbs2-0108" title="VamvakasEC , StraussRG . Meta‐analysis of controlled clinical trials studying the efficacy of rHuEPO in reducing blood transfusions in the anemia of prematurity. Transfusion2001;41(3):406‐15. [PUBMED: 11274599] ">Vamvakas 2001</a>; <a href="./references#CD004863-bbs2-0077" title='GarciaMG , HutsonAD , ChristensenRD . Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta‐analysis. Journal of Perinatology2002;22(2):108‐11. [DOI: 10.1038/sj.jp.7210677; PUBMED: 11896514] '>Garcia 2002</a>; <a href="./references#CD004863-bbs2-0088" title='Kotto‐KomeAC , GarciaMG , CalhounDA , ChristensenRD . Effect of beginning recombinant erythropoietin treatment within the first week of life, among very‐low‐birth‐weight neonates, on "early" and "late" erythrocyte transfusions: a meta‐analysis. Journal of Perinatology2004;24(1):24‐9. [DOI: 10.1038/sj.jp.7211018; PUBMED: 14726934] '>Kotto‐Kome 2004</a>). Those reviews noted similar effect sizes for transfusion needs and reported on statistically significant between‐study heterogeneity. </p> <p><a href="./references#CD004863-bbs2-0113" title="XuXJ , HuangHY , ChenHL . Erythropoietin and retinopathy of prematurity: a meta‐analysis. European Journal of Pediatrics2014;173(10):1355‐64. [DOI: 10.1007/s00431‐014‐2332‐4; PUBMED: 24849614] ">Xu 2014</a> performed a meta‐analysis of EPO and ROP. Review authors included randomised controlled trials (RCTs), observational cohort studies, and retrospective case–control studies. They concluded that EPO treatment is not associated with development of ROP in preterm infants, but this conclusion should be confirmed by further high‐quality research. <a href="./references#CD004863-bbs2-0069" title="ChouHH , ChungMY , ZhouXG , LinHC . Early erythropoietin administration does not increase the risk of retinopathy in preterm infants. Pediatrics and Neonatology2017;58(1):48‐56. [DOI: 10.1016/j.pedneo.2016.03.006; PUBMED: 27346390] ">Chou 2017</a> performed a systematic review of early and late EPO administration and risk of ROP in preterm infants. These review authors included unpublished data from <a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a>, which we had obtained from trial authors and had included in our Cochrane review. Results provided in <a href="./references#CD004863-bbs2-0069" title="ChouHH , ChungMY , ZhouXG , LinHC . Early erythropoietin administration does not increase the risk of retinopathy in preterm infants. Pediatrics and Neonatology2017;58(1):48‐56. [DOI: 10.1016/j.pedneo.2016.03.006; PUBMED: 27346390] ">Chou 2017</a> for the early EPO group correspond to those of our current updated review, except that we included two additional studies (<a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>), thereby increasing the power of our analysis. Their conclusions that EPO administration did not increase the risk of ROP of any stage reported or of stage ≥ 3 are consistent with our findings in this update. </p> <p><a href="./references#CD004863-bbs2-0114" title="ZhangJ , WangQ , XiangH , XinY , ChangM , LuH . Neuroprotection with erythropoietin in preterm and/or low birth weight infants. Journal of Clinical Neuroscience2014;21(8):1283‐7. [DOI: 10.1016/j.jocn.2013.10.040; PUBMED: 24650681] ">Zhang 2013</a> performed a review titled "Neuroprotection with erythropoietin in preterm and/or low birth weight infants". These review authors included four studies for the primary outcome of neurodevelopmental disability and concluded that use of EPO, to some extent, is associated with a reduction in neurodevelopmental disability in preterm infants. They included the <a href="./references#CD004863-bbs2-0038" title="BiererR , PeceneyMC , HartenbergerCH , OhlsRK . Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics2006;118(3):e635‐40. [DOI: 10.1542/peds.2005‐3186; PUBMED: 16908620] ">Bierer 2006</a> report. One of the authors of this study, Dr. R.K. Ohls, informed us that this study reported on a subgroup of the <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a> study. All outcomes of <a href="./references#CD004863-bbs2-0038" title="BiererR , PeceneyMC , HartenbergerCH , OhlsRK . Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics2006;118(3):e635‐40. [DOI: 10.1542/peds.2005‐3186; PUBMED: 16908620] ">Bierer 2006</a> are included in the 2004 follow‐up publication of the <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a> study. Thus analyses that include results from both <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a> (follow‐up, Ohls 2004) and <a href="./references#CD004863-bbs2-0038" title="BiererR , PeceneyMC , HartenbergerCH , OhlsRK . Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics2006;118(3):e635‐40. [DOI: 10.1542/peds.2005‐3186; PUBMED: 16908620] ">Bierer 2006</a> are incorrect, as they include the same children twice. Under '2.6. Data extraction' review authors write, "All abstracts and published studies identified as potentially relevant by the literature search were assessed for inclusion by two review authors. Each author extracted data separately on a data extraction form. The information was then compared, and differences were resolved by consensus. One review author (A.O.) entered data into RevMan 5.1 Software (Cochrane Collaboration, Oxford, UK), and the other (S.A.) cross‐checked the printout against his own data extraction forms and any errors were corrected. For the studies identified in abstract form, the primary author was contacted to obtain further information". This paragraph has been directly copied from our previous review, including our initials (A.O. and S.A.). That review included results of the <a href="./references#CD004863-bbs2-0093" title="NewtonNR , LeonardCH , PiecuchRE , PhibbsRH . Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. Journal of Perinatology1999;19(6 Pt 1):403‐6. [PUBMED: 10685268] ">Newton 1999</a> report. Trial authors followed up to seven years of age 40 infants who had been enrolled in two pilot studies and one multi‐centre study at the University of California, San Francisco. The three included studies enrolled infants at eight or more days, at 10 to 35 days, and at 23 to 24 days of age. Those infants do not meet our inclusion criterion of age less than eight days. One included study was an observational study (<a href="./references#CD004863-bbs2-0092" title="NeubauerAP , VossW , WachtendorfM , JungmannT . Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Annals of Neurology2010;67(5):657‐66. [DOI: 10.1002/ana.21977; PUBMED: 20437563] ">Neubauer 2010</a>). Owing to the concerns raised above, the results of this review are not valid. </p> <p><a href="./references#CD004863-bbs2-0109" title="WangH , ZhangL , JinY . A meta‐analysis of the protective effect of recombinant human erythropoietin (rhEPO) for neurodevelopment in preterm infants. Cell Biochemistry and Biophysics2015;71(2):795‐802. [DOI: 10.1007/s12013‐014‐0265‐1; PUBMED: 25300689] ">Wang 2015</a> performed a meta‐analysis of the protective effect of EPO for neurodevelopment in preterm infants. Review authors concluded that EPO treatment has beneficial effects on neurodevelopmental outcomes without severe adverse side effects. They included two RCTs and three quasi‐randomised trials. They included the <a href="./references#CD004863-bbs2-0038" title="BiererR , PeceneyMC , HartenbergerCH , OhlsRK . Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics2006;118(3):e635‐40. [DOI: 10.1542/peds.2005‐3186; PUBMED: 16908620] ">Bierer 2006</a> report, which we know from Dr. Ohls is a duplicate publication of her follow‐up study from 2004 (listed under <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>). Thus the seven analyses that include results from both <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a> (follow‐up of Ohls 2004) and <a href="./references#CD004863-bbs2-0038" title="BiererR , PeceneyMC , HartenbergerCH , OhlsRK . Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics2006;118(3):e635‐40. [DOI: 10.1542/peds.2005‐3186; PUBMED: 16908620] ">Bierer 2006</a> are incorrect, and results of this review are not valid. </p> <p><a href="./references#CD004863-bbs2-0076" title="FischerHS , ReibelNJ , BührerC , DameC . Prophylactic early erythropoietin for neuroprotection in preterm infants: a meta‐analysis. Pediatrics2017;139(5):e20164317. [DOI: 10.1542/peds.2016‐4317; PUBMED: 28557760] ">Fischer 2017</a> presented a meta‐analysis of prophylactic early EPO in preterm infants. Review authors included four RCTs and referred to follow‐up studies (Ohls 2004, Ohls 2014, Natalucci 2016) of the original reports ‐ not the report of the primary study, except for <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>, which included long‐term follow‐up in the original report. We included follow‐up reports under the original studies (<a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>; <a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a>; <a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a>; <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>). In addition, we included unpublished information from <a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a>, along with one new study (<a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a>). The primary outcome of the meta‐analysis by <a href="./references#CD004863-bbs2-0076" title="FischerHS , ReibelNJ , BührerC , DameC . Prophylactic early erythropoietin for neuroprotection in preterm infants: a meta‐analysis. Pediatrics2017;139(5):e20164317. [DOI: 10.1542/peds.2016‐4317; PUBMED: 28557760] ">Fischer 2017</a> was the number of infants with a Mental Developmental Index (MDI) &lt; 70 on the Bayley Scales of Infant Development ‐ Second Edition (BSID‐II) at 18 to 24 months’ corrected age. If infants were assessed according to the Third Edition (BSID‐III), review authors used cognitive scores &lt; 85 as the primary outcome. We kept analyses for BSID‐II and BSID‐III separate. <a href="./references#CD004863-bbs2-0103" title="SharpM , DeMauroSB . Counterbalanced comparison of the BSID‐II and Bayley‐III at eighteen to twenty‐two months corrected age. Journal of Developmental and Behavioral Pediatrics2017;38(5):322‐9. [DOI: 10.1097/DBP.0000000000000441; PUBMED: 28538042] ">Sharp 2017</a> in a randomised cross‐over study found that when severity of delay was classified via standardised cut‐points for moderate and severe developmental delay (1 and 2 SDs below reference norm), 40% of children were classified as less severely delayed with the Bayley‐III cognitive composite score than with the BSID‐II MDI, whereas only one child (&lt; 2%) was classified as more severely delayed with the Bayley‐III. <a href="./references#CD004863-bbs2-0103" title="SharpM , DeMauroSB . Counterbalanced comparison of the BSID‐II and Bayley‐III at eighteen to twenty‐two months corrected age. Journal of Developmental and Behavioral Pediatrics2017;38(5):322‐9. [DOI: 10.1097/DBP.0000000000000441; PUBMED: 28538042] ">Sharp 2017</a> concluded that "these findings have critical implications for both the interpretation of clinical research studies and determination of eligibility for services in high‐risk children". <a href="./references#CD004863-bbs2-0076" title="FischerHS , ReibelNJ , BührerC , DameC . Prophylactic early erythropoietin for neuroprotection in preterm infants: a meta‐analysis. Pediatrics2017;139(5):e20164317. [DOI: 10.1542/peds.2016‐4317; PUBMED: 28557760] ">Fischer 2017</a> found that prophylactic EPO improved the cognitive development of very preterm infants as assessed by the MDI at corrected age of 18 to 24 months. However, review authors did not report on the MDI at that age, but on MDI &lt; 70 at corrected age of 18 to 24 months. We found a similar reduction in this outcome and an increase in the WMD in Bayley‐II at 18 to 24 months. Authors of the review state that they followed standard methods of the Cochrane Neonatal Review Group but made two deviations from the Cochrane Neonatal standard method, that is, they used the odds ratio and the random‐effects model when performing these analyses. Review authors concluded that "prophylactic rhEPO improved the cognitive development of very preterm infants, as assessed by the MDI at a corrected age of 18 to 24 months, without affecting other neurodevelopmental outcomes. Current and future RCTs should investigate optimal dosing and timing of prophylactic rhEPO and plan for long‐term neurodevelopmental follow‐up" (<a href="./references#CD004863-bbs2-0076" title="FischerHS , ReibelNJ , BührerC , DameC . Prophylactic early erythropoietin for neuroprotection in preterm infants: a meta‐analysis. Pediatrics2017;139(5):e20164317. [DOI: 10.1542/peds.2016‐4317; PUBMED: 28557760] ">Fischer 2017</a>). Like us, <a href="./references#CD004863-bbs2-0076" title="FischerHS , ReibelNJ , BührerC , DameC . Prophylactic early erythropoietin for neuroprotection in preterm infants: a meta‐analysis. Pediatrics2017;139(5):e20164317. [DOI: 10.1542/peds.2016‐4317; PUBMED: 28557760] ">Fischer 2017</a> raised concerns about lack of blinding, late registration, and differences in primary outcomes between the registration document and the final report in <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> (high risk). We found significant results for several neurodevelopmentally related outcomes in infants treated with EPO; and reduced rates of IVH, PVL, white and grey matter injury at term, any neurodevelopmental impairment at 18 to 22 months' corrected age, moderate/severe neurological disability at 18 to 24 months, and death or moderate/severe neurological disability at 18 to 24 months. Many of these results were strongly influenced by results from <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>, for which both <a href="./references#CD004863-bbs2-0076" title="FischerHS , ReibelNJ , BührerC , DameC . Prophylactic early erythropoietin for neuroprotection in preterm infants: a meta‐analysis. Pediatrics2017;139(5):e20164317. [DOI: 10.1542/peds.2016‐4317; PUBMED: 28557760] ">Fischer 2017</a> and we were concerned about high risk of bias. It is important that ongoing trials such as <a href="./references#CD004863-bbs2-0057" title="NCT01378273 . Preterm Erythropoietin Neuroprotection Trial (PENUT Trial). clinicaltrials.gov/show/NCT01378273 (first received 20 June 2011). ">NCT01378273</a> and <a href="./references#CD004863-bbs2-0058" title="NCT02550054 . Erythropoietin in Premature Infants to Prevent Encephalopathy [Erythropoietin in Premature Infants to Prevent Encephalopathy: A Multi‐centre Randomized Blinded Controlled Study of the Efficacy of Erythropoietin in China]. clinicaltrials.gov/show/NCT02550054 (first received 04 September 2015). ">NCT02550054</a> are conducted and completed, with long‐term follow‐up provided in a timely fashion. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004863-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update." data-id="CD004863-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004863-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004863-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Erythropoietin versus placebo or no treatment, outcome: 1.1 Use of 1 or more red blood cell transfusions (low and high doses of EPO)." data-id="CD004863-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Erythropoietin versus placebo or no treatment, outcome: 1.1 Use of 1 or more red blood cell transfusions (low and high doses of EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Erythropoietin versus placebo or no treatment, outcome: 1.1 Use of 1 or more red blood cell transfusions (low and high doses of EPO)." data-id="CD004863-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Erythropoietin versus placebo or no treatment, outcome: 1.1 Use of 1 or more red blood cell transfusions (low and high doses of EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 1 Use of 1 or more red blood cell transfusions (low and high doses of EPO)." data-id="CD004863-fig-00101" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 1 Use of 1 or more red blood cell transfusions (low and high doses of EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 2 Use of 1 or more blood transfusions (high dose of EPO)." data-id="CD004863-fig-00102" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 2 Use of 1 or more blood transfusions (high dose of EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 3 Use of 1 or more red blood cell transfusions (low‐dose EPO)." data-id="CD004863-fig-00103" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 3 Use of 1 or more red blood cell transfusions (low‐dose EPO). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 4 Total volume (mL/kg) of blood transfused per infant." data-id="CD004863-fig-00104" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 4 Total volume (mL/kg) of blood transfused per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 5 Number of red blood transfusions per infant." data-id="CD004863-fig-00105" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 5 Number of red blood transfusions per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 6 Number of donors to whom the infant was exposed." data-id="CD004863-fig-00106" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 6 Number of donors to whom the infant was exposed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 7 Mortality during initial hospital stay (all causes of mortality)." data-id="CD004863-fig-00107" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 7 Mortality during initial hospital stay (all causes of mortality). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 8 Retinopathy of prematurity (all stages or stage not reported)." data-id="CD004863-fig-00108" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 8 Retinopathy of prematurity (all stages or stage not reported). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 9 Retinopathy of prematurity (stage ≥ 3)." data-id="CD004863-fig-00109" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 9 Retinopathy of prematurity (stage ≥ 3). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 10 Proven sepsis." data-id="CD004863-fig-00110" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 10 Proven sepsis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 11 Necrotising enterocolitis (stage not reported)." data-id="CD004863-fig-00111" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 11 Necrotising enterocolitis (stage not reported). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 12 Intraventricular haemorrhage (all grades)." data-id="CD004863-fig-00112" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 12 Intraventricular haemorrhage (all grades). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 13 Intraventricular haemorrhage (grades III and IV)." data-id="CD004863-fig-00113" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 13 Intraventricular haemorrhage (grades III and IV). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 14 Periventricular leukomalacia." data-id="CD004863-fig-00114" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 14 Periventricular leukomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 15 Length of hospital stay (days)." data-id="CD004863-fig-00115" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 15 Length of hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 16 Bronchopulmonary dysplasia." data-id="CD004863-fig-00116" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 16 Bronchopulmonary dysplasia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 17 Neutropenia." data-id="CD004863-fig-00117" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 17 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 18 Hypertension." data-id="CD004863-fig-00118" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 18 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 19 Hemangioma." data-id="CD004863-fig-00119" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 19 Hemangioma.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 20 Neonatal Behavioral Neurological Assessment at 40 weeks' PMA." data-id="CD004863-fig-00120" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 20 Neonatal Behavioral Neurological Assessment at 40 weeks' PMA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 21 Infants with white matter injury at term‐corrected PMA." data-id="CD004863-fig-00121" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 21 Infants with white matter injury at term‐corrected PMA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 22 Infants with white matter signal abnormality at term‐corrected PMA." data-id="CD004863-fig-00122" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 22 Infants with white matter signal abnormality at term‐corrected PMA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 23 Infants with periventricular white matter loss at term‐corrected PMA." data-id="CD004863-fig-00123" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 23 Infants with periventricular white matter loss at term‐corrected PMA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 24 Infants with grey matter injury at term‐corrected PMA." data-id="CD004863-fig-00124" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 24 Infants with grey matter injury at term‐corrected PMA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 25 Survivors at discharge from hospital without severe IVH, PVL, ROP." data-id="CD004863-fig-00125" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 25 Survivors at discharge from hospital without severe IVH, PVL, ROP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 26 Bayley‐II MDI &lt; 70 at 18 to 24 months' corrected age." data-id="CD004863-fig-00126" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 26 Bayley‐II MDI &lt; 70 at 18 to 24 months' corrected age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 27 Bayley‐II PDI &lt; 70 at 18 to 22 months' corrected age (in children examined)." data-id="CD004863-fig-00127" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 27 Bayley‐II PDI &lt; 70 at 18 to 22 months' corrected age (in children examined). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 28 Bayley‐II MDI at 18 to 24 months." data-id="CD004863-fig-00128" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 28 Bayley‐II MDI at 18 to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 29 Bayley‐II PDI at 18 to 24 months." data-id="CD004863-fig-00129" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 29 Bayley‐II PDI at 18 to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 30 Cerebral palsy at 18 to 24 months' corrected age." data-id="CD004863-fig-00130" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 30 Cerebral palsy at 18 to 24 months' corrected age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 31 Any neurodevelopmental impairment at 18 to 22 months' corrected age (in children examined)." data-id="CD004863-fig-00131" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 31 Any neurodevelopmental impairment at 18 to 22 months' corrected age (in children examined). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 32 Visual impairment at 18 to 24 months' corrected age." data-id="CD004863-fig-00132" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 32 Visual impairment at 18 to 24 months' corrected age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 33 Hearing impairment at 18 to 24 months' corrected age." data-id="CD004863-fig-00133" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 33 Hearing impairment at 18 to 24 months' corrected age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 34 BSID‐III composite cognitive scores at 18 to 22 months." data-id="CD004863-fig-00134" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 34 BSID‐III composite cognitive scores at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 35 BSID‐III composite language score." data-id="CD004863-fig-00135" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 35 BSID‐III composite language score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 36 BSID‐III composite social/emotional score." data-id="CD004863-fig-00136" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 36 BSID‐III composite social/emotional score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 37 BSID‐III object performance (OP) score." data-id="CD004863-fig-00137" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 37 BSID‐III object performance (OP) score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 38 WPPSI‐III FSIQ at 3.5 to 4 years of age." data-id="CD004863-fig-00138" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 38 WPPSI‐III FSIQ at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 39 WPPSI‐III VIQ at 3.5 to 4 years of age." data-id="CD004863-fig-00139" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 39 WPPSI‐III VIQ at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 40 WPPSI‐III PIQ at 3.5 to 4 years of age." data-id="CD004863-fig-00140" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 40 WPPSI‐III PIQ at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 41 WPPSI‐III GLC at 3.5 to 4 years of age." data-id="CD004863-fig-00141" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 41 WPPSI‐III GLC at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 42 Executive function at 3.5 to 4 years of age." data-id="CD004863-fig-00142" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 42 Executive function at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 43 Working memory at 3.5 to 4 years of age." data-id="CD004863-fig-00143" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 43 Working memory at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 44 Inhibition at 3.5 to 4 years of age." data-id="CD004863-fig-00144" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 44 Inhibition at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 45 Griffiths Developmental Scale at 2 years of age." data-id="CD004863-fig-00145" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 45 Griffiths Developmental Scale at 2 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 46 Survival without major neurological or neurodevelopmental disorders at 2 years of age." data-id="CD004863-fig-00146" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 46 Survival without major neurological or neurodevelopmental disorders at 2 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 47 Death or moderate/severe neurological disability at 18 to 24 months." data-id="CD004863-fig-00147" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 47 Death or moderate/severe neurological disability at 18 to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-001-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-001-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 48 Moderate/severe neurological disability at 18 to 24 months." data-id="CD004863-fig-00148" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1 Erythropoietin versus placebo or no treatment, Outcome 48 Moderate/severe neurological disability at 18 to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-001-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 1 Use of 1 or more red blood cell transfusions." data-id="CD004863-fig-00201" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 1 Use of 1 or more red blood cell transfusions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 2 Total volume (mL/kg) of blood transfused per infant (all infants)." data-id="CD004863-fig-00202" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 2 Total volume (mL/kg) of blood transfused per infant (all infants). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 3 Total volume (mL/kg) of blood transfused in transfused infants only." data-id="CD004863-fig-00203" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 3 Total volume (mL/kg) of blood transfused in transfused infants only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 4 Number of blood transfusions per infant." data-id="CD004863-fig-00204" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 4 Number of blood transfusions per infant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 5 Number of donors the infant was exposed to." data-id="CD004863-fig-00205" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 5 Number of donors the infant was exposed to. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 6 Mortality during initial hospital stay (all causes of mortality)." data-id="CD004863-fig-00206" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 6 Mortality during initial hospital stay (all causes of mortality). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00207"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 7 Retinopathy of prematurity (all stages)." data-id="CD004863-fig-00207" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 7 Retinopathy of prematurity (all stages). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00207">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00208"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 8 Retinopathy of prematurity (stage ≥ 3)." data-id="CD004863-fig-00208" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 8 Retinopathy of prematurity (stage ≥ 3). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00208">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00209"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 9 Necrotising enterocolitis (&gt; stage 2)." data-id="CD004863-fig-00209" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 9 Necrotising enterocolitis (&gt; stage 2). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00209">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00210"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 10 Proven sepsis." data-id="CD004863-fig-00210" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 10 Proven sepsis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00210">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00211"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 11 Intraventricular haemorrhage (grades III and IV)." data-id="CD004863-fig-00211" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 11 Intraventricular haemorrhage (grades III and IV). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00211">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00212"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 12 Periventricular leukomalacia." data-id="CD004863-fig-00212" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 12 Periventricular leukomalacia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00212">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00213"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 13 Bronchopulmonary dysplasia (supplemental oxygen at 36 weeks' PMA)." data-id="CD004863-fig-00213" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 13 Bronchopulmonary dysplasia (supplemental oxygen at 36 weeks' PMA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00213">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00214"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 14 Length of hospital stay (days)." data-id="CD004863-fig-00214" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 14 Length of hospital stay (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00214">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00215"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 15 Neutropenia." data-id="CD004863-fig-00215" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 15 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00215">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00216"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 16 Hypertension." data-id="CD004863-fig-00216" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 16 Hypertension.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00216">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00217"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 17 Cerebral palsy at 18 to 22 months." data-id="CD004863-fig-00217" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 17 Cerebral palsy at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00217">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00218"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 18 NDI (with CP, visual defect, hearing defect, or cognitive score &lt; 85) at 18 to 22 months." data-id="CD004863-fig-00218" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 18 NDI (with CP, visual defect, hearing defect, or cognitive score &lt; 85) at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00218">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00219"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 19 BSID‐III composite cognitive score at 18 to 22 months." data-id="CD004863-fig-00219" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 19 BSID‐III composite cognitive score at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00219">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00220"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 20 BSID‐III composite language score at 18 to 22 months." data-id="CD004863-fig-00220" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 20 BSID‐III composite language score at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00220">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00221"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 21 Bayley‐III social/emotional score at 18 to 22 months." data-id="CD004863-fig-00221" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 21 Bayley‐III social/emotional score at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00221">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00222"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 22 OP score at 18 to 22 months." data-id="CD004863-fig-00222" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 22 OP score at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00222">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00223"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 23 WPPSI‐III FSIQ at 3.5 to 4 years of age." data-id="CD004863-fig-00223" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 23 WPPSI‐III FSIQ at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00223">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00224"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 24 WPPSI‐III VIQ at 3.5 to 4 years of age." data-id="CD004863-fig-00224" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 24 WPPSI‐III VIQ at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00224">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00225"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 25 WPPSI‐III PIQ at 3.5 to 4 years of age." data-id="CD004863-fig-00225" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 25 WPPSI‐III PIQ at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00225">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00226"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 26 WPPSI‐III GLC at 3.5 to 4 years of age." data-id="CD004863-fig-00226" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 26 WPPSI‐III GLC at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00226">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00227"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 27 Executive function at 3.5 to 4 years of age." data-id="CD004863-fig-00227" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 27 Executive function at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00227">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00228"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 28 Working memory at 3.5 to 4 years of age." data-id="CD004863-fig-00228" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 28 Working memory at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00228">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00229"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-002-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-002-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 29 Inhibition at 3.5 to 4 years of age." data-id="CD004863-fig-00229" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2 Darbepoetin alfa versus placebo or no treatment, Outcome 29 Inhibition at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00229">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-002-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00301"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 1 BSID‐III composite cognitive score at 18 to 22 months." data-id="CD004863-fig-00301" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 1 BSID‐III composite cognitive score at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00301">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00302"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 2 BSID‐III composite language score at 18 to 22 months." data-id="CD004863-fig-00302" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 2 BSID‐III composite language score at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00302">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00303"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 3 BSID‐III composite social/emotional score at 18 to 22 months." data-id="CD004863-fig-00303" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 3 BSID‐III composite social/emotional score at 18 to 22 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00303">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00304"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 4 OP score at 18 to 24 months." data-id="CD004863-fig-00304" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 4 OP score at 18 to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00304">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00305"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 5 BASC‐2 composite scores at 3.5 to 4 years ‐ adaptive skills." data-id="CD004863-fig-00305" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 5 BASC‐2 composite scores at 3.5 to 4 years ‐ adaptive skills. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00305">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00306"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 6 BASC‐2 composite scores at 3.5 to 4 years ‐ behaviour symptoms." data-id="CD004863-fig-00306" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 6 BASC‐2 composite scores at 3.5 to 4 years ‐ behaviour symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00306">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00307"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 7 BASC‐2 composite score at 3.5 to 4 years ‐ externalising problems." data-id="CD004863-fig-00307" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 7 BASC‐2 composite score at 3.5 to 4 years ‐ externalising problems. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00307">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00308"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 8 BASC‐2 composite scores at 3.5 to 4 years ‐ internalising problems." data-id="CD004863-fig-00308" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 8 BASC‐2 composite scores at 3.5 to 4 years ‐ internalising problems. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00308">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00309"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 9 WPPSI‐III FSIQ at 3.5 to 4 years of age." data-id="CD004863-fig-00309" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 9 WPPSI‐III FSIQ at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00309">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00310"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 10 WPPSI‐III VIQ at 3.5 to 4 years of age." data-id="CD004863-fig-00310" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 10 WPPSI‐III VIQ at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00310">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00311"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 11 WPPSI‐III PIQ at 3.5 to 4 years of age." data-id="CD004863-fig-00311" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 11 WPPSI‐III PIQ at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00311">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00312"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 12 WPPSI‐III GLC at 3.5 to 4 years of age." data-id="CD004863-fig-00312" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 12 WPPSI‐III GLC at 3.5 to 4 years of age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00312">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00313"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 13 Executive function at 3.5 to 4 years." data-id="CD004863-fig-00313" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 13 Executive function at 3.5 to 4 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00313">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00314"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 14 Working memory at 3.5 to 4 years." data-id="CD004863-fig-00314" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 14 Working memory at 3.5 to 4 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00314">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00315"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 15 Inhibition at 3.5 to 4 years." data-id="CD004863-fig-00315" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment, Outcome 15 Inhibition at 3.5 to 4 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00315">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004863-fig-00401"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/urn:x-wiley:14651858:media:CD004863:CD004863-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_t/tCD004863-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Erythropoietin versus placebo to improve feeding intolerance, Outcome 1 Time to achieve full enteral feeding (days)." data-id="CD004863-fig-00401" src="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Erythropoietin versus placebo to improve feeding intolerance, Outcome 1 Time to achieve full enteral feeding (days). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-fig-00401">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/media/CDSR/CD004863/image_n/nCD004863-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004863-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Erythropoietin compared with placebo or no treatment for complications of preterm birth ‐ primary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with low birth weight </p> <p><b>Settings:</b> NICU </p> <p><b>Intervention:</b> EPO </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>EPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of 1 or more red blood cell transfusions (low and high doses of EPO)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.79 (95% CI 0.74 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1750<br/> (19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about performance bias and detection bias in 10 of the studies. We downgraded the quality of the evidence by 1 step. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 69% and for the typical RD 62% (both moderate quality). We downgraded the quality of the evidence by 1 step. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1750), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot was symmetrical for all larger studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>694 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>522 per 1000<br/> (0 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any neurodevelopmental impairment at 18 to 22 months' corrected age (in children examined)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.62 (95% CI 0.48 to 0.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1130</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about performance bias and detection bias in 1 of the studies, the largest (n = 613) (<a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>). This study carried a weight of 48.7% in the analysis. We downgraded the quality of the evidence by 1 step. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 76% (high) and for the typical RD 66% (moderate). We downgraded the quality of the evidence by 1 step. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1130), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: Although only 4 studies were included in the funnel plot, the funnel plot was symmetrical. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/> (71 to 438) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bayley‐II MDI at 18 to 24 months</p> <p>Bayley Scales of Infant Development, Second Edition, yields 2 single age‐standardised composite scores (range 50 to 150): a Mental Development Index (MDI), which measures cognition through sensory perception, knowledge, memory, problem‐solving and early language abilities; and a Psychomotor Development Index (PDI), which assesses fine and gross motor skills. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean Bayley‐II MDI ranged across control groups from 84.1 to 94.5.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean Bayley‐II MDI at 18 to 24 months in the intervention groups was 8.22 higher (95% CI 6.52 to 9.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WMD: 8.22 (95% CI 6.52 to 9.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>981<br/> (3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: We had concerns about performance bias and detection bias in one of the studies (<a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>). We downgraded the quality of the evidence by 1 step. <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> carried a weight in the analysis of 76.2%. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for the WMD was 97% (high). We downgraded the quality of the evidence by 1 step. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 981), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: As only 3 studies were included, we did not prepare a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Necrotising enterocolitis (stage not reported)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.69 (95% CI 0.52 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2639<br/> (15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about performance bias and detection bias in 6 of the studies, especially for <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>, the only study that showed a significant reduction in NEC. It carried a weight in the analysis of 47.8%. We downgraded the quality of the evidence by 1 step. </p> <p>Heterogeneity/Consistency: I<sup>2</sup> for the typical RR was 0% and for the typical RD 22% (both low). </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 2639), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000<br/> (0 to 143) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; EPO: erythropoietin; MDI: Mental Development Index; NICU: neonatal intensive care unit; NEC: necrotising enterocolitis; PDI: Psychomotor Development Index; RD: risk difference; RR: risk ratio; WMD: weighted mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004863-tbl-0002"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Erythropoietin compared with placebo or no treatment for complications of preterm birth</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with low birth weight </p> <p><b>Settings:</b> NICU </p> <p><b>Intervention:</b> EPO </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>EPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality during initial hospital stay (all causes of mortality)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.89 (95% CI 0.68 to 1.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2212<br/> (20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> high </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We had concerns about bias (lack of blinding) in 10 of the included studies, but the outcome of mortality is not likely to be affected by researchers knowing the treatment assignment. We did not downgrade the quality of evidence on this item. </p> <p>Heterogeneity/Consistency: We noted no heterogeneity (I<sup>2</sup> = 0%). </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (2212), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/> (0 to 172) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Retinopathy of prematurity (stage ≥ 3)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 1.24 (95% CI 0.81 to 1.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1283<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> high </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We found no risk of bias in any of the studies, except in the smallest study that enrolled 40 neonates. We did not downgrade the quality of evidence. </p> <p>Heterogeneity/Consistency: We noted no heterogeneity for RR (I<sup>2</sup> = 0%) and low (I<sup>2</sup> = 34%) heterogeneity for RD. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1283), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot, which included 8 studies, was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (0 to 195) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intraventricular haemorrhage (grades III and IV)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.60 (95% CI 0.43 to 0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1460<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias:The intervention was not blinded in the largest study, <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> (n= 743). That study carried a weight of 72.8% in the analysis and was the only individual study that showed a significant reduction in IVH (grades III and IV). We downgraded the quality of the evidence by 1 step. </p> <p>Heterogeneity/Consistency: Heterogeneity was low (I<sup>2</sup> = 45%). </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1460), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot, which included 8 studies, was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000<br/> (0 to 126) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Periventricular leukomalacia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.66 (95% CI 0.48 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1469<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: The intervention was not blinded in the largest study, <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> (n = 743). That study carried a weight of 89.2% in the analysis and was the only individual study that showed a significant reduction in PVL. We downgraded the quality of the evidence by 1 step. <br/> Heterogeneity/Consistency: We noted no heterogeneity (I<sup>2</sup> = 5%). </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1469), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: The funnel plot, which included 6 studies, was symmetrical.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000<br/> (0 to 150) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Survivors at discharge from hospital without severe IVH, PVL, ROP</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 1.00 (95% CI 0.93 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>443<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> high </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: We noted low risk of bias.</p> <p>Heterogeneity/Consistency: N/A, as only 1 study.</p> <p>Directness of evidence: The study was conducted in the target population.</p> <p>Precision: Because of the relatively large sample size (n = 443), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: As only 1 study was included, we did not develop a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>855 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>856 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to achieve full enteral feeding (days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean time to achieve full enteral feeding was 16.3 days (SD 5.3) in the control group.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean time to achieve full enteral feeding in the intervention groups was 2.90 days shorter. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD: ‐2.90 (95% CI ‐5.77 to ‐0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: We had concerns about blinding of the intervention and outcome assessments. We downgraded the quality of evidence by 1 step. </p> <p>Heterogeneity/Consistency: N/A, as only 1 study.</p> <p>Directness of evidence: The study was conducted in the target population.</p> <p>Precision: Because of the small sample size (n = 50), the 95% CI around the point estimate was wide. </p> <p>Presence of publication bias: As only 1 study was included, we did not prepare a funnel plot. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; EPO: erythropoietin; IVH: intraventricular haemorrhage; MD: mean difference; N/A: not applicable; NICU: neonatal intensive care unit; PVL: periventricular leukomalacia; RD: risk difference; ROP: retinopathy of prematurity; RR: risk ratio; SD: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004863-tbl-0003"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Erythropoietin compared with placebo or no treatment for complications of preterm birth ‐ long‐term outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preterm infants with low birth weight </p> <p><b>Settings:</b> NICU </p> <p><b>Intervention:</b> EPO </p> <p><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>EPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cerebral palsy at 18 to 24 months' corrected age</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR: 0.72 (95% CI 0.46 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1172<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> high </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bias: Low risk of bias. All assessors of long‐term outcomes were blinded in all trials. In <a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a>, treatment allocation was known to caregivers and probably parents, who could have possibly disclosed that information to assessors at long‐term follow‐up. We did not downgrade the quality of the evidence. </p> <p>Heterogeneity/Consistency: Heterogeneity was low for this outcome (I<sup>2</sup> = 48%). We did not downgraded the evidence. </p> <p>Directness of evidence: Studies were conducted in the target population.</p> <p>Precision: Because of the large sample size (n = 1172), the point estimate was precise with a narrow 95% CI. </p> <p>Presence of publication bias: We included 6 studies in the analysis; we did prepare a funnel plot, which was symmetrical. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>70 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000<br/> (0 to 285) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; EPO: erythropoietin; NICU: neonatal intensive care unit; RR: risk ratio; WMD: weighted mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004863-tbl-0004"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Darbe or EPO (ESA) compared with sham injection for neuro protection ‐ long‐term outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> neonates born preterm with low birth weight </p> <p><b>Settings:</b> NICU </p> <p><b>Intervention:</b> Darbe or EPO (ESA) </p> <p><b>Comparison:</b> sham injection </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sham injection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ESA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BSID‐III composite cognitive scores at 18 to 22 months</p> <p>The Bayley‐III has 3 main sub tests: the Cognitive Scale, which includes items such as attention to familiar and unfamiliar objects, looking for a fallen object, and pretend play; the Language Scale, which taps understanding and expression of language, for example, recognising objects and people, following directions, and naming objects and pictures; and the Motor Scale, which assesses gross and fine motor skills such as grasping, sitting, stacking blocks, and climbing stairs. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean BSID‐III in the control group was 88.7 units (SD 13.5).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean BSID‐III in the intervention group was 7.80 units higher.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 7.80 (95% CI 1.65 to 13.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: Risk of bias was low, but the sample followed was small. We did not reduce the quality of evidence. </p> <p>Heterogeneity/Consistency: Only 1 study was included, so the test for heterogeneity was N/A. </p> <p>Directness of evidence: The study was conducted in the target population.</p> <p>Precision: Because of the small sample size (n = 80), the point estimate had a wide 95% CI. We downgraded the quality of evidence by 1 step. </p> <p>Presence of publication bias: N/A, as only 1 study was included.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WPPSI‐III FSIQ at 3.5 to 4 years of age</p> <p>Composite scores have a mean of 100 and a standard deviation of 15.</p> <p>Average is 90 to 109.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean WPPSI‐III FSIQ in the control group was 79.2 units (SD 18,5).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean WPPSI‐III FSIQ in the intervention group was 11.90 units higher.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 11.90 (95% CI 0.76 to 23.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bias: Risk of bias was low, but the sample followed was even smaller than at 18 to 22 months of age (n = 53). We did reduce the quality of evidence by 1 step. </p> <p>Heterogeneity/Consistency: Only 1 study was included, so the test for heterogeneity was N/A. </p> <p>Directness of evidence: The study was conducted in the target population.</p> <p>Precision: Because of the small sample size (n = 53), the point estimate had a large 95% CI. We downgraded the quality of evidence by 1 step. </p> <p>Presence of publication bias: N/A, as only 1 study was included,</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> BSID‐III: Bayley Scales of Infant Development ‐ Third Edition; CI: confidence interval; EPO: erythropoietin; ESA: erythropoiesis‐stimulating agent; MD: mean difference; N/A: not applicable; NICU: neonatal intensive care unit; RR: risk ratio; SD: standard deviation; WPPSI‐III FSIQ: Wechsler Preschool and Primary Scale of Intelligence ‐ Third Edition. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004863-tbl-0009"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Transfusion guidelines</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Indications</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0001" title="ArifB , FerhanK . Recombinant human erythropoietin therapy in low‐birthweight preterm infants: a prospective controlled study. Pediatrics International2005;47(1):67‐71. [DOI: 10.1111/j.1442‐200x.2005.02007.x; PUBMED: 15693870] ">Arif 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants with Hgb concentrations &lt; 7 g/dL and with a reticulocyte count lower than &lt; 100,000/µL or Hgb concentrations &lt; 8 g/dL having bradycardia, tachypnoea, or apnoea, or who were not able to gain weight despite adequate calorie intake, were chosen as candidates for blood transfusion. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0002" title="AventM , CoryBJ , GalpinJ , BallotDE , CooperPA , ShermanG , et al. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of Tropical Pediatrics2002;48(4):227‐33. [PUBMED: 12200985] ">Avent 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants received blood transfusions if they met the following criteria:<br/> 1. Hgb of 10 g/dL and 1 of the following: (i) an oxygen requirement greater than 30%; (ii) less than 1250 grams body weight<br/> 2. Hgb &lt; 8 g/dL and 1 of the following: (i) 3 or more episodes of apnoea (respiration absent for 20 seconds) or bradycardia (heart rate &lt; 100 beats/min) in a 24‐hour period not due to other causes and not responsive to methylxanthine treatment; (ii) fractional inspired oxygen concentrations increasing by &gt; 10% per week; and (iii) tachycardia (&gt; 170 beats/min) or tachypnoea (&gt; 70 breaths/min) sustained over a 24‐hour period associated with acute cardiac decompression </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0003" title="CarnielliV , MontiniG , DaRiolR , Dall'AmicoR , CantaruttiF . Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. Journal of Pediatrics1992;121(1):98‐102. [PUBMED: 1625101] ">Carnielli 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants were transfused during the first week of life with packed erythrocytes if the Hct level was &lt; 42% or 36%, depending on whether or not the patient was receiving supplemental oxygen. After the first week of life, indications for transfusions were Hct &lt; 36% for oxygen‐dependent patients and 32% if breathing room air. Anaemia was the only indication for giving packed erythrocytes to all infants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0004" title="CarnielliVP , DaRiolR , MontiniG . Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F44‐8. [PUBMED: 9797624] ">Carnielli 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants received transfusions of packed cells during the first week of life if their peripheral Hct (heel stick) was &lt; 42% or 36%, depending on whether or not the patient was receiving supplemental oxygen.<br/> After the first week of life, indications for transfusion were Hct &lt; 36% for oxygen‐dependent patients and 32% if in room air. Hct concentrations for red blood cell transfusions for blood obtained from venipuncture or arterial samples were 4% lower than the above mentioned values (38% and 32% for oxygen‐dependent and non‐oxygen‐dependent patients in the first week, and 0.32 and 0.28 thereafter). All infants received dedicated units of red blood cells. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0005" title="ChangL , LiuW , LiaoC , ZhaoX . Preventive effects of different dosages of recombinant human erythropoietin on anemia of premature infants. Journal of Tongji Medical University/Tong Ji Yi Ke da Xue Xue Bao1998;18(4):239‐42. [PUBMED: 10806855] ">Chang 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0006" title="El‐GanzouryMM , AwadHA , El‐FarrashRA , El‐GammasyTM , IsmailEA , MohamedHE , et al. Enteral granulocyte‐colony stimulating factor and erythropoietin early in life improves feeding tolerance in preterm infants: a randomized controlled trial. Journal of Pediatrics2014;165(6):1140‐5. [DOI: 10.1016/j.jpeds.2014.07.034; PUBMED: 25155966] ">El‐Ganzoury 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0007" title="FauchèreJC , DameC , VontheinR , KollerB , ArriS , WolfM , et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics2008;122(2):375‐82. [DOI: 10.1542/peds.2007‐2591; PUBMED: 18676556] ">Fauchère 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0008" title="FauchèreJC , KollerBM , TschoppA , DameC , RueggerC , BucherHU , Swiss Erythropoietin Neuroprotection Trial Group. Safety of early high‐dose recombinant erythropoietin for neuroprotection in very preterm infants. Journal of Pediatrics2015;167(1):52‐7.e1‐3. [DOI: 10.1016/j.jpeds.2015.02.052; PUBMED: 25863661] LeuchterRH , GuiL , PoncetA , HagmannC , LodygenskyGA , MartinE , et al. Association between early administration of high‐dose erythropoietin in preterm infants and brain MRI abnormality at term‐equivalent age. JAMA2014;312(8):817‐24. [DOI: 10.1001/jama.2014.9645; PUBMED: 25157725] NatalucciG , LatalB , KollerB , RueggerC , SickB , HeldL , et al. Swiss EPO Neuroprotection Trial Group. Effect of early prophylactic high‐dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. JAMA2016;315(19):2079‐85. [DOI: 10.1001/jama.2016.5504; PUBMED: 27187300] O'GormanRL , BucherHU , HeldU , KollerBM , HűppiPS , HagmannCF , et al. Swiss EPO Neuroprotection Trial Group. Tract‐based spatial statistics to assess the neuroprotective effect of early erythropoietin on white matter development in preterm infants. Brain2015;138(Pt 2):388‐97. [DOI: 10.1093/brain/awu363; PUBMED: 25534356] ">Fauchère 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0009" title="HaidenN , CardonaF , SchwindtJ , BergerA , KuhleS , HomoncikM , et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thrombosis and Haemostasis2005;93(1):118‐23. [DOI: 10.1160/TH04‐02‐0093; PUBMED: 15630501] ">Haiden 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants were transfused at Hct &lt; 20%:<br/> 1. if asymptomatic with reticulocytes &lt; 100,000/µL<br/> <br/> Infants were transfused at Hct &lt; 30%:<br/> 1. if receiving &lt; 35% supplemental hood oxygen<br/> 2. if on CPAP or mechanical ventilation with mean air way pressure &lt; 6 cmH<sub>2</sub>O<br/> 3. if significant apnoea and bradycardia are noted (&gt; 9 episodes in 12 hours or 2 episodes in 24 hours requiring bag and mask ventilation) while receiving therapeutic doses of methylxanthines<br/> 4. if heart rate &gt; 180 beats/min or respiratory rate &gt; 80 breaths/min persists for 24 hours<br/> 5. if weight gain &lt; 10 g/d is observed over 4 days while receiving &gt; 100 kcal/kg/d<br/> 6. if undergoing surgery<br/> <br/> Transfuse for Hct &lt; 35%<br/> 1. if receiving &gt; 35% supplemental hood oxygen<br/> 2. if intubated on CPAP or mechanical ventilation with mean airway pressure &gt; 6 to 8 cmH<sub>2</sub>O<br/> Do not transfuse:<br/> 1. to replace blood removed for laboratory tests alone<br/> 2. for low Hct alone </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0010" title="HeJS , HuangZL , YangH , WengKZ , ZhuSB . Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]2008;10(5):586‐8. [PUBMED: 18947475] ">He 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines are not reported in the English abstract of this study. We have requested the full text in Chinese from trial authors. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0011" title="KhatamiSF , MamouriG , TorkamanM . Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants. Indian Journal of Pediatrics2008;75(12):1227‐30. [DOI: 10.1007/s12098‐008‐0225‐0; PUBMED: 19057854] ">Khatami 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Guidelines for red‐cell transfusions were based on the relatively strict existing policy in the nursery which was used to administer transfusions during the study period". </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0012" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were ordered by the clinicians caring for each infant without consulting the investigators, based on general guidelines for erythrocyte transfusions. According to these guidelines, neonates who were well received transfusions if their hematocrit was &lt; 30% during the third week, &lt; 25% during the fourth week, and &lt; 23% after the first month of life, combined with signs referable to their anaemia, such as poor weight gain, episodes of persistent bradycardia or tachycardia, and apnoea. Neonates with severe respiratory disease (bronchopulmonary dysplasia), particularly those requiring oxygen and/or ventilator support, were given transfusions to maintain their hematocrit level at &gt; 40%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0013" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See <a href="./references#CD004863-bbs2-0012" title="KremenopoulosG , SoubasiV , TsantaliC , DiamantiE , TsakirisD . The best timing of recombinant human erythropoietin administration in anemia of prematurity: a randomized controlled study. International Journal of Pediatric Hematology/Oncology1997;4(4):373‐83. [EMBASE: 1997362607] ">Kremenopoulos 1997A</a>, </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0014" title="LauterbachR , KachlikP , PawlikD , BajorekI . Evaluation of treatment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatria Polska1995;70(9):739‐44. [PUBMED: 8657506] ">Lauterbach 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion was given when the Hct level reached 28% and if clinical symptoms of tachypnoea, tachycardia, and bradycardia were present at Hct of 0.32. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0015" title="Lima‐RogelV , Torres‐MontesA , Espinosa GriesseS , Villegas AlvarezC , Hernandez‐SierraF , Bissett MandevilleP , et al. Efficacy of early erythropoietin use in critically ill very‐low‐birth‐weight premature newborn infants: controlled clinical trial [Eficacia del uso precoz de eritropoyetina en recien nacidos pretermino de muy bajo peso, criticamente enfermos: ensayo clinico controlado]. Sangre1998;43(3):191‐5. [PUBMED: 9741224] ">Lima‐Rogel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>According to criteria published by Klaus and Fanaroff (see text for more info)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0016" title="MaierRF , ObladenM , ScigallaP , LinderkampO , DucG , HieronimiG , et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very‐low‐birth‐weight infants. European Multicentre Erythropoietin Study Group. New England Journal of Medicine1994;330(17):1173‐8. [DOI: 10.1056/NEJM199404283301701; PUBMED: 8139627] ">Maier 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants who were receiving ventilation or who were less than 2 weeks old and had signs of anaemia were given transfusions if their Hct fell below 40%, their Hgb concentration fell below 14 g/dL (8.7 mmol/L), or blood samples totaling at least 9 mL/kg had been obtained from them since their previous transfusion.<br/> Spontaneously breathing infants, more than 2 weeks old, whose FiO<sub>2</sub> was &lt; 0.40, were given transfusions if they had signs of anaemia and their Hct fell below 32% and their Hgb concentration below 11 g/dL (6.8 mmol/L); if they had signs of anaemia, corresponding cutoff values were 27% and 9 g/dL (5.6 mmol/L). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0017" title="MaierRF , ObladenM , Muller‐HansenI , KattnerE , MerzU , ArlettazR , et al. European Multicenter Erythropoietin Beta Study Group. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics2002;141(1):8‐15. [DOI: 10.1067/mpd.2002.124309; PUBMED: 12091844] ">Maier 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants with artificial ventilation or &gt; 40% of inspired oxygen were not transfused unless Hct dropped below 0.40.<br/> Spontaneously breathing infants were not transfused unless Hct dropped below 0.35 during the first 2 weeks of life, 0.30 during the third to fourth weeks, and 0.25 thereafter. Transfusion was allowed when life‐threatening anaemia or hypovolaemia was assumed by the treating neonatologist, or surgery was planned. Twelve of the 14 centres used satellite packs of the original red cell pack to reduce donor exposure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0018" title="MeisterB , MaurerH , SimmaB , KernH , UlmerH , HittmairA , et al. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem Cells1997;15(5):359‐63. [DOI: 10.1002/stem.150359; PUBMED: 9323798] ">Meister 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants more than 2 weeks old who had been breathing spontaneously and whose FiO<sub>2</sub> was less than 0.40 were given transfusions if they had signs of anaemia and their Hct fell below 11 g/dL (6.8 mmol/L); if they had no signs of anaemia, corresponding cutoff values were 27% and 9 g/dL (5.6 mmol/L). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0019" title="MeyerMP , SharmaE , CarsonsM . Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood. Fetal and Neonatal Edition2003;88(1):F41‐5. [PUBMED: 12496225] ">Meyer 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indications for transfusions were:<br/> 1. Hct of 36% to 40% and critically ill with requirement for oxygen &gt; 45% via CPAP; ventilation (mean airway pressure &gt; 10 cmH<sub>2</sub>O); severe sepsis; active bleeding<br/> 2. Hct of 31% to 35% and requirement for oxygen (up to 45%) via CPAP; ventilation (mean airway pressure 7 to 10 cmH<sub>2</sub>O)<br/> 3. Hct of 21% to 30% and gain less than 10 g/d averaged over 1 week; experienced at least 10 to 12 apneic or bradycardic episodes in 12 hours or 2 or more such episodes requiring bag and mask ventilation within a 24‐hour period, not owing to other causes and not responsive to methylxanthine treatment; had a sustained tachycardia (&gt; 170 beats/min) or tachypnoea (&gt; 70/min) per 24 hours and not attributable to other causes; developed cardiac decompensation secondary to a clinically apparent patent ductus arteriosus; positive‐pressure ventilation on low settings (mean airway pressure &lt; 7 cmH<sub>2</sub>O) or nasal CPAP; those requiring surgery<br/> 4. Hct 20% and reticulocyte count &lt; 100 × 10<sup>9</sup>/L </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0020" title="ObladenM , MaierR , SegererH , GrauelEL , HollandBM , StewartG , et al. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European randomized multicenter trial. Contributions to Nephrology1991;88:314‐26. [PUBMED: 2040194] ">Obladen 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indications for transfusion of packed red cells:<br/> 1. If venous Hct &lt; 42%, Hgb &lt; 14 g/dL or &gt; 9 mL/kg blood sampled since last transfusion transfuse if infant is ventilated or requires FiO<sub>2</sub> &gt; 0.40<br/> 2. If age 1 to 2 weeks and symptoms of anaemia (apneic spells, distended abdomen, failure to thrive), transfuse if venous Hct &lt; 36%, Hgb &lt; 12 g/dL, or &gt; 9 mL/kg blood sampled since last transfusion.<br/> 3. If age 3 to 5 weeks and symptoms of anaemia (apneic spells, distended abdomen, failure to thrive), transfuse if venous Hct &lt; 30%, Hgb &lt; 10 g/dL or &gt; 9 mL/kg blood sampled since last transfusion.<br/> 4. If no symptoms of anaemia, transfuse at any age if venous Hct is &lt; 27%, Hgb &lt; 9 g/dL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0021" title="OhlsRK , OsborneKA , ChristensenRD . Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo‐controlled trial. Journal of Pediatrics1995;126(3):421‐6. [PUBMED: 7869205] ">Ohls 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were given during the first 3 weeks of life if Hct was &lt; 33%, and if the infant had 1 or more symptoms thought to be due strictly to anaemia. Symptoms were defined as tachycardia (heart rate &gt; 160 beats/min, calculated as the average of all heart rates recorded by the bedside nurse during the preceding 24‐hour period), an increasing oxygen requirement (an increase in fraction of inspired oxygen of &gt; 0.20 during a 24‐hour period), "lethargy" as assessed by the primary caregiver, or an increase in the number of episodes of bradycardia requiring stimulation to increase the heart rate from less than 60 beats/min (an increase of such episodes by 3 or more per day). Infants in both groups whose Hct were &gt; 33% and yet whose phlebotomy losses exceeded 10 mL/kg body weight received an infusion of 5% albumin, administered in aliquots of not less than 10 mL/kg. Infants were not given transfusions if they were free of symptoms, even if Hct fell to &lt; 33%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0022" title="OhlsRK , HarcumJ , SchiblerKR , ChristensenRD . The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo‐controlled study. Journal of Pediatrics1997;131(5):661‐5. [PUBMED: 9403642] ">Ohls 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusions were administered in both groups according to standardised transfusion criteria: For infants requiring mechanical ventilation, transfusions were given if Hct fell below 33%. For infants not receiving ventilatory support, transfusions were given if Hct fell below 28%, and if the infant was experiencing symptoms. Symptoms were defined as tachycardia (heart rate &gt; 160 beats/min, calculated as the average of all heart rates recorded by the bedside nurse over the preceding 24‐hour period), an increasing oxygen requirement (an increase in FiO<sub>2</sub> of &gt; 0.20 over a 24‐hour period, or an elevated lactate level (&gt; 2.5 mmol/L). In some instances, a new donor would be used each day for the newborn intensive care unit (University of Florida), and in other instances, a unit would be dedicated to a single infant for the life of the unit (University of New Mexico and University of Utah). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>If Hct ≤ 35%/Hgb ≤ 11 g/dL, transfuse infants requiring moderate or significant mechanical ventilation (MAP &gt; 8 cmH<sub>2</sub>O and FiO<sub>2</sub> &gt; 0.4).<br/> If Hct ≤ 30%/Hgb ≤ 10 g/dL, transfuse infants requiring minimal respiratory support (any mechanical ventilation or endotracheal/nasal CPAP &gt; 6 cmH<sub>2</sub>O and FiO<sub>2</sub> ≤ 0.4).<br/> If Hct ≤ 25%/Hgb ≤ 8 g/dL, transfuse infants not requiring mechanical ventilation but who are on supplemental O<sub>2</sub> or CPAP with an FiO<sub>2</sub> ≤ 0.4 and in whom 1 or more of the following is present: 24 hours of tachycardia (180 beats/min) or tachypnoea (&gt;80 breaths/min), an increased oxygen requirement from the previous 48 hours, defined as 4‐fold increase in nasal cannula flow (i.e. 0.25 L/min to 1 L/min), or an increase in nasal CPAP of 20% from the previous 48 hours (i.e. 5 cm to 6 cmH<sub>2</sub>O), weight gain &lt; 10 g/kg/d over the previous 4 days while receiving 100 kcal/kg/d, increase in episodes of apnoea and bradycardia (&gt; 9 episodes in a 24‐hour period or 2 episodes in 24 hours requiring bag‐mask ventilation) while receiving therapeutic doses of methylxanthines, undergoing surgery.<br/> If Hct ≤ 25%/Hgb ≤ 7 g/dL, transfuse asymptomatic infants with absolute reticulocyte count &lt; 100,000 cells/µL. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0024" title="OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001B</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See <a href="./references#CD004863-bbs2-0023" title="EhrenkranzRA , OhlsRK , DasA , VohrBR . Neurodevelopmental outcome and growth at 18‐22 months in extremely low birth weight infants treated with early erythropoietin. Pediatric Research2002;51:291A. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. OhlsRK , EhrenkranzRA , DasA , DusickAM , YoltonK , RomanoE , et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics2004;114(5):1287‐91. [DOI: 10.1542/peds.2003‐1129‐L; PUBMED: 15520109] OhlsRK , EhrenkranzRA , LemonsJA , KoronesSB , StollBJ , StarkAR , et al. A multicenter randomized double‐masked placebo‐controlled trial of early erythropoietin and iron administration to preterm infants. Pediatric Research1999;45:216A. OhlsRK , EhrenkranzRA , WrightLL , LemonsJA , KoronesSB , StollBJ , et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics2001;108(4):934‐42. [PUBMED: 11581447] ">Ohls 2001A</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0025" title="LoweJR , RiegerRE , MossNC , YeoRA , WinterS , PatelS , et al. Impact of erythropoiesis‐stimulating agents on behavioral measures in children born preterm. Journal of Pediatrics2017;184:75‐80.e1. [DOI: 10.1016/j.jpeds.2017.01.020; PUBMED: 28185625] OhlsRK , CannonDC , PhillipsJ , CaprihanA , PatelS , WinterS , et al. Preschool assessment of preterm infants treated with darbepoetin and erythropoietin. Pediatrics2016;137(3):e20153859. [DOI: 10.1542/peds.2015‐3859; PUBMED: 26908704] OhlsRK , ChristensenRD , Kamath‐RayneBD , RosenbergA , WiedmeierSE , RoohiM , et al. A randomized, masked, placebo‐controlled study of darbepoetin alfa in preterm infants. Pediatrics2013;132(1):e119‐27. [DOI: 10.1542/peds.2013‐0143; PUBMED: 23776118] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , FullerJ , et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics2014;133(6):1023‐30. [PUBMED: 24819566] OhlsRK , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , SchraderR , et al. Neurocognitive outcomes at 18‐22 months corrected age are improved in preterm infants administered darbepoetin or erythropoietin. Pediatric Academic Societies' Annual meeting 2013. 2013:E‐PAS2013:1165.5. OhlsRK , McConaghyS , Kamath‐RayneBD , ChristensenRD , WiedmeierSE , RosenbergA , et al. Erythropoietin concentrations correlate with neurocognitive outcomes measured at 18‐22 months. Pediatric Academic Societies' Annual Meeting 2013. 2013:E‐PAS2013:2924.485. ">Ohls 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The PRBC volume transfused was based on Hct/Hgb, respiratory support, and/or symptoms. </p> <p>If Hct ≤ 30/Hgb ≤ 10 and the infant required moderate/significant ventilation (MAP &gt; 8 cmH<sub>2</sub>O and FiO<sub>2</sub> &gt; 0.4), the PRBC volume to be transfused was 15 to 20 mL/kg.<br/> If Hct ≤ 25/Hgb ≤ 8 and the infant required minimal respiratory support (any mechanical ventilation with FiO<sub>2</sub> ≤ 0.4, or CPAP &gt; 6 cmH<sub>2</sub>O and FiO<sub>2</sub>≤ 0.4), the PRBC volume to be transfused was 20 mL/kg.<br/> If Hct was ≤ 20/Hgb ≤ 7 and the infant required supplemental oxygen or CPAP with FiO<sub>2</sub> ≤ 0.4, and at least 1 of the following:<br/> 1. ≥ 24 hours of tachycardia (heart rate &gt; 180) or tachypnoea (RR &gt; 60)<br/> 2. doubling of the oxygen requirement from the previous 48 hours<br/> 3. lactate ≥ 2.5 mEq/L or an acute metabolic acidosis (pH 7.20)<br/> 4. weight gain &lt; 10 g/kg/d over the previous 4 days while receiving ≥ 120 kcal/kg/d<br/> 5. undergoing surgery within 24 hours </p> <p>PRBC volume to be transfused was 20 mL/kg.</p> <p>If Hct ≤18/Hgb ≤ 6 and the infant was asymptomatic and absolute reticulocyte count (ARC) was &lt; 100,000 cells/µL, the PRBC volume to be transfused was 20 mL/kg. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0026" title="PeltoniemiOM , AnttilaE , KaukolaT , BuonocoreG , HallmanM . Randomized trial of early erythropoietin supplementation after preterm birth: iron metabolism and outcome. Early Human Development2017;109:44‐9. [DOI: 10.1016/j.earlhumdev.2017.04.001; PUBMED: 28433798] ">Peltoniemi 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants with the following respiratory needs received 10 to 15 mL/kg of RBC volume based on Hct:<br/> 1. &lt; 0.40 mechanical ventilation, FiO<sub>2</sub> &gt; 0.40<br/> 2. &lt; 0.35 mechanical ventilation, FiO<sub>2</sub> &lt; 0.40, or use of nasal CPAP at the age of &lt; 2 weeks<br/> 3. &lt; 0.30 supplemental oxygen, nasal CPAP, or apneas during later neonatal period<br/> 4. &lt; 0.25 no symptoms during later neonatal period </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0027" title="QiaoL , TangQ , ZhuW , ZhangH , ZhuY , WangH . Effect of early parenteral iron combined erythropoietin in preterm infants. Medicine2017;96(9):e5795. [DOI: 10.1097/MD.0000000000005795; PUBMED: 28248850] ">Qiao 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transfusion guidelines not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0028" title="SalvadoA , RamolfoP , EscobarM , NunezA , AguayoI , StandenJ , et al. Early erythropoietin use for the prevention of anemia in infant premature [Uso precoz de la eritropoyetina en la prevencion de la anemia del prematuro]. Revista Medica de Chile2000;128(12):1313‐7. [PUBMED: 11227239] ">Salvado 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preterm infants with Hct &lt; 20%<br/> Preterm infants with Hct &lt; 30% when presenting with frequent apneas, or tachycardia &gt; 180 beats/min, or requiring surgery </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0029" title="SongJ , SunH , XuF , KangW , GaoL , GuoJ . Recombinant human erythropoietin improves neurological outcomes in very preterm infants. Annals of Neurology2016;80(1):24‐34. [DOI: 10.1002/ana.24677; PUBMED: 27130143] ">Song 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion criteria followed strict clinical criteria as used by <a href="./references#CD004863-bbs2-0055" title="Vázquez LópezMÁ , LlamasMÁ , GaleraR , SanchezAR , LendinezF , Gonzalez‐RipollM , et al. Comparison between one and three doses a week of recombinant erythropoietin in very low birth weight infants. Journal of Perinatology2011;31(2):118‐24. [DOI: 10.1038/jp.2010.80; PUBMED: 20689518] ">Vázquez López 2011</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0030" title="SoubasiV , KremenopoulosG , DiamandiE , TsantaliC , TsakirisD . In which neonates does early recombinant human erythropoietin treatment prevent anemia of prematurity? Results of a randomized, controlled study. Pediatric Research1993;34(5):675‐9. [DOI: 10.1203/00006450‐199311000‐00022; PUBMED: 8284109] ">Soubasi 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neonates who were well were transfused if their Hct was &lt; 25% combined with signs referable to their anaemia, such as poor weight gain, persistent episodes of bradycardia or tachypnoea, and apnoea. Neonates with severe respiratory disease (BPD), particularly those requiring oxygen and/or ventilator support, received transfusions to maintain Hct level at &gt; 40%. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0031" title="SoubasiV , KremenopoulosG , DiamantiE , TsantaliC , SarafidisK , TsakirisD . Follow‐up of very low birth weight infants after erythropoietin treatment to prevent anemia of prematurity. Journal of Pediatrics1995;127(2):291‐7. [PUBMED: 7636658] ">Soubasi 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants who were receiving mechanical ventilation or who were less than 2 weeks old were given transfusion if their Hct fell below 40%. Spontaneously breathing infants more than 2 weeks old whose FiO<sub>2</sub> was less than 0.35 were given transfusion if they had signs of anaemia and their Hct fell below 30%; if they had no signs of anaemia, transfusion was given if Hct fell below 0.25. Growing, asymptomatic infants were transfused if Hct fell below 20%. Signs of anaemia included tachycardia, (&gt; 170 beats/min) or tachypnoea (&gt; 70/min) sustained over a 24‐hour period or associated with acute cardiac decompression; recurrent apnoea (respirations absent for 20 seconds) or bradycardia (heart rate &lt; 100 beats/min) in a 24‐hour period not due to other causes and not responsive to methylxanthine treatment; an increase in fractional oxygen requirement by 20% or more over a 24‐hour period; or weight gain &lt; 10 g/d averaged over a 1‐week period while on adequate caloric intake. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0032" title="SoubasiV , KremenopoulosG , TsantaliC , SavopoulouP , MussafirisC , DimitrouM . Use of erythropoietin and its effects on blood lactate and 2,3‐diphosphoglycerate in premature neonates. Biology of the Neonate2000;78(4):281‐7. [DOI: 14280; PUBMED: 11093007] ">Soubasi 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neonates were transfused when Hct was &lt; 20%, if they were asymptomatic, or &lt; 30% if they were receiving O<sub>2</sub> &lt; 0.35 and/or unexplained breathing disorders combined with signs referable to their anaemia, such as poor weight gain, episodes of persistent bradycardia or tachycardia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0033" title="YasmeenBHN , ChowdhuryMA , HoqueMM , HossainMM , JahanR , AktarS . Effect of short term recombinant human erythropoietin therapy in the prevention of anemia of prematurity in very low birth weight infants. Bangladesh Medical Research Council Bulletin2012;38(3):119‐23. [PUBMED: 23540189] ">Yasmeen 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After discharge from hospital, any patient with Hgb level ≤ 7 g/dL was readmitted to the hospital and managed with packed red cell transfusion. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004863-bbs2-0034" title="YeoCL , ChooS , HoLY . Effect of recombinant human erythropoietin on transfusion needs in preterm infants. Journal of Paediatrics and Child Health2001;37(4):352‐8. [PUBMED: 11532054] ">Yeo 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infants who were receiving mechanical ventilation or who were less than 2 weeks old were given transfusion if their Hct fell below 40%. Spontaneously breathing infants more than 2 weeks old whose FiO<sub>2</sub> was less than 35% were given transfusion if they had signs of anaemia and their Hct fell below 30%; if they had no signs of anaemia, transfusion was given if Hct fell below 25%. Growing, asymptomatic infants were transfused if Hct fell below 20%. Signs of anaemia included tachycardia, (&gt; 170 beats/min) or tachypnoea (&gt; 70/min) sustained over a 24‐hour period or associated with acute cardiac decompression; recurrent apnoea (respirations absent for 20 seconds) or bradycardia (heart rate &lt; 100 beats/min) in a 24‐hour period not due to other causes and not responsive to methylxanthine treatment; increased fractional oxygen requirement by 20% or more over a 24‐hour period; or weight gain &lt; 10 g/d averaged over a 1‐week period while on adequate caloric intake. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>ARC: absolute reticulocyte count.<br/> BPD: bronchopulmonary dysplasia.<br/> CPAP: continuous positive airway pressure.<br/> FiO<sub>2</sub>: fraction of inspired oxygen.<br/> Hct: hematocrit.<br/> Hgb: haemoglobin.<br/> MAP: mean airway pressure.<br/> PRBC: packed red blood cells.<br/> RBC: red blood cell.<br/> RR: respiratory rate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Transfusion guidelines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/full#CD004863-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004863-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Erythropoietin versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Use of 1 or more red blood cell transfusions (low and high doses of EPO) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.74, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Use of 1 or more blood transfusions (high dose of EPO) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.74, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐dose iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.77, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐dose iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.62, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Use of 1 or more red blood cell transfusions (low‐dose EPO) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.65, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 High‐dose iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.61, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Low‐dose iron</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.60, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total volume (mL/kg) of blood transfused per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.82 [‐11.52, ‐2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of red blood transfusions per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.68, ‐0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of donors to whom the infant was exposed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Among all randomised infants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐0.89, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Among infants who were transfused</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.33, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mortality during initial hospital stay (all causes of mortality) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Retinopathy of prematurity (all stages or stage not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Retinopathy of prematurity (stage ≥ 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.81, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Proven sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Necrotising enterocolitis (stage not reported) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.52, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Intraventricular haemorrhage (all grades) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Intraventricular haemorrhage (grades III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.43, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.48, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐5.34, ‐1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Bronchopulmonary dysplasia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Supplemental oxygen at 28 days of age</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.50, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Supplemental oxygen at 36 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.81, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Age at diagnosis not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.61, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.53, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.14, 6.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Hemangioma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.79, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Neonatal Behavioral Neurological Assessment at 40 weeks' PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.26, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Infants with white matter injury at term‐corrected PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.37, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Infants with white matter signal abnormality at term‐corrected PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.05, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Infants with periventricular white matter loss at term‐corrected PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.32, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Infants with grey matter injury at term‐corrected PMA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.13, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Survivors at discharge from hospital without severe IVH, PVL, ROP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Bayley‐II MDI &lt; 70 at 18 to 24 months' corrected age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.39, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Bayley‐II PDI &lt; 70 at 18 to 22 months' corrected age (in children examined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.88, 2.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Bayley‐II MDI at 18 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.22 [6.52, 9.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Bayley‐II PDI at 18 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Cerebral palsy at 18 to 24 months' corrected age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.46, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Any neurodevelopmental impairment at 18 to 22 months' corrected age (in children examined) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Visual impairment at 18 to 24 months' corrected age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.26, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Hearing impairment at 18 to 24 months' corrected age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.13, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 BSID‐III composite cognitive scores at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.20 [1.70, 16.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 BSID‐III composite language score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.30 [‐2.20, 14.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 BSID‐III composite social/emotional score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [‐7.84, 13.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 BSID‐III object performance (OP) score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.32, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 WPPSI‐III FSIQ at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.42 [‐1.96, 22.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 WPPSI‐III VIQ at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.64 [‐0.73, 22.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 WPPSI‐III PIQ at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.12 [‐2.67, 22.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 WPPSI‐III GLC at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [‐8.37, 14.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Executive function at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.82 [‐1.97, 15.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Working memory at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.74 [‐4.56, 18.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Inhibition at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.86 [‐4.56, 18.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 Griffiths Developmental Scale at 2 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [‐3.75, 9.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 Survival without major neurological or neurodevelopmental disorders at 2 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 Death or moderate/severe neurological disability at 18 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.35, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 Moderate/severe neurological disability at 18 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.24, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Erythropoietin versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004863-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Darbepoetin alfa versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Use of 1 or more red blood cell transfusions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.38, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total volume (mL/kg) of blood transfused per infant (all infants) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.0 [‐50.72, 8.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total volume (mL/kg) of blood transfused in transfused infants only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.10 [‐53.71, 43.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of blood transfusions per infant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.2 [‐2.48, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of donors the infant was exposed to <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐1.10, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality during initial hospital stay (all causes of mortality) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.12, 3.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Retinopathy of prematurity (all stages) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.50, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Retinopathy of prematurity (stage ≥ 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.09, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Necrotising enterocolitis (&gt; stage 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.14, 6.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Proven sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.38, 3.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Intraventricular haemorrhage (grades III and IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.11, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Bronchopulmonary dysplasia (supplemental oxygen at 36 weeks' PMA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.73, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Length of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐17.84, 21.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.18, 19.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Cerebral palsy at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 NDI (with CP, visual defect, hearing defect, or cognitive score &lt; 85) at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.08, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 BSID‐III composite cognitive score at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.5 [1.44, 13.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 BSID‐III composite language score at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.80 [1.57, 16.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Bayley‐III social/emotional score at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.80 [‐3.82, 17.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 OP score at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.17, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 WPPSI‐III FSIQ at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.27 [2.60, 27.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 WPPSI‐III VIQ at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.17 [‐2.86, 21.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 WPPSI‐III PIQ at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.97 [1.89, 28.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 WPPSI‐III GLC at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.94 [‐4.18, 20.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Executive function at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.81 [2.83, 18.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Working memory at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.77 [2.68, 22.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Inhibition at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.77 [‐2.47, 20.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Darbepoetin alfa versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004863-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 BSID‐III composite cognitive score at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.80 [1.65, 13.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 BSID‐III composite language score at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.10 [0.49, 13.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 BSID‐III composite social/emotional score at 18 to 22 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.20 [‐5.06, 13.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 OP score at 18 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.04, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 BASC‐2 composite scores at 3.5 to 4 years ‐ adaptive skills <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [‐3.58, 8.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 BASC‐2 composite scores at 3.5 to 4 years ‐ behaviour symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.66 [‐18.01, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 BASC‐2 composite score at 3.5 to 4 years ‐ externalising problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.0 [‐15.94, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 BASC‐2 composite scores at 3.5 to 4 years ‐ internalising problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.56 [‐9.25, 4.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 WPPSI‐III FSIQ at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.90 [0.76, 23.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 WPPSI‐III VIQ at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.80 [‐1.75, 19.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 WPPSI‐III PIQ at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.5 [1.98, 25.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 WPPSI‐III GLC at 3.5 to 4 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.13 [‐5.30, 15.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Executive function at 3.5 to 4 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.36 [0.51, 16.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Working memory at 3.5 to 4 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.06 [‐1.06, 19.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Inhibition at 3.5 to 4 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.60 [‐2.79, 17.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Darbepoetin alfa or erythropoietin (erythropoiesis‐stimulating agents ‐ ESAs) versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004863-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Erythropoietin versus placebo to improve feeding intolerance</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to achieve full enteral feeding (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐5.77, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Erythropoietin versus placebo to improve feeding intolerance</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004863.pub6/references#CD004863-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004863.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004863-note-1206">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004863-note-1205">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD004863-note-1204">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004863\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004863\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004863\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004863\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004863\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004863.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004863.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004863.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004863.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004863.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713903354"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004863.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713903357"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004863.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d619b998b937a',t:'MTc0MDcxMzkwMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 